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1. Introduction: Nanoparticulate drug delivery 
“…, wir müssen zielen lernen, chemisch zielen lernen!” – “we have to learn how to aim 
chemically” [1]. This famous appeal, proclaimed by Paul Ehrlich in 1909, set the paradigm for a 
rational development of tailored drugs precisely targeting disease-affected sites in patients 
while circumventing adverse effects [2]. More than a century later, Ehrlich’s concept of the 
“magic bullet” was most closely realized in nanoparticulate drug delivery systems, whose 
function as targeted drug carriers strive to advance the treatment and diagnosis of various 
diseases [3].  
Drug encapsulation into a carrier system aims to refine drug characteristics via three major 
pathways. Firstly, physico-chemical properties may be improved. This includes improvement of 
solubility [4] or the prevention of drug degradation during storage and administration [5].  
Secondly, pharmacokinetics can be controlled. This includes extension of systemic circulation 
time by a reduced glomerular filtration in the kidney [6] or prevention of drug metabolism during 
circulation [7]. Furthermore, prolonged release after local administration may be achieved [8, 9]. 
A major pharmacokinetic benefit, and key relation towards Paul Ehrlich’s magic bullet, is the 
prevention of drug distribution in vulnerable healthy tissues [10, 11], and vice versa the option 
to selectively target the carrier towards disease-affected tissues and cells [12].  
Thirdly, pharmacodynamics may be improved. This improvement may in some cases be primarily 
explained by pharmacokinetic effects [10, 13]. However, especially large, non-permeable drugs 
require particulate drug delivery systems to cross cell membranes and subsequently exhibit 
intracellular effects. This is due to the unique interaction of nanoparticles with cells, leading to 
cellular uptake by active processes including endocytosis, (macro-)pinocytosis and phagocytosis 
[14]. Prominent examples are nanoparticulate formulated vaccines [15-17] or nucleic acid-
loaded vectors utilized in gene therapy [18]. 
These three principle mechanisms contribute – alone or in combination [13] – to the possibility 
to improve the efficacy and safety of drugs via encapsulation in carrier systems. Recent decades 
of research in biomedical nanotechnology resulted in a large selection of such colloidal drug 
carriers composed of a plethora of materials with different dimensions, shapes and surface 
varieties [3]. The following work will focus on liposomal drug carriers due to their marked 
versatility and biocompatibility among the currently available drug delivery systems.  
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2. Liposomal drug carriers 
Within the nanotechnological toolbox, liposomes have been most extensively studied as drug 
carriers since their discovery by Alec Bangham et al. in 1964 [19] and have been commercialized 
in several products (Table 1). According to a definition by Vladimir Torchilin, liposomes are 
“spherical, self-closed structures formed by one or several concentric lipid bilayers with an 
aqueous phase inside and between the lipid bilayers” [12]. The presence of both aqueous and 
lipid compartments offers the potential to encapsulate either hydrophilic, hydrophobic or 
amphiphilic drugs into the carrier [5]. Therapeutic liposomes are typically composed of 
amphiphilic phospholipids, cholesterol and stabilizing components, such as charged or polymer-
conjugated lipids [4]. Hence, the main building blocks of liposomes are naturally occurring 
cell membrane components. This may explain the popularity of liposomal drug delivery systems 
due to the material’s inherent biocompatibility, represented e.g. through degradability and low 
toxicity. Liposome dimensions and bilayer number (lamellarity), composition or surface 
modalities such as charge or ligand coating are commonly used for classification of liposomes 
[5]. In general, the liposomal size can vary between 20 nm and several micrometers, with 
100 nm and 1000 nm used as thresholds discriminating small, large and giant vesicles. 
Furthermore, a single liposome can consist of one (unilamellar) or several (oligo- to 
multilamellar) bilayers. Drugs can be encapsulated [5, 20] or adsorbed to the liposomal surface 
[21]. Drug encapsulation occurs passively during liposome formation, or via remote loading, 
which is based on drug accumulation in the liposomal interior due to pH- or salt-gradients over 
the liposome bilayer [20].  
Intravenous application is the most important route of administration for liposomal formulations 
(Table 1). After injection or infusion, the liposomes are subsequently distributed via the systemic 
circulation through narrow capillaries or strongly vascularized tissues. Hence, the liposome size 
has a significant impact on the in vivo fate of the carrier and is therefore a crucial formulation 
parameter [22, 23]. The average liposome size as well as the heterogeneity of the underlying size 
distribution strongly depend on the liposome manufacturing strategy. Different techniques were 
developed over the recent years to facilitate the formation of liposomes in an aqueous system 
from lipid components. These include hydration of thin lipid films, (supercritical) reverse-phase 
evaporation, coacervation, detergent depletion, solvent injection, microfluidic techniques or 
spray-drying of proliposomes [5]. Additional sonication steps or vesicle extrusion through 
membranes with a defined pore size lead to a subsequent sizing of the liposomes, where large and 
occasionally oligolamellar structures are processed into small or large unilamellar vesicles [5]. 
Especially the latter group of liposomes, characterized by a monomodal size distribution with a 
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mean diameter around 100 nm and a single bilayer architecture, was revealed as most suitable for 
the systemic administration of liposomal drugs (Table 1, [22]).  
Table 1: Marketed liposomal drugs (modified from [22]). 
drug route of administration indication diameter  reference 
doxorubicin  
(Doxil®, Myocet®, Evacet®) intravenous 
Kaposi’s sarcoma, ovarian 
and breast cancer 
100 nm / 
180 nm [10] 
daunorubicin 
(DaunoXome®) intravenous Kaposi’s sarcoma 45 nm [24] 
vincristine 
(Marqibo®) intravenous 
acute lymphoblastic 
leukemia 100 nm [13] 
irinotecan 
(Onivyde®) intravenous 
metastatic 
adenocarcinoma of the 
pancreas 
110 nm [25] 
amphotericin B 
(AmBisome®, Amphotec®) intravenous fungal infections 100 nm [11] 
mifamurtide 
(Mepact®) intravenous osteosarcoma < 100 nm [26] 
verteporfin 
(Visudyne®) intravenous 
age-related macular 
degeneration 150-300 nm [27] 
daunorubicin, cytarabine 
(Vyxeos®) intravenous acute myeloid leukemia 100 nm [28] 
cytarabine 
(DepoCyte®) intrathecal 
neoplastic meningitis, 
lymphomatous meningitis 3-30 µm [29] 
bupivacaine 
(Exparel®) subcutaneous local anesthesia 24-31 µm [9] 
morphine sulfate 
(DepoDur®) epidural pain management 17-23 µm [8] 
inactivated hepatitis A virus 
(Epaxal®) intramuscular hepatitis A 150 nm [16] 
inactivated hemagglutinine  
(Inflexal V®) intramuscular influenza 150 nm 
[17] 
 
3. Liposomal drug targeting 
The major indication for liposomal drugs is the treatment of cancer (Table 1). 
Chemotherapeutics typically have a low therapeutic index due to their unfavorable safety 
profile. Therefore, they can in particular profit from liposomal encapsulation if (i) the drug 
remains encapsulated in the carrier during circulation, (ii) the liposome is selectively delivered 
towards a tumor and (iii) the drug is able to reach its target and exhibit the pharmacodynamic 
effect [10]. Such behavior was observed for stable liposomes showing an extended systemic 
circulation, which is achieved by several key formulation attributes [10]. Firstly, this is the 
grafting of a polyethylene glycol (PEG) layer on the liposome surface, which avoids unspecific 
carrier uptake via the mononuclear phagocyte system (MPS). Furthermore, usage of high-
melting lipids together with cholesterol and active loading technology leads to efficient and 
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stable drug encapsulation. Such long-circulating liposomes with an approximated size of 100 nm 
are known to exploit a passive targeting via the enhanced permeability and retention (EPR) 
effect [5]. The EPR effect is based on widely-fenestrated, “leaky” vascularization found in solid 
tumors, but also in inflammatory tissues [30]. Large molecules or nanoparticles can escape the 
circulation via a passage through endothelial gaps (extravasation) and reach the tumor 
interstitium [30]. This vascular hyperpermeability, together with an impaired lymphatic 
drainage, leads to an elevated interstitial fluid pressure. Latter reduces the convective transport 
of nanoparticles in the interstitium, while diffusion is hindered by a dense extracellular matrix 
[31]. Both mechanisms are responsible for an accumulation of drug carriers in the tumor 
interstitium [30]. After distribution in the tumor tissue, the drug may then be released from the 
carrier and permeate into surrounding cells. Alternatively, cellular uptake of the whole carrier 
occurs, followed by an intracellular drug release, e.g. promoted by enzymatic degradation in 
lysosomes [23]. Finally, both mechanisms lead to a site-selective availability of 
pharmacodynamically active drugs. 
This EPR-based passive targeting is limited as it relies on specific physiological conditions, 
meaning the unique combination of leaky vascularization and low lymphatic drainage. It would, 
besides tremendous doubts on the overall clinical relevance [30], only be applicable to solid 
tumors and a limited number of other diseases [5] without any specificity towards special cell 
types. This cellular specificity of drug delivery can be increased by active targeting. Active 
targeting strives for a site-selective drug delivery by combining carriers with ligands binding 
towards disease-specific receptors. Specificity of active targeting is therefore closely correlated 
with expression patterns of the receptors of interest [32]. Especially tumor cells or tumor 
vasculature overexpress receptors which can be exploited as targets due to a virtual absence on 
healthy cells. This discovery has firstly led to the approval of a huge amount of biological entities 
such as monoclonal antibodies [2], which can bind to such targets with high specificity and 
thereby exhibit desired pharmacodynamic effects. In a second stage, these binders were 
conjugated with toxic molecules (antibody-drug conjugates, ADCs), combining the specificity of 
the ligand with the potency of the toxin, thereby increasing therapeutic indices of the latter [33]. 
The conjugation of ligands on the surface of liposomal carriers, yielding so called 
“immunoliposomes”, is therefore a reasonable approach to achieve a targeting effect additional 
on passive targeting. Furthermore, the targeting is independent from physiologic prerequisites 
such as tissues showing an EPR effect, what enables targeting of e.g. blood [34, 35] or 
endothelial cells [36].  
Besides monoclonal antibodies (mAb), a huge variety of structures was employed as liposomal 
targeting moieties in the past. This includes antibody-derivatives such as fragment antigen-
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binding (Fab or Fab’), single-chain variable fragment (scFv), single-domain antibodies or 
peptides, carbohydrate structures and small molecules (for a recent review see [37]). Choice of 
the ligand design can have significant impact on the in vivo behavior of the targeted liposomes. 
This is due to differences in ligand-induced immunogenicity, impact on pharmacokinetics (e.g. 
via Fc-receptor mediated clearance), opsonization or in vivo stability [37]. Furthermore, tumor 
penetration may strongly depend on the type of ligand used. Especially a homogenous tumor 
distribution was shown to be more effective with low-affine scFvs than high-affine mAbs or Fabs, 
explained via the so called “binding site barrier” phenomenon [37, 38]. This was also transferred 
to immunoliposomes, assuming that targeted carriers stick to the first encountered, target-
positive cells after extravasation, preventing pervasive drug delivery throughout the tumor 
tissue [35, 39]. Hence, especially small binder formats such as Fab’s or scFvs are nowadays 
preferred over whole antibodies when utilized as ligands on liposomes [35, 40-43].  
Depending on the utilized receptor and ligand type, carriers may solely bind to target cells or 
undergo receptor-mediated internalization [37]. Especially for the delivery of permeable small 
molecules, internalization of the carrier may not be a prerequisite, since a liposomal drug release 
in target proximity can be sufficient for increasing therapeutic efficiency over non-liposomal drug 
[35]. In contrast, large impermeable macromolecules such as proteins will most likely require a 
drug delivery system which promotes internalization and cytosolic delivery of the cargo [44, 45].  
Compared to direct conjugates of drug and targeting moiety, such as ADCs [33], actively targeted 
carriers may profit from two major benefits [45]. Firstly, this is the comparably high ratio of drug 
to ligand that can be achieved [46], especially when state-of-the-art remote loading techniques 
(such as the ammonium sulfate gradient method) are employed [20]. Secondly, nanoparticulate 
platforms bind in a multivalent fashion towards their target cells [45, 47, 48], meaning that a 
single carrier utilizes several surface receptors during interaction with the cell. This may lead to 
an enhanced internalization of carriers [44, 48]. Multivalent binding may also gain specificity 
over off-target tissues, as targeting ligands with low affinity can be utilized. The high avidity of 
the multivalent carrier counterbalances the low affinity of the individual ligand, and lead to a 
sufficiently strong binding. This allows avoidance of high-affinity ligands, which may also bind to 
off-target cells with a low target density [47]. 
4. Liposomal surface modifications 
Actively targeted liposomes necessarily require a stable anchoring of the ligand in the outer 
liposomal bilayer. This consequently requires lipidation of the ligand, meaning the attachment 
of a hydrophobic tail via typically covalent [46, 49] or more rarely used high-affinity non-
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covalent [50] bonds. Three general functionalization procedures can be distinguished, which can 
be titled as “pre-insertion”, “post-insertion” and “post-functionalization” approaches [46]. 
Pre- and post-insertion separate the lipidation reaction from the liposome formation process. 
Pre-insertion implies presence of the lipidated ligand in the lipid blend during the liposome 
formation, thereby integrating the targeting ligand into the inner and outer bilayer leaflet of the 
liposome. During post-insertion, the lipidated ligand is inserted into the outer bilayer leaflet of 
preformed liposomes, typically above the phase transition temperature of the liposome bilayer 
[51]. Post-functionalization implies introduction of head-group reactive lipids during liposome 
formation. The lipidation and ligand anchoring is then performed directly on the liposomal 
surface. All methods have advantages and disadvantages depending e.g. on chemical nature of 
the ligand, available ligand quantitiy, or effectivity (for a detailed discussion see [46]).  
What they all have in common is the requirement to modify the chemical structure of the 
targeting ligand. The majority of targeting ligands has a proteinaceous origin. Proteins as 
macromolecules possess several reactive sites. Those may be accessible for lipid conjugation via 
amide bond, disulfide or thioether formation, either directly (cysteines, lysines) or after 
activating steps (such as thiolation, reduction, crosslinker-condensation or carboxylic-acid 
activation). These three linker principles are merely examples of the most abundantly used 
chemical conjugation strategies, whose vast diversity is summarized in several reviews [46, 49]. 
Importantly, due to the presence of manifold reactive sites per protein, most of these reactions 
suffer from poor chemical selectivity, leading to heterogeneous conjugation products. Besides 
regio-specific chemical conjugation methods (such as copper-assisted azide-alkyne 
cycloaddition, native chemical ligation (NCL) or the Staudinger ligation) [52], chemoenzymatic 
ligation is a promising tool to avoid unspecific conjugation products by yielding chemically well 
defined protein modifications due to the inherent site-selectivity of enzymes [53]. 
Among the chemoenzymatic tools, Sortase-A is one of the most established enzymes promoting 
a regio-specific protein modifciation. Sortases are transpeptidases, originally discovered as 
house-keeping enzymes in gram-positive bacteria, where they mediate protein anchoring on the 
peptidoglycan layer [53]. Sortase-A, derived from Staphylococcus aureus, recognizes a 
C-terminal LPxTG (leucine, proline, any amino acid, threonine, glycine)-motif in the target 
protein and forms a thioacyl intermediate with the threonine and a cysteine in the catalytic 
center of the enzyme [53].  
Equation 1: General scheme of Sortase-A mediated transpeptidation. 
𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷-𝑳𝑳𝑷𝑷𝑳𝑳𝑳𝑳𝑳𝑳-𝑹𝑹𝟏𝟏-𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 + 𝐶𝐶2𝑁𝑁-𝑳𝑳-𝑹𝑹𝟐𝟐  𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆-𝐴𝐴�⎯⎯⎯⎯⎯�  𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷-𝑳𝑳𝑷𝑷𝑳𝑳𝑳𝑳𝑳𝑳-𝑹𝑹𝟐𝟐 + 𝐶𝐶2𝑁𝑁-𝑳𝑳-𝑹𝑹𝟏𝟏-𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 
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The amide bond towards the glycine is cleaved and subsequently replaced during the 
transpeptidation reaction with an incoming nucleophilic N-Terminus (Equation 1), e.g. of 
oligoglycines [53] or other primary amines [54, 55].  
After its discovery in 1994 by Schneewind et al. [56] and subsequent recognition of the 
technological value of the “sortagging” reaction, Sortase variants have been used for a vast 
diversity of applications. This includes for example protein-protein fusion, protein modification 
(e.g. with carbohydrates, dyes or lipids), drug conjugation to antibodies, in vitro labeling of living 
cells or intracellular transpeptidation (for a comprehensive review see [53]). 
Also, particulate drug delivery and diagnostic systems have been modified using Sortase-A 
technology. A scFv binding specifically to activated platelets has been conjugated via Sortase-A 
mediated transpeptidation to iron-oxide particles. This targeted contrast agent was able to 
specifically image thrombi in mice [57]. Similar targeting was achieved using a PEGylated, 
polymer-based layer-by-layer nano-capsule conjugated to a thrombus-specific scFv via 
Sortase-A [58, 59]. In another example, microparticles were modified with glucose-oxidase via 
Sortase-A, resulting (together with a biotin-immobilized horseradish peroxidase) in a construct 
ready for detecting glucose [60]. Other reports related to drug delivery describe the use of 
Sortase-A for the labelling of lipid nanodiscs [61], surface functionalization of hydrogels [62] or 
ligand-conjugation to polymeric micelles [55]. Liposomes have also been modified using 
Sortase-A. Guo et al. firstly described the conjugation of a model protein to diglycine-modified 
liposomes [63]. Tabata et al. optimized reaction conditions of a novel recombinant Sortase-A 
variant on pentaglycine-polystyrene beads. This was followed by verifying these optimized 
conditions by conjugation of a biotinylated LPETG-peptide on a liposomal surface [64]. 
Afterwards, the same group successfully conjugated a lung-tumor binding peptide to liposomes 
via Sortase-A, showing a selective delivery of these targeted liposomes to a lung-cancer cell line 
in vitro [65]. In a more recent study, Silvius et al. investigated reaction kinetics and coupling 
yields of protein conjugation to liposomes equipped with differently composed oligopeptide-
modified acceptor lipids [66]. The authors showed that especially a reversible pre-binding of 
Sortase-A to the liposomes can enhance coupling yields during the manufacturing of 
protein-modified liposomes.  
These examples indicate the potentials of Sortase-A mediated conjugation applied for the 
manufacturing of drug delivery systems, thus making proceeding investigations on this 
technology attractive for the pharmaceutical technology. 
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5. Aim of thesis 
The use of Sortase-A as conjugation tool to attach targeting ligands on liposomes was considered 
as promising research field due to the marked versatility, the conjugation feasibility at mild 
reaction conditions, and the inherent site-specificity of the reaction. Only a limited number of 
reports described Sortase-mediated transpeptidation for ligand grafting on liposomal drug 
delivery systems at the start of this thesis [63-65]. This encouraged the author to gain deeper 
insights into the analytical and manufacturing challenges of such chemoenzymatically produced 
immunoliposomes, but also into their potential to improve in vitro and in vivo delivery of marker 
molecules and drugs. 
The sortagging of liposomes requires integration of suitable lipid-anchored peptide sequences 
in the bilayer, serving as recognition motif for the transpeptidase. The stable insertion of such 
pentaglycine-lipids into the liposomal membrane and the integrity of the whole liposomal 
bilayer composition during manufacturing is indispensable for reliable downstream processes 
and meaningful biological read-outs. The development and validation of a highly versatile 
chromatographic method for the quantification of the individual lipid components of several 
sortaggable liposomal formulations was therefore aimed and is described in Chapter 2.  
Ligand conjugation to liposomes implies a reaction on a surface, whose kinetics or efficiency 
may be considerably different from reactions in solution. The influence of liposomal surface 
properties and further conditions on kinetics and efficiency of the Sortase-A catalyzed 
conjugation of llama-derived single-domain antibodies was investigated in detail. Furthermore, 
the selective binding and uptake of such single-domain antibody-modified liposomes targeted 
against the immune cell receptor CD11b was tested on human peripheral blood mononuclear 
cells (Chapter 3). 
A drawback of Sortase-A transpeptidation is the reversibility of the reaction. Traces of the 
enzyme in a drug product can be responsible for cleavage of the ligand from the liposomal 
system and can therefore lead to a loss of the targeting function during storage. This function is 
essential for immunoliposomes to specifically deliver substances towards target cells in living 
organisms. Thus, different formulation properties and purification methods were screened 
regarding efficiency of Sortase-A depletion from the reaction bulk and influence on drug product 
stability (Chapter 4). Most importantly, the chapter investigates CD11b-targeted 
immunoliposomes for the in vivo delivery of marker molecules towards immune-regulatory 
myeloid-derived suppressors cells with regard to specificity over T and B cells.  
Aim of thesis 
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Lipidated single-domain antibodies may be inserted into preformed liposomes to obtain 
immunoliposomes via the post-insertion technique, thus obviating above mentioned 
purification efforts. The post-insertion technique demands a method to isolate the lipidated 
ligand from Sortase-A and unreacted educts while retaining target affinity of the ligand. 
Furthermore, such lipidated but soluble ligands may be inserted into biological membranes, 
thereby promoting non-natural cell-cell interactions. Studies elucidating the synthesis and 
isolation of lipidated single-domain antibodies as well as their insertion into liposomal and 
cellular membranes are described in Chapter 5.  
Liposomal encapsulation may enable cytosolic delivery of impermeable macromolecules such as 
proteins via different intracellular routing. Pseudomonas exotoxin A is a proteinaceous inhibitor 
of the protein biosynthesis with high cytotoxic potency as soon as it reaches the cytosol. 
Chapter 6 reports the attempt to exhibit specific toxicity against myeloid-derived suppressor 
cells via the cytosolic delivery of the catalytic domain of Pseudomonas exotoxin A using diverse 
chemoenzymatically prepared immunoliposomal formulations. 
Doxorubicin is an important chemotherapy medication that has been further refined by 
liposomal encapsulation. Conventional conjugates of liposomal doxorubicin and anti-epidermal 
growth factor receptor (EGFR) derived targeting ligands have recently reached clinical 
development. The usage of site-specific conjugation chemistries may improve such clinical 
assets by yielding products with higher homogenity. Chapter 7 aims to explore the formulation 
development and remote-loading of doxorubicin into sortaggable liposomes. It gives insights 
into sortagging kinetics of full-length monoclonal antibodies to these liposomes and 
demonstrates the specific cytotoxicity of EGFR-targeted immunoliposomes on a cancer cell line.   
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Abstract 
The quantification of lipids and assessment of lipid composition is an indispensable step during 
the pharmaceutical development of lipid-based drug delivery systems such as liposomes. Broad 
excipient screenings of such formulations raise the need for versatile analytical methods. Even 
more demanding complexity is generated by introduction of targeted systems requiring 
functionalized lipids. We addressed this demand by developing an rp-HPLC-based analytical 
method with evaporative light scattering detection (ELSD) for the simultaneous analysis of 
commonly used phosphatidylcholines, cholesterol and bilayer surface-modifying cationic, 
anionic or PEGylated lipids, which can be analyzed in combination with novel pentaglycine lipids 
suitable as targeting ligand anchor. The method was validated for specificity, precision, accuracy 
and sample stability. We monitor the continuous and scalable manufacturing of two 
pentaglycine-modified liposomal formulations and track the modification of these drug delivery 
systems with a single-domain antibody utilizing bioorthogonal Sortase-A technology. Both the 
presented analytical and preparative techniques can help to improve the quality control and to 
accelerate the pharmaceutical development of such targeted drug delivery systems.
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1. Introduction 
Lipid excipients have become an indispensable part of the formulation scientists’ toolbox. Their 
versatility and broad applicability e.g. in topical [1], oral [2], parenteral [3, 4] or pulmonary [5] 
dosage forms has progressively led to the synthesis of functionalized lipids, depending on the 
formulation purpose. Especially in lipid-based nanoparticulate drug delivery systems like 
liposomes, head group modification and hydrophobic chain properties are crucial parameters 
for formulation characteristics and in vivo performance [6]. A thorough screening of the bilayer 
composition is therefore an important part of the formulation development, and corresponding 
lipid analytics are essential to monitor composition and concentration over the usually multi-
step formulation processes. Although several rp-HPLC methods for lipid quantification have 
been published in the past, bilayer analyses are frequently carried out using unspecific 
colorimetric assays, which typically do not take phosphate-free lipids into account [7], or are not 
conducted at all. Mass-sensitive evaporative light scattering [8-13] is besides charged aerosol 
detection (CAD) [14] the detection method of choice for lipid structures having no or few 
chromophores. It is preferred over other mass-sensitive detectors using refractive index 
detection (e.g. due to the higher detectability and compatibility with gradient elution), or mass-
spectrometers especially due to the low costs and convenience of operation and 
instrumentation [15]. Besides those advantages, ELSDs have several limitations, such as the 
requirement of volatile mobile phases, the destructive characteristic and the exponential 
relationship of analyte mass and signal intensity [15]. 
Due to this non-linear response and the influence of the atmospheric pressure in the lab on the 
signal intensity, a time consuming, frequent multi-point calibration is required. This is, together 
with tedious standard preparation, long chromatographic run durations and extensive data 
evaluation, a hurdle for the implementation of such analytical methods, which is further 
enhanced by a lack of method versatility. Previously reported chromatographic methods 
focused on the separation and quantification of phosphatidylcholines, phosphatidylglycerols 
and their lyso-forms [8], or on functionalized lipids like 1,2-dioleoyl-3-trimethylammonium-
propane (R-DOTAP) [10, 13] or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (DSPE-mPEG) [9, 11]. However, none of the published 
methods provides a general approach to analyze vesicles with cationic, anionic and PEGylated 
surfaces, a versatility that would be helpful in early liposome development when the required 
bilayer composition is rather unknown and thus often varied. Furthermore, the quantification 
of “coupling-ready lipids” like maleimide-conjugated lipids or amino acid-modified lipids is 
Chapter 2: rp-HPLC analytics for pentaglycine lipid derivates 
30 
currently disregarded. Especially the latter novel class of lipids currently gains attraction as 
anchor molecules for bioorthogonal bilayer modification [16-18].  
In the past, liposomes have been successfully modified with ligands to target the drug delivery 
system to specific cell surface structures [19]. For that purpose, mainly chemically-based 
conjugation methods are employed, making use of free thiol-, carboxy- or amino-groups in 
proteins or peptides [20]. As every accessible reactive amino acid side chain can participate in 
the reaction, a broad conjugation product profile might be obtained, as e.g. reported by 
Lukyanov et al., where up to 32 PEGylated phosphoethanolamines were conjugated to free 
amine groups of a full length antibody [21]. Unspecific protein modifications lead to product 
heterogeneity, an unfavorable hindrance for the transfer of targeted nanotherapeutics from 
bench to the clinic. For that reason site selective reactions, mainly driven from currently rising 
antibody-drug conjugate technology [22], are an emerging field in the bioconjugation research. 
Amongst them, enzyme-based, bioorthogonal Sortase-A transpeptidation technology has been 
established as versatile tool to promote efficient conjugation between LPxTG (leucine, proline, 
any amino acid, threonine, glycine) and oligoglycine amino acid motifs [23]. Working under mild 
conditions, Sortase-A conjugation offers a favorable approach to attach targeting ligands with 
the techniques inherent specificity to surfaces and was shown on various particulate constructs, 
amongst them iron oxide particles [24], polystyrene microparticles [25], silica nanoparticles [26] 
and liposomes [16-18].  
In the present work, we firstly show the development of an rp-HPLC-ELSD method allowing us 
to analyze a broad variety of liposomal formulations which shall be ligand-modified by novel 
Sortase-A bioconjugation technique. We describe useful protocols to minimize time-consuming 
HPLC-standard preparation in daily lab-work while considering overall analysis times. As 
demonstration, we apply the method to an industry-relevant multi-step liposomal preparation 
process, which is especially challenging to be followed by analytics as composition can change 
in every step. We describe the formulation and characterization of two differently PEGylated 
pentaglycine-modified liposome types suitable for the active loading of weak bases. 
Furthermore, enzyme-mediated conjugation of a single-domain antibody of camelid heavy-
chain only antibodies (VHH) is used as exemplary bilayer modification reaction. The presented 
method and manufacturing procedures can help to accelerate liposomal development processes 
as they provide suitable early-development analytics and scalable manufacturing for a targeted 
liposome platform that may be loaded with desired active-loading compatible drug and 
sortaggable ligand. 
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2. Materials 
Pentaglycine-modified lipids (Figure 1) are based on two myristyl alcohols ether linked to an 
amino-propandiol moiety being coupled to the δ-carboxy-group of an iso-glutamine by an amide 
linkage. The pentaglycine motif is either directly (here called DMA-G5) C-terminally linked to the 
α-standing amino function of the iso-glutamine, or spaced via a 2000 Da monodisperse 
polyethylene linker (DMA-PEG-G5) [27]. Both compounds, as well as (R)-1,2-dioleoyl-3-
trimethylammonium-propane (R-DOTAP) were obtained from Merck & Cie (Schaffhausen, 
Switzerland). 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-
3-phospho-(1'-rac-glycerol) (DPPG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[meth-oxy (polyethylene glycol)-2000] (DSPE-mPEG), 1,2-dioleoyl-sn-glycero-3-phospho-
ethanolamine (DOPE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), lyso-phosphatidyl-
choline reference standard and hydrogenated soy phosphatidylcholine (HSPC) were from Lipoid 
GmbH (Ludwigshafen, Germany). Dulbecco’s phosphate buffered saline (DPBS, D1408, tenfold 
stock), cholesterol and 3β-hydroxy-5-cholestene 3-hemisuccinate (CHEMS) were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
(lissamine rhodamine B sulfonyl) (Liss-Rhod-PE) and 1,2-distearoyl-sn-glycero-3-phospho-
ethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPE-PEG-Mal) were obtained from 
Avanti Polar Lipids (Alabaster, AL, USA). Doxorubicin (DXR) was purchased from Ark Pharma 
(Arlington Heights, IL, USA). 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indotricarbocyanine iodide 
(DiR) was from Thermo Fisher Scientific (Waltham, MA, USA). Trifluoroacetic acid (TFA), 
methanol and ethanol (both gradient grade) as well as dimethylsulfoxide (DMSO) were obtained 
from Merck KGaA (Darmstadt, Germany). Water was purified by a Milli-Q system (Merck 
Millipore, Billerica, MA, USA).  
 
Figure 1: Chemical structure of A: DMA-G5, 897 Da and B: DMA-PEG-G5, 2554 Da. 
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3. Methods 
3.1. Chromatographic conditions 
Final method utilized an XSelect CSH C18 column with a particle size of 5 µm, an inner diameter 
of 4.6 mm, a length of 150 mm (Waters Corporation, Milford, MA, USA) and a binary 
pseudopolar gradient pattern (Table 1) for compound separation. Eluent A consisted of water-
methanol (1:1 v/v), eluent B was methanol-ethanol (3:2 v/v) supplemented with 0.01 % TFA v/v. 
Analysis was performed on an Agilent 1260 Infinity HPLC system equipped with a degasser 
(G4225A), binary pump (G1312B), autosampler (G1329B), thermostat (G1330B), column oven 
(1316A), diode array detector VL+ (DAD, G1315C) and evaporative light scattering detector 
(ELSD, G4260B), controlled by EZChrom Elite Software. Column temperature was set to 35 °C, 
autosampler temperature was set to 4 °C. Standard injection volumes were 50 µL or 25 µL to 
adjust signal intensities between compounds occurring at very high (DPPC) and low molar 
fractions. Flow rate was 2.5 mL/min. Data was recorded using DAD set to 485, 560 and 750 nm 
to detect DXR and dyes. ELSD settings were 1.5 standard liter per minute for nitrogen nebulizer 
gas, 60 °C for nebulizer and 80 °C for evaporator, a sampling frequency of 10 Hz, detector-
inherent signal smoothing of “30”, LED power of 100 % and a photomultiplier tube gain of “1”. 
All analyses were performed with duplicate runs. To avoid lipid carry-over on subsequent 
injections, injection needle was cleaned after each injection in a wash-vial filled with chloroform-
methanol-water (4.5 : 4.5 : 1 v/v, further called diluent). 
3.2. Analytical lipid blend ready mixes 
Lipids shown in Table 3 were weighed on a daily calibrated balance (AG245, Mettler Toledo, 
Columbus, OH, USA), dissolved in methanol to the upper concentration and aliquoted in HPLC 
vials. Solvent was evaporated in a vacuum oven (VT 6060 M-BL, Thermo Scientific, Waltham, 
MA, USA) at 25 °C (0-2 h: 200 mbar, 1 h at 50 mbar, further 10 min at 1-2 mbar) to prepare 
ready-to-use blends. Blends were stored in a nitrogen atmosphere at -20 °C. For evaluation of 
separation and method optimization, single lipids or blends were dissolved in diluent and 50 µL 
were injected.  
Table 1: Gradient pattern. 
time [min] gradient 
0.0 – 1.0 100 % A 
1.0 – 2.0  100 % A – 20 % A 
2.0 – 12.0 20 % A – 0 % A 
12.0 – 12.1 0 % A – 100 % A 
12.1 – 17.0 100 % A 
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3.3. Calibration, accuracy, precision and sample stability 
Ready-to-use lipid blends described in section 3.2 were dissolved in the diluent and injected with 
varying injection volumes to calibrate the ELSD over five levels, achieving calibration ranges from 
60-125 % of each expected lipid concentration, related to its molar liposomal fraction (see 
section 3.4) of a target sample molarity of 1 mM total lipid. Signal-to-noise ratio (SNR) was 
determined for the lowest calibration point, no further chromatogram smoothening was 
applied. Limit of detection (LOD) was determined visually due to the ELS inherent non-linear 
signal response. Subsequently increasing amounts were injected on the column until a peak 
could be reliably detected. Accuracy of method was determined by quantification of individually 
weighed lipid blends over three days. Intra-day precision and retention robustness was 
determined as the relative standard deviation of the mean peak area of 10 consecutive 
injections, inter-day precision and retention robustness of equally concentrated samples 
analyzed in duplicate at three consecutive days. Sample stability in diluent was tested as the 
recovery rate of three samples analyzed over three consecutive days with daily-actual 
calibrations. 
3.4. Liposome preparation 
Liposome samples were prepared by a continuous solvent injection process. Lipid powder 
blends consisting of 59.4 mol% DPPC, 34.7 mol% cholesterol, 1.0 mol% DMA-PEG-G5 and either 
5.0 mol% DSPE-mPEG (referred to as “PEG-NP”) or DPPG (referred to as “Anionic-NP”) were 
dissolved to 119 mM (PEG-NP) and 48 mM (Anionic-NP) in chloroform-methanol. The solution 
was aliquoted and vacuum-dried from 400 mbar subsequently to 2 mbar in a vacuum centrifuge 
(RVC 2-33 IR, Martin Christ, Osterode am Harz, Germany). The films were nitrogen gassed, sealed 
and stored at -20 °C as ready-to-use mixes. For solvent injection, lipids were redissolved to a 
target molarity of 90 mM in ethanol (PEG-NP) or 16 mM in methanol (Anionic-NP). Alcohol 
solutions were injected computer-controlled utilizing a syringe pump (PHD Ultra4400, Harvard 
Apparatus, Holliston, MA, USA) and a customized T-piece at a flow rate of 10 mL/min into a 
stream of ammonium sulfate buffer (pH 5.4, 250 mM) conveyed by a peristaltic pump (Ismatec 
IP65, Cole-Parmer, Wertheim, Germany) at 120 mL/min for PEG-NP or 200 mL/min for Anionic-
NP.  
3.5. Tangential flow filtration 
Dispersions obtained from solvent injection were refined using a tangential flow filtration (TFF) 
system equipped with a MicroKros® Filter module (Spectrum Labs, Los Angeles, CA, USA) with a 
500 kDa cut-off and 20 cm2 surface area. The TFF was fed at a flow rate of 100 mL/min 
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pump speed and filtration pressure < 2 bar. A known amount of liposomal dispersion was 
concentrated to a target molarity of ≈30 mM, followed by purification of alcohol and 
replacement of the outer buffer by DPBS for 10 diafiltration volumes. For lipid analytics, 
liposomal samples were firstly diluted tenfold with chloroform-methanol (1:1 v/v), followed by 
a further dilution with diluent to an estimated concentration of 1 mM to maintain an equal 
aqueous sample content of 10 % (v/v), previously shown to be relevant for lipid analytics [11]. 
Lipid analytic was applied before and after TFF to control bilayer composition changes, and the 
lipid recovery was calculated by Equation 1. For Anionic-NP, lipid concentration before TFF was 
calculated from pump flow rate ratio during solvent injection due to the sample concentration 
being below the limit of quantification. 
Equation 1 
𝑇𝑇𝑇𝑇𝑇𝑇 𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦 [%] = 𝑚𝑚𝑑𝑑𝑑𝑑𝑆𝑆𝑑𝑑𝑆𝑆𝑆𝑆𝑆𝑆𝑑𝑑𝑆𝑆𝑑𝑑[𝑚𝑚𝑚𝑚] ∗ 𝑐𝑐𝑙𝑙𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑[𝑚𝑚𝑚𝑚](𝑇𝑇𝑇𝑇𝑇𝑇 𝑜𝑜𝑜𝑜𝑜𝑜)
𝑚𝑚𝑑𝑑𝑑𝑑𝑆𝑆𝑑𝑑𝑆𝑆𝑆𝑆𝑆𝑆𝑑𝑑𝑆𝑆𝑑𝑑[𝑚𝑚𝑚𝑚] ∗ 𝑐𝑐𝑙𝑙𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑  [𝑚𝑚𝑚𝑚] (𝑇𝑇𝑇𝑇𝑇𝑇 𝑦𝑦𝑖𝑖) ∗ 100 
3.6. Ligand conjugation 
Particles were surface-modified using a Sortase-A mediated transpeptidation approach. 
Ca2+-independent Sortase-A variant SortA7m and LPETG (leucine, proline, glutamic acid, 
threonine, glycine)-modified VHH were prepared as described elsewhere [28, 29]. Purified 
liposomes (100 µM total pentaglycine) were mixed with 50 µM VHH and 25 µM Sortase-A. The 
mixture was incubated for 4 h at 4 °C, until the reaction was stopped by dilution (1:9) with 
chloroform-methanol (1:1 v/v). Precipitated proteins were removed by centrifugation 
(5 minutes at 10,000 × g), and the supernatant was analyzed for decrease of DMA-PEG-G5 in the 
bilayer. Statistical significance was tested using a paired t-test (SigmaPlot, Systat Sofware, 
San Jose, CA, USA). 
3.7. Physical liposome characterization 
Liposomal mean hydrodynamic diameter and polydispersity were measured by dynamic light 
scattering using a DynaPro Plate Reader II (Wyatt, Santa Barbara, CA, USA). Typically, liposomes 
were diluted to 0.1-1 mM total lipid in the respective surrounding buffer and measured in 
triplicate wells. Zeta potential was determined in triplicate using laser Doppler electrophoresis 
(Malvern Zetasizer, Worcestershire, UK) after a dilution of 30 µL sample in 970 µL 10 mM NaCl.  
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4. Results and discussion 
4.1. Method development  
During method development, focus was set on the separation of pentaglycine-modified lipids 
from common bilayer components used in liposome research to enable a fast and simple lipid 
quantification of highly diverse formulations in early composition screening. Previously 
published methods for versatile lipid analysis investigated neutral phospholipids and anionic 
phosphatidylglycerols, cholesterol and their hydrolysis products [8]. It was here in our interest 
to extend the analytical scope toward the simultaneous analysis of either cationic, anionic and 
PEGylated surface-modifying lipids in combination with different phospholipids and cholesterol. 
Versatility of such a method would allow a broad screening of formulations with wide 
applicability such as long-circulating PEGylated vesicles [30], controlled drug release through 
phosphatidylcholines with different chain lengths [31] as well as a vaccination purpose utilizing 
adjuvant-acting R-DOTAP [32]. The arbitrary combinability with novel pentaglycine-modified 
lipids (Figure 1) for enzymatic ligand attachment would allow easy transfer of such traditional 
liposome formulations toward immunoliposomes for targeted drug delivery without additional 
analytical development. 
C18-phase rp-columns with ammonium acetate buffered pseudopolar eluents were previously 
used for separation of PEGylated lipids from cholesterol and phosphatidylcholines [9, 11]. 
Applying a method published by Oswald et al. [9], we were not able to separate DMA-G5 from 
DSPE-mPEG even after various optimization steps in the gradient profile. Therefore, a water-
methanol gradient with TFA as ion-pairing additive [13] was selected as alternative eluent 
system. Decrease of polarity by addition of ethanol to eluent B led to the ability to elute DPPG 
and separate it from DSPE-mPEG, both structures with negative formal charge at the phosphate 
group, which might be lost due to TFA presence, leading to strong column interaction. We varied 
column temperature and decreased TFA content in eluent B, which had further promising 
influence on the separation of DPPG and DSPE-mPEG, as well as the two pentaglycine-modified 
lipids. Finally, we chose a column temperature of 35 °C and 40 % ethanol in eluent B 
supplemented with 0.01 % TFA, leading to the separation of DMA-G5 and DMA-PEG-G5 
(RS = 2.0) and DSPE-mPEG and DPPG (RS = 1.5), as well as R-DOTAP, cholesterol and DPPC, the 
major lipid combinations applied in our lab (Figure 2A) within a short analysis time of 17 min.  
CHEMS is a cholesterol ester that can be protonated in acidic environment leading to 
pH-dependent polymorphic states [33]. CHEMS is therefore used as membrane component in 
pH-sensitive formulations [34]. Eluting at 7.1 min, CHEMS is not separated from 
cholesterol (7.0 min), however CHEMS typically replaces cholesterol when combined with DOPE 
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in pH-sensitive formulations. As both CHEMS and DOPE are well separated (Figure 2B), the 
analysis of such pH-sensitive formulations can be provided by the presented method.  
 
Figure 2: Representative chromatograms showing suitability to separate frequently literature-described liposomal 
formulations in combination with sortaggable pentaglycine lipids. A: Typical calibration standard relevant for the 
analysis of formulations consisting of 60 mol% DPPC, 35 mol% CHOL, 1 mol% DMA-PEG-G5 or DMA-G5 as well as 
5 mol% R-DOTAP, DSPE-mPEG or DPPG. DPPC is calibrated with half of the expected molar fraction to align absolute 
signal intensities of different bilayer ingredients within the detector range. Liposomal sample is then analyzed for 
DPPC with decreased injection volume. B: CHEMS and DOPE (40:60 mol% at 0.8 mM total lipid shown), typical 
ingredients of pH-sensitive formulations, can be baseline-separated in combination with PEGylated lipids. C: Widely 
used formulation of 60 mol% HSPC, 35 mol% CHOL and 5 mol% DSPE-mPEG, with separation of the two major 
ingredients of naturally derived HSPC (concentration: 1 mM total lipid). 
HSPC is a naturally derived palmitoyl and stearoyl phosphatidylcholine mix [11] forming rigid 
liposomes with low drug leakage together with cholesterol and DSPE-mPEG [35]. The method 
(Figure 2C) separates two peaks, from which HSPC-2 was identified as DSPC (18:0 PC, Figure 3) 
by a reference standard. HSPC-1 is assumed to be 1-palmitoyl-2-stearoyl-sn-glycero-3-phospho-
choline (16:0-18:0 PC), according to the fatty acid distribution of HSPC [11] and the elution 
between DPPC (16:0 PC) and DSPC, related to its expected hydrophobicity. Excipients of both 
the pH-sensitive and rigid, HSPC-based formulation are well separated from the pentaglycine 
lipids, enabling a simultaneous bilayer analysis of such formulations with a targeting purpose. 
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Figure 3: Elution profiles of lyso-PC reference and further frequently used lipids in liposome research. HSPC-2 was 
identified as DSPC by a reference standard. 
DSPE-mPEG (Figure 2) or DSPE-PEG-Mal (Figure 3), latter used for conjugation of ligands with 
free thiol groups, show broader peak profiles probably due to the polydispersity of the polymer 
spacer. Comparable C18:0-chain carrying lipid DSPC (Table 2) has a similar elution time. This 
indicates a minor influence of the 2 kDa PEG-group on the column interaction, which seems to 
be predominantly determined by the C18-acyl-chains. Furthermore, common dyes DiR and 
Liss-Rhod-PE used in liposome bioimaging or fluorimetric studies may be analyzed with parallel 
UV-VIS detection (Figure 4), although peak tailing requires method optimization for 
Liss-Rhod-PE. 
Table 2: Retention times of all tested compounds. 
compound retention time [min] 
doxorubicin 2.6 
lyso-PC reference standard 3.6, 4.0 
DMA-PEG-G5 4.3 
DMA-G5 4.6 
R-DOTAP 5.4 
CHOL 7.0 
CHEMS 7.1 
DPPC 7.9 
DOPE 8.3 
DiR 8.7 
HSPC-1 8.9 
DSPE-PEG-Mal 9.5-11.6 
DSPC / HSPC-2 9.9 
Liss-Rhod-PE 10.2-13.2 
DSPE-mPEG 10.7 
DPPG 12.1 
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Figure 4: Analysis of dyes and DXR with parallel UV detection. DXR elutes at 2.6 min, indicating compatibility with 
analysis of pentaglycine lipids. Furthermore, frequently used dyes in liposome research may be quantified using 
parallel UV-VIS detection. 
Typical degradation products of phospholipids are monoacylphosphatidylcholines or 
phosphoglycerol [36]. Specificity was therefore checked with a lyso-phosphatidylcholine 
standard containing relevant palmitoyl- and stearoyl fatty acid esters whether possible 
degradation products were also detectable and separated from the investigated lipids. We 
found the lyso-structures elute at 3.6 min and 4.0 min, indicating adequate separation to the 
pentaglycine lipids (Figure 3). A quantification of the lyso-forms was not of interest in this study. 
Finally, widely used liposomal drug doxorubicin (DXR) was found to elute at 2.6 min (Figure 4), 
indicating compatibility with the lipid analytic as well. 
4.2. Precision, calibration and accuracy  
It is known that ELS detection can be influenced by daily variabilities like device performance or 
lab conditions such as temperature and atmospheric pressure. Especially the latter is affected 
by night-time reduction of the lab’s ventilation system, changing signal intensities by different 
droplet and particle formation during nebulization and evaporation processes. Improved 
exhaust conditions with reduced direct contact to the fume system led to decrease of those 
fluctuations down to 3-5 %, nonetheless we tried to avoid analyzes overnight. Use of an internal 
standard may circumvent such limitations, but adds further complexity to the analyte mixture 
and was therefore not considered here. Intra- and inter-day retention robustness and precision 
(Table 3) were both evaluated to investigate the reproducibility of the chromatography and 
ELSD. We found the RSD (relative standard deviation) of the retention time of 10 consecutive 
injections less than 0.2 % for all tested compounds, and slightly higher (< 0.6 %) for 6 injections 
on three different days, indicating minor influences of different eluent preparations.  
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Table 3: Intra- and inter-day retention time robustness and precision, expressed as relative standard deviation of 
10 consecutive analyses or 6 analyses on three different days, respectively. 
 retention time (RSD) precision (RSD) 
compound intra-day inter-day intra-day inter-day 
DMA-PEG-G5 0.07 % 0.30 % 1.02 % 1.88 % 
DMA-G5 0.06 % 0.27 % 1.82 % 6.11 % 
R-DOTAP 0.06 % 0.25 % 1.15 % 1.86 % 
CHOL 0.04 % 0.04 % 0.96 % 2.53 % 
DPPC 0.04 % 0.04 % 1.13 % 2.70 % 
DSPE-mPEG 0.13 % 0.44 % 1.30 % 1.45 % 
DPPG 0.17 % 0.59 % 1.76 % 7.23 % 
 
Similar results were observed for precision analysis, which was found to be reproducible 
(RSD < 2 %) within a daily analysis, but less reproducible over three days. Increases were 
observed for DPPG and DMA-G5, and might be due to fluctuations in TFA content of eluent B 
[13], or indicate the need to increase the injected sample mass to improve the low signal-to-
noise ratio for these two lipids (Table 4). The results obtained from precision analysis are 
comparable to those published earlier [8] and indicate suitability of this method for early 
research purposes.  
The described method was calibrated automatically by decreasing injection volumes for lipids 
given in Table 4 on three different days using a five-point calibration (Figure 5). Alteration of 
injection volume had no impact on retention times (Supplementary Table 1). 
Table 4: Calibration range and curve characteristics. Lower limit of calibration represents the here stated limit of 
quantification (LOQ). Slope, intercept, correlation coefficient and SNR of lowest calibration point are reported as 
mean ± standard deviation of three daily-actual calibrations using a logarithmic fit of the equation 𝑎𝑎𝑎𝑎𝑦𝑦𝑎𝑎 =
𝑐𝑐𝑜𝑜𝑖𝑖𝑐𝑐𝑦𝑦𝑖𝑖𝑜𝑜𝑎𝑎𝑎𝑎𝑜𝑜𝑦𝑦𝑜𝑜𝑖𝑖𝑆𝑆𝑙𝑙𝑆𝑆𝑑𝑑𝑆𝑆 ∗ 𝑦𝑦𝑖𝑖𝑜𝑜𝑦𝑦𝑎𝑎𝑐𝑐𝑦𝑦𝑖𝑖𝑜𝑜. LOD was determined by injection of decreasing quantities on the column until a 
peak could be reliably recognized. 
compound 
ng on column / 
µM 
slope intercept correlation SNR LOD 
[ng] 
DMA-PEG-G5 
1115 - 2322 / 
9 - 18 
1.6589 ± 0.0204 7.9458 ± 0.0477 0.9997 ± 0.0004 137 ± 10 139 
DMA-G5 
269 - 561 / 
6 - 13 
1.4766 ± 0.0593 7.3009 ± 0.0987 0.9991 ± 0.0003 28 ± 2 135 
R-DOTAP 
1084 - 2258 / 
31 - 65 
1.5221 ± 0.0131 7.0739 ± 0.0350 0.9994 ± 0.0003 307 ± 25 45 
CHOL 
3964 - 8258 / 
205 - 427 
1.4393 ± 0.0148 6.7772 ± 0.0731 0.9994 ± 0.0003 2248 ± 165 83 
DPPC 
6043 - 12590 / 
165 - 343 
1.4321 ± 0.0323 7.4575 ± 0.1579 0.9997 ± 0.0002 2842 ± 197 126 
DSPE-mPEG 
4282 - 8920 / 
31 - 64 
1.7430 ± 0.0058 6.9389 ± 0.0027 0.9999 ± 0.0000 76 ± 5 535 
DPPG 
1321 - 2752 / 
35 - 74 
1.8183 ± 0.0416 4.3966 ± 0.2332 0.9984 ± 0.0009 15 ± 1 660 
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Figure 5: Calibration curves for simultaneous composition assessment of commonly used formulations modified with 
pentaglycine lipids. Calibration was performed in narrow ranges between 60-125 % of the expected sample 
concentration (1 mM total lipid) to enable simultaneous and rapid determination of low- and high-containing lipids. 
Linear relationships (Table 4) were obtained using a logarithmic fit according to the ELSD manufactures instruction, 
error bars show standard deviations of three calibrations on three different days. 
As the signal-mass response during evaporative light scattering detection typically follows an 
exponential relationship, we obtained good linearity (R2 > 0.999) after a logarithmic fit for every 
lipid except DPPG, which had slightly higher variability (R2 > 0.998). We checked the accuracy 
(Table 5) of the calibration over three consecutive days with freshly dissolved blends and found 
recovery rates between 97-100 % at day 0 for all lipids.  
Table 5: Accuracy. The recovery rate of the actual calibration was tested by analyzing individually prepared lipid 
solutions on three consecutive days. Standard deviations shown of three independent experiments. 
compound day 0 day 1 day 2 
DMA-PEG-G5 98.6 ± 0.9 %  98.8 ± 1.6 %  98.2 ± 1.2 %  
DMA-G5 98.9 ± 1.6 %  99.4 ± 4.5 %  97.1 ± 4.2 %  
R-DOTAP 100.7 ± 0.9 %  99.9 ± 0.9 %  99.0 ± 1.0 %  
CHOL 100.0 ± 0.8 %  99.4 ± 1.6 %  98.9 ± 2.2 %  
DPPC 100.0 ± 0.9 %  99.8 ± 1.9 %  99.6 ± 3.5 %  
DSPE-mPEG 100.3 ± 0.5 %  99.1 ± 0.3 %  98.0 ± 0.7 %  
DPPG 98.9 ± 0.9 %  94.8 ± 0.7 %  92.2 ± 0.9 %  
 
Similar recovery rates which resulted from calibration with analytical lipid blend ready mixes 
(Section 3.2) were achieved with blends stored up to 6 months at the described conditions, 
indicating the stability of the blends. Accuracy was constant for analysis over 3 consecutive days, 
only DPPG showed slightly decreasing recovery rates over time (Table 5).  
As we observed relevant degradation of an ethanolic R-DOTAP sample stored in ambient-
temperature autosampler in previous method developments (data not shown), we decreased 
the sample temperature to 4 °C in this method and investigated the sample stability, expressed 
as recovery rates of autosampler-stored samples with daily-actual calibrations (Table 6). We 
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found the lipids to be stable indicated by recovery rates ranging from 97 % to 100 %, however 
DPPG showed decreasing recovery rates down to 91 %. Sample instability may occur over time, 
for example precipitation of the sparingly soluble DPPG. Nevertheless, this does not explain the 
lower DPPG recovery of freshly prepared samples after inter-day-calibration analysis (Table 5). 
Furthermore, lipid precipitation in the diluent was excluded after visual inspection of HPLC vials 
stored for 2 days in the cooled autosampler using a cold light source. Avoidance of TFA 
fluctuations, increase of the injected sample mass to improve the SNR (Table 4) or slight gradient 
adaptions to enhance separation from DSPE-mPEG could be means to further improve the 
quantification of DPPG.  
Table 6: Sample stability. Stability of lipids in chloroform-methanol-water (4.5 : 4.5 : 1 v/v/v) was investigated as 
recovery rate of lipid solutions (n=3) of known concentrations stored in HPLC autosampler at 4 °C over two days.  
compound day 0 day 1 day 2 
DMA-PEG-G5 98.3 ± 0.7 %  97.3 ± 0.7 %  97.6 ± 0.3 %  
DMA-G5 98.9 ± 2.0 %  97.7 ± 0.8 %  96.9 ± 0.7 %  
R-DOTAP 100.4 ± 0.9 %  98.0 ± 1.7 %  96.9 ± 0.6 %  
CHOL 100.1 ± 0.9 %  99.2 ± 0.6 %  98.9 ± 0.2 %  
DPPC 100.0 ± 1.1 %  100.4 ± 0.7 %  100.1 ± 0.7 %  
DSPE-mPEG 100.2 ± 0.6 %  98.9 ± 1.1 %  97.6 ± 0.6 %  
DPPG 98.9 ± 1.1 %  97.7 ± 2.4 %  91.3 ± 1.8 %  
 
4.3. Application of the analytical method 
The preparation of liposomal formulations is a multistep process, involving blending of 
numerous lipids, the dissolution in organic solvents, extrusion or other homogenization 
processes, functionalization and purification steps. As lipids tend to be sticky compounds with 
the potential to adsorb to surfaces [37], the composition may change over the process. A proper 
analytical method for process monitoring is required. This is especially relevant for 
functionalized lipids like DSPE-mPEG, whose function as shield-layer around the drug carrier 
against the reticuloendothelial system of humans is widely described, and where definite 
correlations between molecular fraction in the bilayer and biological effect were revealed [30]. 
Same relevance has the quantification of lipids for the conjugation of targeting ligands, whose 
exact concentration is required for controlling consistent downstream process conditions. We 
applied an industry-relevant continuous solvent injection process [38] for the formation of 
pentaglycine-modified liposomes, followed by an easily scalable [39] tangential flow filtration 
step for purification and concentration. Here concentration changes may occur due to imperfect 
pump conveying, adsorption to the syringe, tubing or the membrane of the TFF device, as well 
as a wash-out of lipids during long-lasting crossflow process. Lipids for conjugation need to be 
inserted into the liposomal bilayer only to minor amounts, making the preparation of such 
blends in early development (usually small-scale) a demanding task due to very low weighed 
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portions. Larger exact blends were therefore prepared for two DMA-PEG-G5 containing 
formulations, aliquoted and dried as lipid film to be used as ready-to-use mix. The developed 
HPLC method was applied to monitor lipid amounts and composition throughout the 
preparation process (Table 7). It confirmed an accurate film preparation and re-dissolution in 
alcohols for injection with a DMA-PEG-G5 fraction of 1.0 mol%. Absolute lipid concentrations 
were in a suitable range for both formulations (recoveries > 95 %). Especially latter is highly 
relevant for reproducible particle size distributions during solvent injection processes [40]. The 
concentration of DPPG was about 1 mol% lower than expected from weighing. Jeschek et al. 
reported slight losses of phosphatidylglycerols during a film hydration and extrusion process and 
attributed the differences to weight and transfer losses or solubility reasons [8]. Those or above-
mentioned recovery issues may explain the observed decrease here. 
Table 7: Purification of liposomes using tangential flow filtration. Particles were prepared by solvent injection and 
purified and concentrated by TFF. Lipid composition and lipid mass recovery was evaluated by monitoring lipid 
concentration during liposome preparation. Analyses for lipid stock values done for two (PEG-NP) or one (Anionic-NP) 
individual blend preparations analyzed in triplicate. Analyses of liposomes after solvent injection and TFF done for 
three liposomal batches.  
PEG-NP molecular bilayer composition [mol%] 
  theoretical lipid stock solvent injection TFF 
DMA-PEG-G5 1.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 
CHOL 34.7 34.4 ± 0.3 34.0 ± 0.4 33.8 ± 0.4 
DPPC 59.4 59.9 ± 0.5 60.2 ± 0.4 60.6 ± 0.3 
DSPE-mPEG 5.0 4.7 ± 0.1 4.7 ± 0.1 4.6 ± 0.1 
absolute conc. [mM] 90.1 85.7 ± 1.9 6.7 ± 0.1 25.4 ± 4.3 
recovery [%]  95.1 ± 2.0 97.4 ± 2.7 92.0 ± 7.0 
      
Anionic-NP  molecular bilayer composition [mol%] 
  theoretical lipid stock solvent injection TFF 
DMA-PEG-G5 1.0 1.0 ± 0.0 n.d. 1.0 ± 0.0 
CHOL 34.7 34.6 ± 0.1 n.d. 34.5 ± 0.2 
DPPC 59.3 60.5 ± 0.1 n.d. 60.6 ± 0.2 
DPPG 5.0 4.0 ± 0.1 n.d. 3.9 ± 0.1 
absolute conc. [mM] 16.0 16.0 ± 0.1 n.d. 26.2 ± 2.9 
recovery [%]  99.7 ± 0.7 n.d. 88.4 ± 9.9 
 
We were able to reproducibly prepare and purify liposomes within a size range of 150 nm 
(± 10 %) with acceptable polydispersity (< 0.25) without applying any further homogenization 
steps (Table 8). Zeta potential was -8 mV for PEGylated and -23 mV for liposomes being 
stabilized via a pronounced anionic surface charge, respectively, which is comparable to 
previously reported formulations [41, 42]. The pumps for solvent injection worked with good 
reliability, shown by the 97 % lipid recovery calculated from the theoretical concentration based 
on the flow rates. 
Tangential flow filtration was used to exchange the external buffer ammonium sulfate to DPBS 
and to concentrate the liposomal dispersions to a target concentration of 30 mM, required for 
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downstream processes like drug loading and ligand modification. The lipid composition did not 
change during processing, especially the relevant conjugation-lipid DMA-PEG-G5 maintained its 
molar fraction of 1.0 mol%. Furthermore, good lipid yields around 90 % were obtained from TFF 
equipment, indicating low loss due to adsorption to the membrane or hold-up volume of the 
system. 
Active loading is the state of the art technology in liposomal drug delivery achieving high drug 
loads and encapsulation efficacies for small molecules that can be retained interior of vesicles 
by charge, salt formation, precipitation or complexation mechanisms [43]. The combination of 
scalable manufacturing techniques for sortaggable liposomes, widely applicable active loading 
and versatile analytics would offer a broad platform for the industrial development of targeted, 
toxin-loaded liposomes. We therefore analyzed if the pentaglycine-modified liposomes could be 
actively loaded with a model compound, acridine orange, and fluorescence analysis [44] showed 
a quick accumulation inside the liposomes for both formulations (data not shown in publication, 
meanwhile displayed in Chapter 6, Figure 2). This indicates a stable ammonium sulfate gradient 
generation by tangential flow filtration, suitable for the active loading of weak bases like 
doxorubicin [43], an active compound compatible with the presented analytical method (Figure 
4).  
Sortase-A technology [23] was then used to modify the pentaglycine-liposomes with a LPETG-
modified model VHH specific for the enhanced green fluorescent protein (eGFP) [45]. This 
transpeptidation reaction offers site-specific ligand conjugation to the drug delivery system 
yielding a homogenous product profile, what is highly desired for quality controls and regulatory 
authorities. A mix of Sortase-A, LPTEG-modified VHH and pentaglycine-modified liposomes was 
incubated for 4 h to allow VHH coupling. Dynamic light scattering showed no relevant changes 
of the hydrodynamic diameter or the polydispersity index, indicating that no sub-visible 
precipitation or aggregation occurred (Table 8).  
Table 8: Physical properties of liposomes before and after incubation of liposomes with 25 µM Sortase-A and 50 µM 
VHH. Standard deviations shown for experiments done with three liposome batches.  
formulation process step dh [nm] PDI zeta potential [mV] 
PEG-NP before reaction 143 ± 5 0.24 ± 0.00 -8.1 ± 0.4 
after reaction 138 ± 4 0.24 ± 0.01 -6.1 ± 0.4 
Anionic-NP before reaction 148 ± 1 0.24 ± 0.02 -23.3 ± 0.6 
after reaction 152 ± 1 0.23 ± 0.01 -18.1 ± 1.2 
 
Furthermore, minor changes (PEG-NP: -2 mV, Anionic-NP: -5 mV) in zeta potential were 
detected, hinting at surface modifications, however the small absolute changes can also be 
attributed to measurement fluctuations. Influence of the reaction on the molar fraction of 
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DMA-PEG-G5 in the bilayer of three liposomal batches was analyzed after dissolution of the 
liposomes in diluent and removal of precipitated protein by centrifugation. This procedure had 
no impact on the accuracy as verified by analysis of an accuracy sample spiked with VHH and 
Sortase-A prior diluent addition (Supplementary Table 2). Statistically significant decreases 
down to 0.87 ± 0.02 mol% for PEG-NP (p < 0.005) and 0.88 ± 0.01 mol% for Anionic-NP 
(p < 0.009) were found. Roughly half of the pentaglycine molecules are expected to be present 
at the outer bilayer leaflet due to homogenous lipid distribution during vesicle formation after 
solvent injection. As only those are accessible for Sortase-A reaction, this decrease indicates that 
about 24 % of the accessible lipids have reacted with the VHH, however further protein-based 
methods for direct protein quantification are required to give valid statements on reaction 
efficacy and VHH-load on the drug delivery system. 
5. Conclusion and outlook 
A versatile rp-HPLC-based analytical method applying evaporative light scattering detection was 
developed for numerous liposomal concepts. It covers formulations with different particle 
surface properties by separation of positive (R-DOTAP), negative (DPPG) or PEGylated lipids 
(DSPE-mPEG) from frequently used phosphatidylcholines (DPPC, HSPC, DSPC) and cholesterol. 
Furthermore, pH-sensitive lipid combinations of CHEMS with DOPE or dye-labeled (DiR, 
Liss-Rhod-PE) formulations can be analyzed. Conjugation of ligands towards liposomes for a 
targeted drug delivery requires integration of reactive lipid anchors in the bilayer. These lipids 
include novel pentaglycine lipids for Sortase-A mediated chemoenzymatic conjugation 
(sortagging) of proteinaceous ligands. Two variants of pentaglycine lipids could be quantified 
simultaneously with above mentioned excipients, ensuring analyzability of various bilayer 
combinations. This completes the proposed analytical method as a supportive tool in 
formulation screens for targeted drug delivery.  
The method validation for the pentaglycine lipids and selected helper lipids showed good 
analytical performance. The bilayer fraction of DMA-PEG-G5 in an anionic and in a PEGylated, 
DPPC-based liposomal formulation was tracked over an industry-relevant manufacturing 
process. Results obtained with the newly developed method indicated no adsorption to surfaces 
of the instruments and materials being in use in production, or wash-out during cross-flow 
filtration. This shows a stable bilayer anchoring of the pentaglycine moiety by the two myristyl 
chains. A subsequent sortagging reaction was monitored by following the decrease of the 
pentaglycine substrate fraction in the bilayer due to the coupling with a single-domain antibody.  
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Besides the here extensively described process monitoring of rigid, DPPC-based liposomal 
formulations, we utilized the method in our lab to successfully analyze other sortaggable 
liposomal constructs. This included analysis of a Doxil® like doxorubicin-loaded stealth liposome 
formulation (DMA-PEG-G5 : DSPE-mPEG : CHOL : HSPC) and PEGylated, pH-sensitive liposomes 
(DMA-PEG-G5 : DSPE-mPEG : CHEMS : DOPE).  
Proceeding work for the lipid characterization of sortaggable liposomes may involve the 
separation and quantification of lipid degradation products. This would be especially relevant 
after the required lipid combination was chosen from first in vitro or in vivo screenings. Within 
the current method, analysis of lipid degradation products may be feasible by expansion of the 
gradient towards more hydrophilic fractions. However, this will probably lead to extended 
analysis times, which is less desired for preliminary formulation screening experiments and was 
therefore not in scope of this method development. 
On the contrary, due to the fast and versatile approach, the here presented reliable 
quantification of numerous lipid combinations together with sortaggable lipids can help to 
accelerate a rational early formulation development of targeted liposomal systems.  
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Supplementary Data 
Supplementary Table 1: Retention time is independent of the applied injection volume.  
  retention time [min] 
injection volume [µL] DMA-PEG-G5 DMA-G5 R-DOTAP CHOL DPPC DSPE-mPEG DPPG 
50 4.37 4.65 5.43 6.98 7.88 10.67 12.17 
42 4.38 4.67 5.45 7.01 7.92 10.74 12.24 
38 4.37 4.65 5.44 7.00 7.91 10.79 12.25 
32 4.36 4.65 5.44 7.00 7.91 10.84 12.39 
24 4.36 4.65 5.44 7.00 7.91 10.88 12.09 
 
Supplementary Table 2: Influence of protein presence on lipid quantification accuracy. 50 µM VHH ENH and 25 µM 
Sortase-A were spiked to an aqueous lipid blend, and the reaction was immediately quenched by dilution of the blend 
in the diluent methanol-chloroform (1:1, v/v). Precipitated proteins were removed by centrifugation. Two individual 
mixtures were analyzed in duplicate runs.  
compound target [µM] recovery n1 recovery n2 
DMA-PEG-G5 13.7 101 % 102 % 
DMA-G5 12.5 103 % 97 % 
R-DOTAP 49.5 101 % 102 % 
CHOL 276.7 104 % 103 % 
DPPC 264.2 104 % 105 % 
DSPE-mPEG 51.5 105 % 106 % 
DPPG 60.7 92 % 98 % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is published as: Wöll, S., Bachran, C., Schiller, S., Schröder, M., Conrad, L., Swee, L.K., 
Scherließ, R.: Sortaggable liposomes: Evaluation of reaction conditions for single-domain antibody 
conjugation by Sortase-A and targeting of CD11b+ myeloid cells.  
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https://doi.org/10.1016/j.ejpb.2018.09.017 
 
 
 
 
Chapter 3 
Sortaggable liposomes: Evaluation of 
reaction conditions for single-domain 
antibody conjugation by Sortase-A and 
targeting of CD11b+ myeloid cells 
    
 
 
 
Abstract 
 
51 
Abstract 
Active targeting with ligand coated liposomal drug delivery systems is a means to increase the 
therapeutic index of drugs. Stable ligand coating requires bilayer anchorage of the commonly 
proteinaceous ligands and hence a conjugation of lipid structures towards amino acids. This 
often leads to heterogeneous reaction products especially when chemical coupling methods are 
employed. Chemoenzymatic Sortase-A mediated transpeptidation (sortagging) is a useful tool 
to avoid this protein heterogeneity through its site-specific, bioorthogonal ligation mechanism. 
Manufacturing of such sortaggable, pentaglycine-modified liposomes was developed by 
adaption of a scalable solvent injection technique. The pentaglycine liposomes were prepared 
with different degrees of PEGylation and steric accessibility of the pentaglycine motif. 
Comparable hydrodynamic diameters (146-188 nm) of the different formulations were obtained 
after a flow rate screening. The sortagging reactivity of a single-domain antibody (VHH) towards 
the pentaglycine liposomes was strongly dependent on the steric accessibility of the 
pentaglycine nucleophile. Adjusting the pentaglycine to ligand ratio improved conversion rates 
up to 80 %. The liposome-bound VHH was accessible for its soluble antigen as shown by a 
chromatography-based binding assay. Mono- and granulocytes could be selectively targeted in 
vitro by conjugation of BMX1, a VHH directed towards human myeloid cell surface marker 
CD11b. Confocal microscopy revealed intracellular localization of the targeted liposomes. The 
developability of those pentaglycine liposomes as well as their proof of principle for targeted 
drug delivery shows their potential for further investigation, for example as delivery platform 
for diagnostics or drugs into the tumor microenvironment.
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1. Introduction 
The therapeutic index is one of the most crucial criteria for a novel drug. A means to increase 
the therapeutic index is the site-selective delivery of drugs to affected cells while avoiding side 
effects on healthy tissues. This “concept of the magic bullet” introduced by Paul Ehrlich remains 
a highly desirable aim in pharmaceutical research [1]. Significant progress has been achieved 
with targeted therapies utilizing antibody-drug conjugates [2] or “actively”, meaning ligand 
mediated targeted drug delivery systems such as liposomes [3]. A key technology in the design 
of actively targeted liposomes is the conjugation between ligand and drug carrier [4]. The 
conjugation reaction between labile ligands and liposomes should be feasible under mild 
conditions in aqueous environment, it should conjugate expensive proteins with high yields and 
deliver homogenous reaction products that are reliably anchored in the bilayer. First attempts 
attached targeting motifs in an adsorptive fashion [5, 6], followed by covalent IgG coupling with 
unspecific amine-cross linkers [7], disulfide [8] and thiol-maleimide chemistry [9] or more 
sophisticated methods, as reviewed by Marques-Gallego et al. [4]. Although conjugation 
methods evolved towards regio-specific reactions [10], these strategies are still not routinely 
used for ligand attachment in current scientific reports. This is probably due to their superior 
applicability for small targeting entities [11-13] rather than large proteins and the requirement 
of substrates with difficult commercial accessibility [14]. Amongst other enzymatic methods 
[15], the chemo-selective, bioorthogonal Sortase-A mediated conjugation (sortagging) of 
proteins to liposomes [14] or lipid anchors [16, 17] has been shown as a convenient and efficient 
tool to overcome these hurdles. Sortase-A transpeptidase is derived from Staphylococcus 
aureus, where it physiologically anchors surface proteins in the bacterial cell wall. It recognizes 
a C-terminal LPxTG (leucine, proline, any amino acid, threonine, glycine) motif and forms a 
thioacyl intermediate with the threonine while cleaving the amide bond towards the glycine. 
This is followed by the transpeptidation reaction with an incoming nucleophilic N-Terminus of 
oligoglycines [18] or other primary amines [19, 20]. Sortase-A is used in several isoforms 
developed with different technological advantages such as Ca2+-independency [21] or a shift of 
the pH-optimum to the weakly acidic spectrum [22]. Several studies have investigated Sortase-A 
as a tool to promote linkage between model proteins or ligands and single lipid structures [16], 
recognition motif carrying vesicles [14, 22-24] or even whole cells [17]. Main advantage of the 
Sortase-A reaction is the inherent site-selectivity, which leads to homogeneous conjugation 
products [18]. This is a decisive advantage over traditional chemical linkage approaches 
considering regulatory demands on product uniformity and quality controls.  
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Scheme 1: Sortase-A mediated reaction of a LPETG-modified VHH with pentaglycine-modified liposomes. Sortase-A 
recognizes LPETG-modified single-domain antibodies (VHHs) and forms a thioester-intermediate between the VHH’s 
threonine and a cysteine residue at the active site of the enzyme. The amino-group of a liposome-anchored 
oligoglycine serves as nucleophile, which forms a peptide bond between the targeting ligand (the VHH) and the 
liposome in a transpeptidation reaction.  
To apply Sortase-A technology for manufacturing of targeted liposomes (Scheme 1), the relevant 
transpeptidation motif, typically an oligoglycine, is conjugated to a lipid component serving as 
anchor molecule [14, 16, 24]. The synthesis of such amino acid lipids circumvents involvement 
of labile proteins and liposomal structures during the critical linkage between amino acids and 
the lipid anchor. Therefore, it can be conducted as chemical synthesis, e.g. on a solid phase [25]. 
The subsequent conjugation between ligand and amino acid lipid can be done on enzymatic, 
meaning site-selective basis by a transpeptidation, forming a peptide bond between the protein 
and amino acid lipid [4]. This approach yields chemically defined reaction products without 
implications on ligands paratope regions. Sortase-A reaction conditions for modification of 
soluble substrates have been investigated in various studies [18]. However, the enzymatic 
reaction behavior of artificial surfaces, such as differently polyethylene glycol coated 
(PEGylated) bilayers, might greatly differ from the ideal reaction behavior of soluble substrates. 
Silvius et al. [23] examined various glycine-nucleophiles integrated in non-PEGylated, fluid 
DOPC/POPG vesicles for their reaction kinetics with a model protein (green fluorescent protein, 
GFP) or a human enzyme. The authors showed a dramatic increase of conversion rates for 
membrane-bound Sortase-A over a soluble one. Furthermore, Guo et al. [14] revealed a 
drastically reduced reaction efficacy of a glycine-motif hidden by a surrounding PEG-layer for 
the conjugation of GFP. As PEGylation is a key factor for the in vivo fate of nanotherapeutics 
[26], it is of high importance to carefully adjust the degree of PEGylation for targeted liposomes. 
To gain deeper insights in PEG- and surface dependent Sortase-A reactivity, we altered a 
liposomal surface either by integration of PEGylated (2 kDa) distearoyl-
phosphatidylethanolamine (DSPE) or anionic dipalmitoyl-phosphoglycerol (DPPG) as an 
alternative stabilizing agent. A PEG-spaced or a bilayer-proximal located pentaglycine motif was 
SH
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integrated in the composition. This enabled the investigation of the reaction conditions of 
Sortase-A mediated ligand attachment towards liposomes with closely similar bilayer properties, 
but clear differences in surface properties and steric accessibility of the reaction partner 
(Scheme 2). Tabata et al. [22] investigated reaction conditions of a pH-sensitive Sortase-A 
mutant with a model protein (GFP) or a peptide for lung cancer targeting [24]. As the latter was 
the only report where a liposomal drug delivery system was modified by Sortase-A with a 
targeting ligand, it was here the intention to gain further insights into the conjugation of 
antibody-derived ligands with respect to the liposomal surface properties. Therefore, we here 
employed a sortaggable single-domain antibody [27] for kinetic investigations of the conjugation 
towards liposomal surfaces differing in PEGylation and steric accessibility of the pentaglycine 
motif. Single-domain antibodies or VHHs (single-domain antibody of camelid heavy-chain only 
antibodies) are promising candidates as novel targeting ligands for drug delivery systems [28]. 
They provide favorable physicochemical properties like high refolding capacity [29], high 
solubility, affinity and specificity comparable to Fab’ ligands [30, 31] while their molecular 
weight is drastically reduced to ≈15 kDa. This is advantageous for the colloidal stability and 
physiologic behavior of nanomedicines due to the low impact on size and weight of the 
particulate construct, even at high ligand densities. VHHs have been reported as liposomal 
targeting ligands against model proteins [32] and the cellular targets HER2 [33], EGFR [34-37] 
and HIV-1 env [38].  
To demonstrate proof of concept for a targeted drug delivery with the presented sortaggable 
liposomes, dye-labeled liposomes were modified with a novel VHH against human CD11b and 
tested in vitro for their selective binding and uptake in human peripheral blood mononuclear 
cells (hPBMCs). CD11b is a cell surface marker found on myeloid cells in the tumor 
microenvironment such as myeloid-derived suppressor cells (MDSC). MDSC are a 
heterogeneous cell population involved in the control of immune responses of several 
inflammatory and proliferative diseases [39]. A drug targeting to such cells would therefore offer 
new opportunities in the treatment of cancer or autoimmune diseases via an 
immunomodulatory approach [40]. 
In the presented work, a solvent injection process was chosen to prepare pentaglycine-modified 
liposomes due to the technique’s inherent scalability and the option to control product 
characteristics by rational parameter selection [41]. Firstly, this tunable process was adjusted to 
obtain liposomes with comparable size distribution, but different surface structures, in 
particular the steric accessibility of the pentaglycine moiety (Scheme 2). Secondly, we 
thoroughly evaluated the reaction kinetics and optimized conditions of Sortase-A mediated VHH 
conjugation for these formulations. To investigate whether the VHHs grafted on the liposome 
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surface maintained their ability to bind their corresponding antigen, a size exclusion 
chromatography-based assay was employed. Finally, the CD11b-dependent specific binding and 
uptake of selected formulations by hPBMCs was investigated. The presented work therefore 
provides a profound development of sortaggable liposomal formulations combined with a 
detailed investigation of a novel conjugation technique. In addition, proof of principle for a 
targeted drug delivery utilizing a promising class of antibody species against an exploratory 
target is demonstrated, enabling a deeper investigation of nanoparticulate drug delivery 
systems in rising therapeutic areas like immuno-oncology. 
 
Scheme 2: Differently PEGylated, pentaglycine-modified formulations. Formulation A and B are stabilized through a 
PEG-shell, whereas formulation C and D are stabilized via an anionic phosphoglycerol (DPPG).  
2. Materials 
Pentaglycine-modified lipids (Merck & Cie, Schaffhausen, Switzerland) consist of a dimyristyl-
amino-propandiol scaffold (DMA) linked directly (DMA-G5, 897 Da, formulation B and D, 
Scheme 2) or via a 2 kDa PEG spacer (DMA-PEG-G5, 2554 Da, formulation A and C, Scheme 2) to 
a pentaglycine-motif (G5) and are described in detail in [42]. 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DPPG), 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] 
(DSPE-mPEG) were a kind gift of Lipoid GmbH (Ludwigshafen, Germany). Dulbecco’s phosphate 
buffered saline (DPBS D1408, 10fold stock), FITC-dextran 10 kDa, cholesterol (CHOL) and 
Triton X-100 were obtained from Sigma-Aldrich (St. Louis, MO, USA). 1,2-dipalmitoyl-sn-glycero-
3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (Liss-Rhod-PE) was obtained from 
Avanti Polar Lipids (Alabaster, AL, USA). Acetonitrile, trifluoroacetic acid (TFA), sodium chloride 
(NaCl), hydrochloric acid (HCl), methanol and ethanol (both gradient grade) as well as 
dimethylsulfoxide (DMSO) were obtained from Merck KGaA (Darmstadt, Germany). Water was 
purified by a Milli-Q system (Merck Millipore, Billerica, MA, USA). LPETG (leucine, proline, 
glutamic acid, threonine, glycine)-modified single-domain antibodies of camelid heavy-chain 
only antibodies (VHH) VHH ENH (14237 Da), VHH BMX1 (16541 Da) and Sortase-A variant 
SortA7m were prepared as described in [40]. VHH BMX1 was obtained by phage display from an 
alpaca immune library (supplementary information). Enhanced green fluorescent protein (eGFP) 
was prepared as described in [43].  
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3. Methods 
3.1. Liposomal formulation development 
Pentaglycine-modified liposomes were prepared by a continuous solvent injection process. 
Either DMA-PEG-G5 or DMA-G5 were combined with a DSPE-mPEG or DPPG containing lipid 
blend (Table 1). Lipid blends for formulation A and B were dissolved in ethanol to 90 mM, blends 
for formulation C and D were dissolved in methanol to 32 mM. Due to solubility reasons, 
DMA-G5 was spiked to the alcohol solution from a DMSO solution (5 mg/mL). Lipid solutions 
were filled into a plastic syringe (B. Braun, Melsungen, Germany) and injected utilizing a syringe 
pump (PHD Ultra4400, Harvard Apparatus, Holliston, MA, USA) into a stream of DPBS pH 7.4 
conveyed by a peristaltic pump (Ismatec IP65, Cole-Parmer, Wertheim, Germany). A 
combination of flexible tubing (3.2 mm inner diameter, PharMed BPT, Saint Gobain, Courbevoie, 
France) and rigid tubing (2.0 mm inner diameter, Bola FEP, Bohlender GmbH, Grünsfeld, 
Germany) was used to reduce overall dead volume. Lipid and buffer stream were connected via 
a stainless-steel T-piece (Unimed SA, Lausanne, Switzerland), which was customized with a 27 G 
needle for lipid injection. Different flow rate combinations were applied to screen the resulting 
dispersions for hydrodynamic diameter (dh) and polydispersity index (PDI) with short injection 
times of 1-2 s. Selected flow rates (formulation A and B: 80 and 10 mL/min, formulation C and 
D: 90 and 13.5 mL/min for buffer and lipid flow rate, respectively) were used to prepare four 
different formulations in larger scales applying injection times of 12 s (formulation A and B, 
yielding ≈130 mg total lipid) or 19 s (formulation C and D, yielding ≈87 mg total lipid). The 
dispersions were purified from alcohol and concentrated using a tangential flow filtration 
process (TFF) as described in [42]. Liposomes were stored in Teflon-sealed vials at 4 °C and 
analyzed regarding physical stability. For in vitro experiments, formulation A and C were labeled 
in a dual dye approach. FITC-Dextran 10 kDa was dissolved to 10 mg/mL in the injection buffer 
to label the aqueous liposomal core. The liposomal bilayer was stained by adding 0.1 mol% 
Liss-Rhod-PE to the alcohol stock solution. Labeled liposomes were purified by tangential flow 
filtration as described above.  
Table 1: Theoretical molecular lipid compositions (mol%) of differently PEGylated and charged formulations A-D.  
formulation DMA-PEG-G5 DMA-G5 DPPC CHOL DSPE-mPEG DPPG 
A 1.0 - 59.4 34.7 5.0 - 
B - 1.0 59.4 34.7 5.0 - 
C 1.0 - 59.4 34.7 - 5.0 
D - 1.0 59.4 34.7 - 5.0 
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3.2. Liposome characterization 
Liposomal mean hydrodynamic diameter (dh) and PDI were measured by dynamic light 
scattering using the DynaPro Plate Reader II (Wyatt, Santa Barbara, CA, USA) in a 96-half-well 
plate (#3679, Corning Inc., Corning, NY, USA). Liposomes were diluted with DPBS in triplicate 
wells to 3 % (v/v) of the initial lipid concentration to diminish influence of alcohol on 
measurement and to obtain dispersions with suitable turbidity (normalized intensity: 
107-109 counts/s) for dynamic light scattering. Laser power and attenuation were determined 
automatically. 100 µL sample per well were equilibrated at 25 °C, rested for 5 min, and data was 
acquired over 10 acquisitions with each 5 s. Data was processed with Dynals cumulants analysis 
(Dynamics V7.1.7), results of each well were averaged. 
Zeta potential was determined by laser Doppler electrophoresis (Malvern Zetasizer Nano ZS, 
Worcestershire, UK). 30 µL liposomal sample were diluted in 970 µL 10 mM NaCl (resulting 
sample pH: 7.4) and filled into a capillary cell (DTS1070). The sample was equilibrated at 25 °C 
for 1 min, after which zeta potential was measured with minimum 10 runs and automatic 
attenuation and voltage selection. Typical conductivity and count rate were between 1-2 mS/cm 
and 60-400 kcounts/s. Data was analyzed using Smoluchowski model, three measurements per 
sample were averaged.  
Pentaglycine and further lipid quantification was performed using an rp-HPLC-ELSD 
chromatographic method as described in [42]. FITC-dextran content was determined by 
fluorimetry (M200 plate reader, Tecan Group, Männedorf, Switzerland) after lysis of the 
liposomes with Triton X-100. 
3.3. Ligand conjugation, monitoring of transpeptidation and final purification 
Sortase-A variant SrtA7m was used to promote transpeptidation between LPETG-modified 
single-domain antibodies and pentaglycine-modified liposomes. To investigate reaction kinetics, 
liposomes (100 µM, based on pentaglycine content) were mixed with 5-50 µM VHH ENH, 
25 µM Sortase-A and incubated at 4 or 37 °C over 14 h. Reaction was monitored in 30 min 
intervals by an rp-HPLC-based method that separated Sortase-A and unbound VHH from lipid-
modified VHH and further liposomal components. This method utilized an Aeris Widepore 
column (stationary phase: C4, particle size: 3.6 µm, dimensions: 100 mm x 2.1 mm, 
manufacturer: Phenomenex, Torrance, CA, USA). Eluent A was 0.1 % TFA in water, eluent B 
0.05 % TFA in acetonitrile. Eluent profile started with 95 % of eluent A with a gradient phase to 
45.5 % A (5.5 min), followed by a shallow gradient phase to 18.5 % eluent A (15.0 min), a steep 
shift to 5 % eluent A until 18.0 min, followed by a flushing step at initial conditions until 27.5 min. 
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5 µL of the reaction mixture were injected and analyzed for the reaction product using UV-
detection at 280 nm. Conversion rate was calculated according to Equation 1, where ti is the 
timepoint of interest, Aconjugate the peak area of the conjugate and AVHH the peak area of the native 
VHH at the initial concentration (c0) at the start of reaction. No relevant shift in UV-absorption 
coefficient by the lipid modification was observed. All reactions were monitored in triplicate. 
Statistical analysis (One-Way Anova, all pairwise multiple comparison procedures using the 
Holm-Sidak method) was conducted for 14 h values of all recorded reaction kinetics and showed 
significant differences (p < 0.05) for all combinations. 
Equation 1 
𝑐𝑐𝑜𝑜𝑖𝑖𝑐𝑐𝑦𝑦𝑎𝑎𝑐𝑐𝑦𝑦𝑜𝑜𝑖𝑖 [%] 𝑎𝑎𝑜𝑜 𝑜𝑜𝑑𝑑 = 𝐴𝐴𝑐𝑐𝑆𝑆𝑑𝑑𝑐𝑐𝑐𝑐𝑐𝑐𝑆𝑆𝑆𝑆𝑆𝑆(𝑜𝑜𝑑𝑑�𝐴𝐴𝑉𝑉𝑉𝑉𝑉𝑉(𝑐𝑐0) ∗ 100 
To verify the reaction product by mass spectrometry, the method was transferred to a similar 
HPLC system equipped with an ESI-MS (amaZon SL, Bruker Corporation, Billerica, Massachusetts, 
USA). Ion source type was set to ESI with positive polarity. Capillary exit was 140 V, trap drive 
was set to “94”. The mass range mode was set to enhanced resolution, with a scanning range 
from 100-2200 m/z. 5 spectra were averaged per run and the molecular masses were 
determined by deconvolution.  
Absolute concentrations of VHH on the liposomes were determined from the conjugate peak 
area and a calibration curve based on unmodified VHH (4 point, 5-50 µM, R2 = 0.999). Liposome 
count per volume was estimated from lipid content, an average lipid headgroup area of 0.6 nm2, 
a bilayer thickness of 5 nm, the hydrodynamic diameter and the assumption of spherical, 
unilamellar liposome appearance [44]. 
To evaluate Sortase-A concentration influence on reaction, 30 µL of 10 µM VHH ENH, liposomes 
(100 µM of pentaglycine lipid) and various concentrations of Sortase-A were incubated in DPBS 
for 4 h at 4 °C. The reaction was stopped by addition of 15 µL 1 N HCl as described by Kruger et 
al. [45]. Effective suppression of transpeptidation was tested by spiking equal amounts of HCl to 
the reaction mixture prior to Sortase-A addition. No enzyme activity was found at these 
conditions (pH < 1.0). Conversion extent was determined based on the peak area at 280 nm of 
6.66 µM VHH ENH.  
For in vitro experiments, liposomes were incubated with either 50 µM of non-binding isotype 
control VHH ENH (“ENH-liposomes”) or human CD11b binding VHH BMX1 (“BMX1-liposomes”) 
and 25 µM Sortase-A for 4 h at 4 °C. Liposomes for in vitro experiments were purified from 
unbound VHH and Sortase-A by dialysis (Float-A-Lyzer, MWCO 1000 kDa, G235037, Spectrum 
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Labs, Los Angeles, CA, USA) against 100-200fold acceptor medium (DPBS) with three buffer 
changes over 24 h. 
3.4. Liposomal antigen capturing 
The four liposomal types (Scheme 2) with differently accessible pentaglycine motif were 
incubated (100 µM pentaglycine lipid) with 50 µM VHH ENH and with or without 25 µM 
Sortase-A for 4 h at 4 °C to assess the effect of covalent, Sortase-A mediated VHH conjugation 
compared to a potential passive VHH adsorption. After dialysis and lipid quantification, 1 mM 
liposomes (based on total lipid content) were mixed with 15 µM eGFP (enhanced green 
fluorescent protein) and incubated for at least 30 min. Liposome-eGFP mixture was then 
separated by analytical size exclusion chromatography based on a method published earlier [46] 
utilizing a Tosoh TSKgel PWxL G4000 (length: 30 cm, diameter: 7.8 mm, particle size: 10 µm). 
Column temperature was set to 25 °C, eluent was the liposomal medium buffer DPBS pH 7.4, 
flow rate was 0.6 mL/min and the overall run time 30 min. eGFP was detected using a 
fluorescence detector (Agilent Technologies, Santa Clara, California, USA) with excitation set to 
494 nm, emission 510 nm and gain of photomultiplier tube set to 8. Chromatograms were 
merged to visualize differences in eGFP binding.  
3.5. Cell culture and in vitro binding 
hPBMCs were obtained from remainders of blood donations from healthy volunteers. Written 
consent was obtained from all donors. Human whole blood leukocytes were isolated by lysis of 
red blood cells. 1 mL of blood was incubated with 9 mL ACK lysis buffer (Thermo Fisher Scientific, 
#A1049201) for 5 min at room temperature and centrifuged for 5 min at 300 × g. The pellet was 
resuspended in FACS buffer (1 × PBS with 2 % heat-inactivated fetal bovine serum (Life 
Technologies, #10270106) and cells were counted after pipetting through cell strainer (Corning, 
#352350).  
For FACS binding experiments, 0.5 × 106 cells were seeded in a total volume of 200 µL complete 
RPMI: RPMI1640 medium (Life Technologies, #21875-034) supplemented with 10 % heat-
inactivated fetal bovine serum, 100 U/mL penicillin (Life Technologies, #15140122), 100 µg/mL 
streptomycin (Life Technologies, #15140122), 1 mM sodium pyruvate (Life Technologies, 
#11360070), 50 µM 2-mercaptoethanol (Life Technologies, #31350-010), and 1 × non-essential 
amino acids (Life Technologies, #11140-035). 100 µM liposomes (based on total lipid content of 
FITC- and rhodamine-labeled formulation A and C, either as pentaglycine-coated control, 
VHH ENH-coated or VHH BMX1-coated sample) were added to each sample in V-bottom-shaped 
96-well plates and incubated at 37 °C for 4 h in the presence of 5 % CO2. Medium containing 
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unbound liposomes was removed by centrifugation (300 × g for 1 min) and cells were washed 
with FACS buffer. Antibody staining of cells was performed in presence of Fc receptor block 
(TruStain fcX BioLegend, #422302) in FACS buffer. SytoxBlue (Thermo Fisher Scientific, S34857) 
was used for exclusion of dead cells. Following antibodies from BioLegend were used for flow 
cytometry: allophycocyanin (APC)-Cy7-anti-CD14 (#325620) or APC-anti-CD15 (#323008) or 
biotin-anti CD3 (#317320) or biotin-anti-CD19 (#302203) and streptavidin-APC (#405207) for 
biotin-conjugated antibodies. 
3.6. Confocal microscopy 
For confocal microscopy, 0.5 × 106 cells were seeded in a total volume of 200 µL complete RPMI. 
100 µM liposomes were added to each sample in V-bottom-shaped 96-well plates and incubated 
at 37 °C for 4 h in the presence of 5 % CO2. Cells were stained with CellMask Deep Red Plasma 
membrane stain (1:5000) (Life Technologies, #C10046) and Hoechst 33342 (1:2000) (Thermo 
Scientific, #62249) for 15 min at 37 °C in the presence of 5 % CO2. The medium was removed by 
centrifugation (1 min at 300 × g), cells washed with FACS buffer and transferred in 100 µL FACS 
buffer on polyethyleneimine-coated cover slips (microscope cover glasses from Marienfeld, 
18 mm diameter, #0117580) and incubated for 10 min at 37 °C. Cells were fixed on cover slips 
with paraformaldehyde (final concentration 4 %) for 15 min. Cover slips were washed with 1fold 
PBS and mounted on cover glass (neoLab, #1-6273) using anti-fade ProLong Diamond mounting 
medium (Invitrogen, #P36961). The cells were analyzed after 18 h with a Leica TCS SP5 confocal 
microscope using HCX Plan APO 40 × /1.30 Oil CS objective. For image analysis Leica Application 
Suite software was used. 
4. Results and discussion  
4.1. Liposomal formulation development 
Adapting a continuous solvent injection technique, differently PEGylated and pentaglycine-
modified liposomes (Table 1, Scheme 2) in comparable size ranges were prepared as substrates 
for kinetic investigations. The formation of liposomes via solvent injection is based on a solvent-
antisolvent mixing process followed by a self-assembly [41] of the lipids in an aqueous buffer. 
Therefore, this technique requires a complete solution of lipid excipients in a water miscible 
organic solvent to ensure homogenous lipid distribution upon liposome formation. Major lipids 
DPPC, cholesterol and DSPE-mPEG (formulation A and B) were well soluble in ethanol. DPPG has 
low solubility in alcohols and limited the choice of solvents for formulation C and D to methanol 
with a maximum total lipid concentration of 32 mM. DMA-PEG-G5 easily dissolved in 
aforementioned solvents. Due to its limited solubility, non-PEGylated DMA-G5 was spiked from 
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a DMSO stock solution to the alcoholic solutions of major lipids prior solvent injection. No 
precipitation was observed before the solvent injection procedure as analyzed by visual 
inspection with cold light.  
To obtain liposomes with different degree of PEGylation and pentaglycine accessibility 
(Scheme 2), but comparable physical properties such as dh and PDI, dh was screened for 
formulation A-D by flow rate alteration (Table 2). 
Table 2: Flow rate screening. Different combinations of flow rates during solvent injection were screened to obtain 
liposomes with comparable hydrodynamic diameter and polydispersity (mean ± standard deviation shown for 
different solvent injections). 
formulation  flow rate 
buffer 
[mL/min] 
flow rate 
lipid  
[mL/min] 
Clipid dispersion 
 
[mM] 
production 
rate  
[g/h] 
dh 
 
[nm] 
PDI  
 
A.U. 
reps 
A 40 5.00 10.0 20 200 ± 20 0.18 ± 0.03 n=4 
  80 10.00 10.0 40 149 ± 7 0.22 ± 0.01 n=4 
  100 12.50 10.0 50 132 ± 11 0.24 ± 0.01 n=4 
  150 12.50 6.9 50 125 ± 2 0.23 ± 0.00 n=4 
  180 12.50 5.8 50 106 0.24 n=1 
B 40 5.00 10.0 19 200 ± 18 0.21 ± 0.01 n=3 
  80 10.00 10.0 39 150 ± 6 0.23 ± 0.01 n=3 
  100 12.50 10.0 48 137 ± 3 0.23 ± 0.01 n=3 
  150 12.50 6.9 48 126 ± 7 0.24 ± 0.00 n=3 
C 45 6.75 4.2 8 230 ± 20 0.22 ± 0.01 n=4 
  90 13.50 4.2 16 180 ± 3 0.20 ± 0.02 n=4 
  135 13.50 2.9 16 163 ± 13 0.19 ± 0.01 n=4 
  180 13.50 2.2 16 153 0.19 n=1 
D 45 6.75 4.2 8 188 ± 21 0.18 ± 0.06 n=4 
  90 13.50 4.2 16 145 ± 13 0.18 ± 0.02 n=4 
  135 13.50 2.9 16 130 ± 3 0.19 ± 0.02 n=4 
  180 13.50 2.2 16 95 0.19 n=1 
 
Increase of the total flow rate with constant flow rate ratio of buffer-to-lipid = 8 (formulation A) 
led to subsequent decrease of the dh down to 125 nm while maintaining acceptable PDIs < 0.25 
(Table 2). Further increase of the buffer flow decreased the dh to ≈100 nm, previously found as 
most suitable liposome size for in vivo tumor targeting with liposomes [47]. This decrease is due 
to an increased shearing and turbulence at the injection site [41]. The lipid concentration after 
injection was 10 mM for formulation A, representing a high value compared to other reports on 
liposome production by solvent injection [41, 48]. The lipid concentration after injection is an 
important factor to consider for the encapsulation of hydrophilic compounds. Here, the 
encapsulation efficacy is mainly determined by the volume ratio of the aqueous liposome 
interior to the surrounding buffer. This ratio is determined by the liposome diameter and the 
lipid concentration. Hence, high lipid concentrations after liposome formation are favorable for 
efficient cargo encapsulation. The production rate ranged for formulation A and B from 
19-50 g/h (Table 2). In solvent injection processes, the production rate is dependent on the 
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injection speed and the concentration of the lipid solution. Although this rate can impact the 
final process duration, it should be kept in mind that during large-scale preparations other 
downstream processes (like tangential flow filtration with a low filtration rate [49]) may 
determine the absolute production rate. Formulation A and B were prepared with similar size 
distributions, indicating minor influence of the different pentaglycine lipids, probably due to the 
low fraction in the bilayer of 1 mol%.  
Due to the limited solubility of DPPG, formulation C and D had an overall lower final lipid 
concentration and production rate. Thus, lipid flow was set to the maximum pump rate of 
13.5 mL/min for small (2-5 mL) syringes in most experiments. Interestingly, a high influence of 
the PEGylated pentaglycine lipid on mean size was observed for formulation C. The dh of 
formulation C was 30-50 nm larger compared to the non-PEGylated formulation D (Table 2), 
although other parameters (solvent, lipid concentration, flow rates) were similar. A comparable 
1.9 kDa PEG-group was previously reported to increase the dh of liposomes by 3-15 nm after a 
post insertion processes, depending on the bilayer fraction and further experimental conditions 
[50]. In the present study, not only the PEG-group, but also the pentaglycine group (0.375 kDa) 
may contribute to the extension of the dh.  
 
Figure 1: Predictivity of flow rate screening experiments towards manufacturing of the pentaglycine-modified 
liposomes. Flow rates yielding comparable dh and PDI in the screening were applied to prepare formulations A-D in 
larger scale. DLS confirmed the screening results for larger scale manufacturing with mean sizes between 150 nm and 
180 nm. Furthermore, subsequent purification and concentration utilizing tangential flow filtration did not alter size, 
PDI or zeta potential of the formulations (data shown as mean ± standard deviations of three experiments).  
Flow rates predicting comparable dh and PDI were selected with respect to final lipid 
concentration from screening experiments and applied to prepare formulations A-D in a larger 
scale. Similar dh and PDI were obtained in screening and larger scale preparation (Figure 1), 
indicating predictivity of the screening experiment. Tangential flow filtration was used to 
concentrate and purify the dispersion from residual alcohol. No relevant changes of physical 
properties (size, PDI, zeta potential) occurred over the process (Figure 1). Zeta potential was 
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≈-10 mV for formulation A and B, and distinctly more negative for formulation C (-27 mV) and D 
(-40 mV) due to the anionic stabilizer DPPG.  
The bilayer composition was analyzed by rp-HPLC-ELSD and did not show relevant changes over 
TFF processing (Table 3). Most important, the pentaglycine lipids showed sufficient bilayer 
anchorage, maintaining their bilayer fraction of 1 mol%. Physical stability of the four 
pentaglycine-modified formulations was investigated over 8 weeks at 2-8 °C. As result, neither 
dh, PDI nor zeta potential showed relevant changes over time (Figure 2). 
Table 3: Bilayer compositions after tangential flow filtration, determined by rp-HPLC-ELSD (mean ± standard 
deviations shown for three batches). 
formulation G5 lipid [mol%] CHOL [mol%] DPPC [mol%] DSPE-mPEG / DPPG [mol%] 
theoretical 1.0 34.7 59.4 5.0 
A 1.0 ± 0.1 33.5 ± 0.5 61.1 ± 0.5 4.4 ± 0.2 
B 1.0 ± 0.1 33.7 ± 1.3 60.1 ± 0.9 5.2 ± 0.7 
C 1.0 ± 0.0 33.9 ± 1.1 60.4 ± 0.8 4.7 ± 0.4 
D 1.0 ± 0.1 33.9 ± 1.7 60.5 ± 1.0 4.6 ± 0.7 
 
 
Figure 2: Physical stability (size, PDI and zeta potential) of pentaglycine-modified liposomes over an 8 weeks storage 
at 2-8 °C (mean ± standard deviations shown for three batches). 
4.2. Investigation of reaction kinetics on liposomes 
We monitored the conjugation of a model VHH (VHH ENH) towards differently PEGylated 
liposomal formulations (Scheme 2) over 14 h by rp-HPLC (Figure 3A). ESI-MS confirmed the 
calculated theoretical molecular masses for the PEGylated or non-PEGylated lipid-modified 
antibody structure (Figure 4A and B). Low reaction efficacies (< 10 %) were found for a 
pentaglycine motif hidden by surrounding PEG-groups (Figure 3B, formulation B). 
Formulation D, lacking the shielding PEG-groups, had a higher steric accessibility of the bilayer-
proximal nucleophile and showed an increased conversion extent of ≈15 % after 4 h. In contrast, 
both formulations equipped with the PEG-spaced pentaglycine showed much higher reaction 
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rate and overall reactivity, reaching educt conversion of 40 ± 1 % (formulation A) or 33 ± 3 % 
(formulation C) after 4 h. This is probably due to the increased steric accessibility of the 
pentaglycine moiety towards Sortase-A, and a higher degree of freedom through the flexible 
PEG-spacer. This might enable conformational changes that facilitate the access of the amino-
function to the thioester intermediate at the active site.  
 
Figure 3: A: Representative rp-HPLC chromatograms of DMA-G5 (solid line)- or DMA-PEG-G5 (dotted line)-modified, 
PEGylated liposomes after 14 h incubation with 50 µM VHH ENH and 25 µM Sortase-A. B: Influence of PEGylation 
status on Sortase-A reaction kinetics (100 µM pentaglycine, 50 µM VHH ENH and 25 µM Sortase-A, 4 °C). C: Influence 
of temperature on reaction kinetics of PEG-shielded (formulation B) or exposed (formulation A) pentaglycine motifs 
(100 µM pentaglycine, 50 µM VHH ENH and 25 µM Sortase-A). D: Optimization of Sortase-A concentration (100 µM 
pentaglycine of formulation A, 10 µM VHH ENH, 4 °C). After 4 h, reaction was stopped by HCl and the dispersion 
analyzed for the reaction product. E: Optimization of targeting ligand reaction efficacy (100 µM pentaglycine of 
formulation A, 25 µM Sortase-A, 4 °C). F: Calculated ligand density on the drug delivery system based on conversion 
data (4 h) of experiment in 6E. All data: mean ± standard deviation of three experiments. 
Interestingly, the fully PEGylated formulation A showed slightly higher conversion rate and 
extent than formulation C. This may be explained by the observation of Silvius et al. [23], who 
showed that bilayer-immobilization of Sortase-A drastically enhanced the reaction efficacy 
compared to soluble Sortase-A . We observed unspecific binding of Sortase-A towards PEGylated 
liposomal bilayer surfaces, indicated by Sortase-A residuals after a dialysis step (Figure 5). This 
may lead to an increased conversion rate and extent for formulation A, comparable to Silvius et 
al. [23]. Whether attraction of Sortase-A towards the PEGylated formulations is due to an 
interaction with PEG or electrostatics remains unclear. As the zeta potential of formulation A 
and C distinctly differ from each other by ≈17 mV, charge may also be a reason for Sortase-A 
interaction with PEGylated formulations.  
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Figure 4: Confirmation of conjugation products by ESI-MS. Target mass was calculated as native VHH mass plus lipid 
mass minus mass of the his-tag cleaved from the native VHH during transpeptidation (GGH6, 955 Da). A: Conjugate of 
VHH ENH (14237 Da) and DMA-PEG-G5 (2554 Da). B: Conjugate of VHH ENH and DMA-G5 (897 Da). C: Conjugate of 
BMX1 (16541 Da) and DMA-PEG-G5.  
 Formulation C showed a tendency for the reverse reaction, indicated by a decrease of the 
conjugate product after 14 h. The reverse reaction occurs after a re-recognition of the newly 
formed LPETG5-motif between VHH and lipid anchor by Sortase-A. Subsequently, a thioester is 
formed and hydrolyzed through the attack of a water molecule as alternative nucleophile [18]. 
It was concluded that the higher degree of flexibility of the PEG-pentaglycine in formulation C 
compared to A leads to a higher accessibility of the LPETG-motif after transpeptidation, and 
therefore a higher rate of the reverse reaction. 
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Negligible impact of temperature was previously described for Sortase-A variant SortA7m [40]. 
Low reaction temperature of 4 °C was therefore chosen as standard condition to reduce overall 
impact on the liposomes and their potentially labile cargos. However, to overcome low reactivity 
of PEG-shielded pentaglycine-motifs, the impact of temperature (namely an increase from 4 °C 
to 37 °C) on the conversion extent (Figure 3C) was analyzed. Interestingly, in case of a freely 
accessible nucleophile (formulation A), slight increase in conversion rate, but low impact on final 
VHH conversion over 14 h was observed. Formulation B showed a drastic increase in reaction 
efficacy by increase of temperature. This effect can be attributed to a higher accessibility of the 
hidden pentaglycine motif to the active site of the enzyme due to a higher mobility of the 
PEG-groups. Their decreased viscosity at elevated temperature may lead to a less rigid shielding 
layer of the pentaglycine-coated bilayer surface, therefore increasing overall conversion over 
time. This effect might enable manufacturing of multi-layered liposomes by integration of 
additional DMA-G5 lipid in formulation A. One could firstly saturate an outer layer of PEG-spaced 
glycine motifs at low temperature and subsequently modify a PEG-shielded nucleophilic layer 
by increasing temperature. This would add a further dimension of selectivity towards enzyme-
mediated bilayer modification.  
Sortase-A concentration was evaluated between 1-50 µM for the reaction of 10 µM VHH ENH 
to formulation A (Figure 3D). Optimal conversion was found for 10 µM Sortase-A. At higher 
concentrations, decreasing conversion extents were observed. A possible reason may be an 
increased reverse reaction over the 4 h incubation time, indicating that increased enzyme 
concentrations require decreased incubation times. 
Initial VHH concentration was evaluated between 5-50 µM (Figure 3E). Increased conversion up 
to 80 % was achieved with a decrease of VHH concentration. This can be explained by the higher 
ratio of the nucleophile pentaglycine to the electrophilic thioester intermediate of the 
Sortase-A-VHH complex. Interestingly, the higher standard deviations observed with decreasing 
VHH concentrations hint at a less uniform reaction process. This might be explained by a 
heterogeneous educt distribution during the reaction due to slow diffusion at low temperatures 
and indicate the need for stirring during conjugation.  
The ligand density on the liposomal surface is an important parameter for an efficient targeting 
effect. Furthermore, it plays a critical role for the colloidal stability and also determines the drug-
to-ligand ratio. Here, ligand density could be controlled by variation of the initial VHH 
concentration (Figure 3F). The density ranged from 0.6-3 nM ligand per µM phospholipid, 
corresponding to 110-430 VHHs per liposome. This covers a ligand density previously described 
as suitable for the targeting of immunoliposomes to raji cells [51].  
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4.3. Purification from Sortase-A and target binding 
Pentaglycine-modified formulations were sortagged with VHH ENH and purified by dialysis. 
Samples incubated without Sortase-A served as controls. DLS and LDE (Table 4) indicated 
physical stability over the reaction although a slight increase in PDI of formulation B was 
observed. Furthermore, conjugated samples had a slightly less negative zeta potential, probably 
due to the charge of the conjugated VHH ENH. As described above, PEGylated formulations A 
and B tended to bind a much higher amount of Sortase-A which was thus not removed by the 
dialysis process (Figure 5).  
Table 4: Physicochemical properties of liposomes after ligand conjugation and dialysis (with / without Sortase-A, data 
shown as mean ± standard deviation of three measurements).  
formulation dh [nm] PDI zeta potential [mV] 
A 143 ± 2 / 151 ± 1 0.23 ± 0.00 / 0.22 ± 0.01 -7.0 ± 0.2 / -8.5 ± 0.2 
B 146 ± 6 / 161 ± 2 0.32 ± 0.06 / 0.24 ± 0.00 -7.4 ± 0.3 / -8.6 ± 0.8 
C 174 ± 2 / 173 ± 2 0.23 ± 0.01 / 0.22 ± 0.01 -18.3 ± 1.2 / -26.3 ± 1.7 
D 139 ± 1 / 138 ± 1 0.19 ± 0.01 / 0.20 ± 0.02 -32.8 ± 1.7 / -40.0 ± 2.2 
 
 
Figure 5: Effectivity of Sortase-A removal by dialysis. Formulations A-D were incubated with 50 µM VHH ENH and 
25 µM Sortase-A and purified by dialysis (cut-off: 1000 kDa) overnight with 3 buffer changes. Substantial residuals of 
Sortase-A (peak 1) and, to a minor degree, native VHH (peak 2) were found by rp-HPLC analysis in the PEGylated 
formulations A and B. Furthermore, PEGylation and spacer dependent conversion efficacy is obvious when peak areas 
of non-spaced (peak 3) and PEG-spaced (peak 4) VHH-lipid conjugate are compared. 
This interaction may be a critical factor influencing stability of the targeted system as Sortase-A 
is known for pronounced reverse reaction [18], which would cleave the targeting ligand from 
the liposome during storage. Additionally, liposome associated Sortase-A is likely to act as a 
strong immunogen, since it is derived from Staphylococcus aureus, a widespread pathogen 
bacterium. Traces of this protein may lead to serious adverse events like allergic reactions, 
antibody-formation against the drug delivery system or in worst case, fatal anaphylactic shocks. 
Initial evaluations revealed that up to 6.0 µM of Sortase-A remained in formulation A after 
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dialysis. Improvement of Sortase-A purification from liposomal drug carriers is therefore 
required to ensure a safe application to patients, and is currently under investigation with regard 
to the liposomal surface properties. 
To investigate the ability of the immunoliposomes to bind towards antigens, the VHH ENH-
modified dispersions were incubated with the target protein eGFP. Free eGFP and liposomes 
were separated by analytical size exclusion chromatography (Figure 6) and analyzed by 
fluorescence detection. 
 
Figure 6: Binding of eGFP to VHH ENH-modified liposomes. Liposomes (1 mM total lipid) precedingly incubated with 
VHH ENH and with (solid) or without (dotted) 25 µM Sortase-A were mixed with 15 µM eGFP and separated by size 
exclusion chromatography. Increase of liposome peak intensity (8-10 min) as well as decrease of free eGFP 
fluorescence (15-18 min) indicates eGFP binding to the formulations. Formulation A-D as assigned in chromatograms.  
Although sole presence of unmodified liposomes in the fluorescence detector caused 
background noise, probably through light scattering effects, a clear increase in fluorescence of 
the liposome peak was found for the sortagged liposomes for formulation A, C and D. Hardly 
any increase was observed for formulation B, reflecting the lower reactivity of the PEG-shielded 
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nucleophile, though height of free eGFP peak of formulation B was decreased for sortagged 
liposomes. This should consequently indicate a binding towards the sortagged liposome higher 
than for the control formulation. VHH ENH is known to enhance the intrinsic fluorescence of 
eGFP [43]. Higher amounts of residual, unbound VHH ENH in the control formulation might 
therefore have led to increased fluorescence intensities of free eGFP. These considerations 
hamper the use of this assay for absolute quantification of ligand activity on the liposomes. 
However, if one can work with a ligand-target system without mutual influence on the 
fluorescence intensity, such as other fluorescent proteins or fluorophore-labeled target 
proteins, the presented SEC method might serve as convenient quantitative tool for 
liposome-target protein interaction studies.  
4.4. In vitro targeting of myeloid cells 
Formulation A and C were investigated regarding their ability to bind in vitro towards a relevant 
target, namely CD11b+ human myeloid cells. For that purpose, both bilayer and liposomal core 
were stained with fluorescent dyes. Encapsulation efficiency of FITC-dextran 10 kDa was 
determined by fluorimetry after TX-100 lysis and was < 1 % for both formulations, indicating a 
complete passive encapsulation during solvent injection without any specific bilayer interaction. 
Liss-Rhod-PE content was analyzed after TFF and maintained its molar fraction of 0.1 mol%. Dye-
labeled formulations were modified with VHH BMX1, a VHH binding CD11b (Supplementary 
Figure 1), or with VHH ENH as isotype control. Staining and ligand conjugation had no influence 
on physicochemical properties of the liposomes. Furthermore, liposomes were physically stable 
for 4 weeks (Supplementary Table 1). Mass spectrometry showed successful conjugation of 
VHH BMX1 towards the lipid anchor molecule DMA-PEG-G5 (Figure 4). hPBMCs were collected 
from the buffy coat of blood donations from healthy donors. Subsequent co-staining of surface 
receptors for T cells, B cells, monocytes and granulocytes enabled a simultaneous assessment 
of targeting feasibility and specificity. According to the CD11b expression (CD11b is expressed 
on myeloid-derived CD14+ granulocytes and CD15+ monocytes, but not on lymphoid-derived 
CD3+ T cells and CD19+ B cells), we found specific targeting towards CD14+CD11b+ and 
CD15+CD11b+ cells (Figure 7). Neither isotype control VHH ENH nor unmodified liposomes bound 
to a relevant extent. It is difficult to estimate from the current data whether the fully PEGylated 
formulation A or minimally PEGylated formulation C (by the PEG-spacer between ligand and 
bilayer) showed different behavior in binding. There might be a trend for a higher interaction of 
formulation C, indicated by stronger shifts in FACS analysis. This could be reasoned in the overall 
decreased unspecific uptake of PEGylated particulate systems [26].  
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Figure 7: Targeting of CD11b+ myeloid cells. FITC-labeled formulation A and C were incubated with hPBMCs. FACS 
analysis of CD3+CD11b- (T lymphocytes), CD19+CD11b- (B lymphocytes), CD14+CD11b+ (monocytes) and CD15+CD11b+ 
(granulocytes) cells revealed selective binding of VHH BMX1-modified liposomes towards the CD11b+ mono- and 
granulocytes. 
Confocal microcopy revealed a selective staining of the cells (Figure 8) only by BMX1-liposomes 
with intracellular aggregations of liposomes (Supplementary Video 1 and 2). Co-localization of 
liposome-labels Liss-Rhod-PE (liposome bilayer) and FITC-dextran (liposome core / cargo) 
showed internalization of intact liposomes. These focal spots of intact liposomes rather than 
confluent FITC-fluorescence over the cytosol may indicate the necessity to improve the 
intracellular cargo release in further formulation developments. However, as focus of this work 
was the investigation of reaction conditions and proof of concept for targeting feasibility with 
chemoenzymatically VHH-modified liposomes, these considerations were not part of this work.  
 
Figure 8: Confocal microscopy of hPBMCs incubated with formulation A (A1-4, upper row) and formulation C (B1-4, 
lower row). 1: uncoated liposomes, 2: ENH-liposomes, 3 and 4: BMX1-liposomes. Yellow and red fluorescence of 
liposomal core and bilayer, respectively, was solely observed on cells incubated with BMX1-liposomes (A3/4, B3/4). 
Co-localization of liposomal membrane dye Liss-Rhod-PE and liposome-core dye FITC-dextran indicated 
internalization of intact liposomes. Only selected cells were stained through the liposomes (A4 / B4). This is due to 
the presence of CD11b-positive and CD11b-negative cells in the hPBMC culture. Color code: yellow: liposomal core, 
red: liposomal bilayer, blue: nucleus, purple: plasma membrane. White scale bars: A1-3: 5 µm, A4: 50 µm, B1-3: 
2.5 µm, B4: 100 µm. 
FITC
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5. Conclusion and outlook 
In the present study, Sortase-A “conjugation-ready” or sortaggable liposomes with different 
surface properties like PEGylation and steric accessibility of the pentaglycine moiety were 
successfully prepared by solvent injection. A flow rate screening allowed us to prepare different 
pentaglycine formulations with comparable size distributions. This enabled us to thoroughly 
investigate reaction conditions and kinetics for the Sortase-A reaction with sole dependency of 
the liposomal surface properties. A single-domain antibody was used as reaction partner during 
transpeptidation, representing a promising novel class of targeting ligands for drug delivery 
systems. Adjusting the pentaglycine to ligand ratio improved conversion extents up to 80 %. We 
further found high dependency of conversion extent on the surface properties and steric 
accessibility of the pentaglycine, which could, in case of a PEG-shielding, be overcome by a 
temperature increase. This gives implications for further research on the modification of 
PEGylated surfaces by Sortase-A, e.g. for the manufacturing of multilayer surfaces, what may be 
realized by utilization of the here presented PEG-spaced and non-spaced pentaglycine lipids. The 
findings in this study further revealed formulation dependent effectivity of Sortase-A 
purification. This indicates need for a deeper investigation of liposome purification processes, 
since Sortase-A residuals may cause serious immunogenic reactions. Additionally, storage 
stability of the protein-lipid conjugate in presence of trace amounts of Sortase-A may be 
impaired, as the enzyme is known for its hydrolytic activity on the LPxTG recognition site.  
Pharmaceutical relevance of the presented work was shown by an effective, specific binding 
towards CD11b+ cells. CD11b is a promising cellular surface marker of myeloid cells in 
inflammatory or proliferative tissues. The presented drug delivery system might be used for 
delivery of toxic payloads or diagnostics towards the tumor microenvironment [27, 39, 40]. For 
this purpose, further improvements like a screening of the bilayer composition, e.g. usage of 
pH-sensitive or fusogenic lipids could be useful to improve intracellular release characteristics. 
Furthermore, investigation of liposomal surface properties, meaning degree of PEGylation as 
well targeting ligand density are relevant formulation parameters for improvement of in vitro 
and in vivo performance. With the presented work, we provide a profound and detailed basis 
for a further rationale formulation development of such drug delivery systems suitable for 
chemoenzymatic ligand modifications.  
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Supplementary Data 
Isolation and characterization of VHH BMX1 
VHH BMX1 was generated by immunization of an alpaca with human myeloid cells following 
standard procedures (PMID24577359). Human myeloid cells were isolated by fluorescence 
activated cell sorting using antibodies against CD33 and CD14 for positive selection and CD3, 
CD19, CD56, and HLA-DR for negative selection. Cells were isolated by Ficoll-density gradient 
centrifugation from human blood donations from several donors, pooled and killed by radiation. 
Panning of the VHH library was performed with similar non-radiated cells. 
The specificity of VHH BMX1 for myeloid cells was determined by flow cytometry using CD11b 
as myeloid marker on human peripheral blood mononuclear cells obtained by Ficoll-density 
gradient centrifugation from human blood donations. VHH BMX1 binding was detected by anti-
His FITC antibody and was restricted to CD11b-positive cells. The staining pattern indicates 
binding of VHH BMX1 to CD11b. 
 
Supplementary Figure 1: Binding of VHH BMX1 (stained by anti-His FITC) to human peripheral blood mononuclear 
cells stained by anti-CD11b. 
VHH BMX1 Sequence: 
AAAQVQLVETGGGLVQAGGSLRLSCAASGRSFSSYDMGWYRQTPGKEREFVAAISWRGGNPDYADSVKG
RFTISRDNAANSLYLQMNSLKPEDTAIYYCNAGVYSDPDWGAESGSWGQGTQVTVSSEPKTPKPQPAR 
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Physical properties and stability of targeted liposomes 
Supplementary Table 1: Size, PDI and zeta potential of dye-labeled and VHH-modified formulation A and C (data 
shown as mean ± standard deviation of three measurements). Liposomes were at least stable for four weeks.  
  dh [nm]  PDI   zeta potential [mV] 
pull point [weeks]  0 4  0 4  0 4 
formulation A          
- G5-liposomes  141 ± 2 140 ± 5  0.23 ± 0.00 0.23 ± 0.01  -8 ± 1 -9 ± 1 
- VHH ENH-modified  135 ± 2 147 ± 2  0.24 ± 0.00 0.22 ± 0.01  -6 ± 0 -7 ± 1 
- VHH BMX1-modified  130 ± 14 155 ± 4  0.24 ± 0.00 0.22 ± 0.00  -13 ± 3 -7 ± 1 
          
formulation C          
- G5-liposomes  194 ± 2 198 ± 3  0.21 ± 0.02 0.23 ± 0.00  -26 ± 2 -25 ± 1 
- VHH ENH-modified  205 ± 2 197 ± 1  0.22 ± 0.02 0.22 ± 0.01  -19 ± 1 -20 ± 1 
- VHH BMX1-modified  193 ± 4 194 ± 2  0.23 ± 0.01 0.23 ± 0.01  -20 ± 1 -20 ± 1 
 
In vitro uptake of BMX1-liposomes in hPBMCs (confocal microscopy) 
 
Supplementary Video 1 can be accessed online at https://doi.org/10.1016/j.ejpb.2018.09.017 and shows hPMBCs 
incubated with BMX1-liposomes. Confocal microscopy reveals the intracellular localization of intact liposomes, 
indicated by the co-localization of the liposomal dyes Liss-Rhod-PE (red) for liposomal bilayer and FITC-dextran 
(yellow) for liposomal core. Formulation A: left video, formulation C: right video. Color code: yellow: liposomal core, 
red: liposomal bilayer, blue: nucleus, purple: plasma membrane. Scale bars: formulation A: 5 µm, formulation C: 
2.5 µm. Replay requires Adobe Flash®. 
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Abstract 
The therapeutic index of drugs can be increased via drug encapsulation in actively targeted, 
meaning ligand modified drug delivery systems. The manufacturing of such targeted drug 
delivery systems, in particular the conjugation between drug carrier and ligand, can be done by 
enzymatic conjugation methods, exploiting the site-specific, bioorthogonal nature of these 
reactions. The use of such enzymes like Sortase-A transpeptidase requires efficient purification 
methods, as residuals of the enzyme may be responsible for immunogenic potential and drug 
product instabilities. These instabilities may be based on the enzymatic reverse reaction, 
meaning here a cleavage between ligand and drug carrier. In the presented work, two differently 
PEGylated formulations were modified with variable fragments of camelid heavy chain-only 
antibodies (VHH) via Sortase-A, purified by different methodologies and tested for ligand 
cleavage upon storage. Strongly PEGylated liposomes (PEGhigh-LS) were found to retain higher 
amounts of Sortase-A than lowly PEGylated ones (PEGlow-LS) after dialysis purification. 
Surprisingly, this did not correlate with ligand stability during storage. PEGhigh-LS were less prone 
for degradation, compared to PEGlow-LS, which showed a ligand cleavage of 20 % after an 
8 weeks storage at 2-8 °C. Nonetheless, overall degradation could be minimized by an additional 
affinity bead purification procedure. Liposomes modified with a CD11b-specific VHH were tested 
for their in vitro and in vivo targeting ability towards CD11b+ cells. Specific targeting of CD11b 
was achieved in vitro and in vivo on various cell types. PEGylation decreased the targeting effect 
in vitro, however no differences between PEGhigh or PEGlow formulations were observed in vivo. 
The obtained results underline the need for a thorough physico-chemical characterization of 
novel conjugation strategies as well as an early in vivo characterization of such targeted drug 
delivery systems.  
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1. Introduction 
The use of enzyme-mediated transpeptidation techniques has proven valuable for protein 
modifications in many examples. These include payload [1] or fluorophore conjugation [2] for 
antibody-drug conjugates and diagnostics, the lipidation [3] and glycosylation [4] of proteins and 
the decoration of drug delivery systems with targeting ligands [5-9]. Amongst other enzymes 
such as transglutaminase [10] and butelase [11], Sortase-A is the most widely used enzyme for 
such applications [3, 12]. The main advantages of Sortase-catalyzed reactions are the inherent 
site-specificity, mild conjugation conditions and short recognition motifs in substrate proteins 
[3, 12]. Sortase variants have been extensively studied regarding structure [13], substrate 
specificity [9], reaction kinetics [14] and conditions [12]. Sortase-A recognizes a C-terminal 
amino acid sequence of LPxTG (leucine, proline, any amino acid, threonine, glycine) and forms a 
thioester as intermediate between threonine and glycine. Subsequently, a nucleophile, typically 
an oligoglycine, forms a peptide bond between threonine’s carboxylic acid group and the 
oligoglycine’s free amine [3, 12]. A major drawback of Sortase-A reaction is the reversibility of 
the transpeptidation [11]. The reverse reaction can be defined as the formation of the thioester 
intermediate of a newly formed LPxTG motif, followed by a nucleophilic attack of a) the 
previously cleaved sequence from the substrate with the N-terminal glycine, b) the desired 
glycine-nucleophile again leading to the reaction product, or c) a water molecule [15, 16]. Latter 
causes hydrolysis of the LPxTG motif and loss of recognition for the transpeptidation reaction. 
This reverse reaction can therefore decrease overall conversion rates [7, 11]. Furthermore, 
although Sortase-A reaction is considered as site-specific and reaction products should be 
homogeneous, structural variants of the product are obtained by reverse reactions especially if 
substrates carry several LPxTG motifs. This is typically the case in the synthesis of antibody-drug 
conjugates [1], where equilibrium processes between payload conjugation and hydrolysis may 
lead to different drug-to-antibody ratio species. Reversibility of the reaction further necessitates 
high demands on product purification. Besides the immunogenic potential of Sortase-A residuals 
in drug products, traces of the enzyme may be responsible for chemical instabilities, manifested 
in the subsequent hydrolysis of the LPxTG motif between the conjugated substrates. This would, 
in case of antibody-drug conjugates, lead to an increase of the free drug, or in case of drug 
delivery systems, cleavage of the targeting ligand from the particulate construct. A robust and 
efficient purification from Sortase-A is therefore of utmost importance for the use of this 
technology.  
We recently demonstrated high dependency of liposomal surface properties on the 
transpeptidation reactivity of pentaglycine-liposomes towards LPETG-modified single-domain 
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antibodies of camelid heavy chain only antibodies (VHHs) [17]. PEG-shielding of a pentaglycine 
moiety on the bilayer surface led to a drastically decreased conversion rate. Furthermore, 
reaction kinetics indicated influence of the PEGylation status on the extent of the reverse 
reaction during the ligand conjugation. Besides this, we observed retention of Sortase-A over 
dialysis purification, which occurred preferentially for 2 kDa PEG-derivatized liposomes. We 
therefore investigated here the stability of the VHH bound to the liposomal system to analyze if 
purification methods or liposomal surface properties influence hydrolysis stability of the 
targeting ligand upon storage.  
In vitro targeting of CD11b+ human myeloid cells with an CD11b-specific VHH-modified liposomal 
system was recently achieved with high specificity [17]. To further demonstrate the feasibility 
to target desired cell types in vivo with sortaggable liposomes, a VHH (VHH DC13) which binds 
murine myeloid cell surface receptor CD11b [2, 18] was employed as targeting ligand. CD11b is 
an integrin expressed on various myeloid cells such as monocytes, granulocytes, dendritic cells, 
macrophages and myeloid-derived suppressor cells (MDSC). MDSC are a heterogeneous cell 
population expanding under pathologic conditions such as cancer, trauma or sepsis that can 
inhibit the function of effector T cells [19]. Specific delivery of cargos such as antigens or toxins 
to myeloid cells can be used for therapeutic purposes as vaccines to increase adaptive immune 
response (antigen cargo) or to deplete cells (toxin cargo) that contribute to cancer progression 
(e.g. MDSC). Recently, VHHs against myeloid cell surface markers Gr-1 and CD11b were 
conjugated to the catalytic domains of Pseudomonas exotoxin A, a potent bacterial toxin. The 
immunotoxins were able to deplete mono- or granulocytes in vivo with a target-, cell- and organ-
dependent activity [18]. In the present work, we investigated whether the described sortaggable 
liposomal drug delivery systems can be decorated with VHH DC13 by Sortase-A and directed 
towards murine CD11b+Gr-1+ myeloid cells. For that purpose, binding of fluorescence-labeled 
liposomes was tested in vitro with different immune cell lines and primary splenocytes. 
Furthermore, specificity of targeting myeloid cells was investigated in vivo and analyzed with 
flow cytometry by staining murine splenocytes for myeloid (Gr-1+/CD11b+) or lymphoid (CD3+ or 
CD19+) subpopulations. With the present work, we analyzed for the first time the active in vivo 
targeting of CD11b+ myeloid cells via a liposomal system. Our results demonstrate feasibility for 
a cell-selective drug delivery towards these immune cells and can be useful for novel therapeutic 
approaches in immuno-oncology. 
2. Materials 
Pentaglycine-modified lipid DMA-PEG-G5 was obtained from Merck & Cie (Schaffhausen, 
Switzerland) and is described in detail elsewhere [17]. In brief, the lipid consists of a pentaglycine 
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structure conjugated to a 2 kDa monodisperse PEG-spacer, followed by a bilayer anchor 
(dimyristyl-amino-propandiol; DMA). 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-
dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DPPG) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-mPEG) were a gift of 
Lipoid GmbH (Ludwigshafen, Germany). DPBS (Dulbecco’s phosphate buffered saline, D1408, 
10fold stock), FITC-dextran 10 kDa and cholesterol were purchased from MilliporeSigma 
(St. Louis, Missouri, USA). Acetonitrile, trifluoroacetic acid (TFA), methanol and ethanol (both 
gradient grade) were obtained from Merck KGaA (Darmstadt, Germany). MilliQ water was taken 
from a Millipore Advantage A 10 with Q-Pod apparatus (Merck KGaA, Darmstadt, Germany). 
Sortase-A and LPETG (leucine, proline, glutamic acid, threonine, glycine)-modified VHH ENH and 
VHH DC13 were prepared as described in [18]. 
3. Methods 
3.1. Liposome preparation 
Pentaglycine-modified liposomes were prepared by a solvent injection process described in 
detail elsewhere [17]. Liposomes consisted of 1 mol% DMA-PEG-G5, DPPC (59.4 mol%), 
cholesterol (34.7 mol%) and 5.0 mol% of either DSPE-mPEG (referred to as “PEGhigh-LS”) or DPPG 
(referred to as “PEGlow-LS”). In brief, the lipids were dissolved to 90 mM in ethanol (PEGhigh-LS) 
or to 32 mM in methanol (PEGlow-LS). The lipid solutions were injected by a syringe pump (PHD 
Ultra4400, Harvard Apparatus, Holliston, Massachusetts, USA) into a stream of DPBS pH 7.4 
conveyed by a peristaltic pump (Ismatec IP65, Cole-Parmer, Wertheim, Germany). Lipid and 
buffer streams were connected via a stainless steel, luer-lock T-piece (Unimed S.A., Lausanne, 
Switzerland), customized with a 27 G needle for lipid injection. 10 mg/mL FITC-dextran was 
added to the injection buffer for the manufacturing of FITC-labeled liposomes. Dispersions 
obtained from injection were purified and concentrated by tangential flow filtration [17]. 
3.2. Ligand conjugation and purification 
For analysis of purification dependent ligand stability, PEGhigh-LS and PEGlow-LS were conjugated 
to the model single-domain antibody VHH ENH [20]. Liposomes (100 µM total pentaglycine), 
VHH ENH (50 µM) and 25 µM of Ca2+-independent, 6-histidin (his) tagged Sortase-A variant 
SortA7m were incubated for 4 h at 4 °C. An aliquot of the reaction mixture was retained for 
further analysis, remaining liposomes were dialyzed (Float-A-Lyzer, MWCO 1000 kDa, G235037, 
Spectrum Labs, Los Angeles, California, USA) against 100-200fold acceptor medium (DPBS) with 
five buffer changes over 24 h. A further aliquot was additionally refined with his-tag binding 
magnetic sepharose-nickel beads (GE Healthcare, Chaltfont St Giles, UK) to remove residual 
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amounts of Sortase-A or VHH. For that, 100 µL bead slurry was washed three times with DPBS 
using a magnetic rack. Supernatant was removed, and the beads were redispersed with 200 µL 
of the liposomal dispersion. After 2 h incubation at 4 °C and gentle shaking, magnetic beads 
were removed. Non-purified, dialyzed and additional bead purified liposomes were stored in 
Teflon-sealed glass vials for analysis of physical liposome stability (hydrodynamic diameter, 
polydispersity index, zeta potential) and chemical stability of the targeting ligand. For in vitro 
and in vivo experiments, FITC-labeled liposomes were either modified with VHH ENH (isotype 
control) or murine CD11b binding VHH DC13, followed by dialysis purification.  
3.3. Liposome characterization 
Liposomes were analyzed for hydrodynamic diameter dh and polydispersity index (PDI) using a 
DynaPro Plate Reader II, Wyatt Technology Corporation, Santa Barbara, California, USA. Zeta 
potential was measured after dilution to 3 % v/v in 10 mM NaCl using a Malvern Zetasizer 
Nano ZS, Worcestershire, UK. Detailed measurement settings are described elsewhere [17]. 
Molecular bilayer compositions were determined by an rp-HPLC method (based on a 
C18-column) with evaporative light scattering as described earlier [17].  
For quantification of conjugated VHH on the liposomes, a second rp-HPLC method (based on a 
C4 column), which separates proteins, DMA-PEG-G5-modified VHHs and lipid components of 
the liposome from each other was used [17]. For that, non-liposomal conjugates were 
synthesized, isolated by rp-HPLC and redispersed in water. Concentration was determined by 
UV-spectroscopy (NP80, Implen, Westlake Village, California, USA) using calculated extinction 
coefficients (ExPASy ProtParam, SIB, Lausanne, Switzerland). Isolated conjugates were used as 
HPLC-reference standard at 280 nm to determine concentration of VHH-lipid conjugates on 
liposomes after injection of 5 µL liposomal dispersion. VHH-conjugate content was normalized 
on phospholipid content, and the reaction efficacy was calculated (Equation 1, ti : after 
sortagging and purification, t0 : start of the reaction). 
Equation 1 
𝑎𝑎𝑦𝑦𝑎𝑎𝑐𝑐𝑜𝑜𝑦𝑦𝑜𝑜𝑖𝑖 𝑦𝑦𝑒𝑒𝑒𝑒𝑦𝑦𝑐𝑐𝑎𝑎𝑐𝑐𝑦𝑦 [%] =   𝑐𝑐𝑉𝑉𝑉𝑉𝑉𝑉−𝑐𝑐𝑆𝑆𝑑𝑑𝑐𝑐𝑐𝑐𝑐𝑐𝑆𝑆𝑆𝑆𝑆𝑆𝑐𝑐𝑙𝑙𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 (𝑜𝑜𝑑𝑑) 𝑐𝑐𝑉𝑉𝑉𝑉𝑉𝑉𝑐𝑐𝑙𝑙𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 (𝑜𝑜0) ∗ 100 
Furthermore, residual amounts of Sortase-A after dialysis or bead purification were determined 
by rp-HPLC based on a 25 µM Sortase-A reference measured at 280 nm. Limit of quantification 
(LOQ) of this method was 3.1 µM for a signal to noise ratio of 10:1 as determined by the 
chromatography software (OpenLab CDS EZChrom, Agilent Technologies).  
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To investigate stability of the targeting ligand regarding hydrolytic cleavage, liposomal samples 
were stored at 2-8 °C for 8 weeks and analyzed by rp-HPLC for change in the relative area of the 
lipidated VHH. Stability was calculated according to Equation 2, where ti is the actual pull point 
and t0 the start value of the study. Results of three batches were averaged. 
Equation 2 
𝑐𝑐𝑜𝑜𝑎𝑎𝑠𝑠𝑦𝑦𝑦𝑦𝑦𝑦𝑜𝑜𝑦𝑦 𝑆𝑆𝑆𝑆𝑆𝑆𝑙𝑙 = 𝑎𝑎𝑎𝑎𝑦𝑦𝑎𝑎%𝑉𝑉𝑉𝑉𝑉𝑉−𝑐𝑐𝑆𝑆𝑑𝑑𝑐𝑐𝑐𝑐𝑐𝑐𝑆𝑆𝑆𝑆𝑆𝑆(𝑜𝑜𝑑𝑑) 𝑎𝑎𝑎𝑎𝑦𝑦𝑎𝑎%𝑉𝑉𝑉𝑉𝑉𝑉−𝑐𝑐𝑆𝑆𝑑𝑑𝑐𝑐𝑐𝑐𝑐𝑐𝑆𝑆𝑆𝑆𝑆𝑆(𝑜𝑜0) 
Total FITC content of dye-labeled batches was determined by fluorimetry (M200 plate reader, 
Tecan Group, Männedorf, Switzerland) after a lysis of the liposomes in Triton X-100. Free FITC-
dextran was determined by analytical size exclusion chromatography described in [17] with 
fluorescence detection (excitation: zero order, emission: 510 nm) separating liposomes and 
non-encapsulated FITC-dextran. Encapsulated FITC-dextran was calculated as total minus free 
FITC-dextran. Encapsulation efficiency was calculated as the ratio of FITC-dextran per lipid of the 
final dispersion, divided by the theoretical ratio of FITC-dextran per lipid after solvent injection.  
3.4. In vitro characterization of VHH DC13-liposomes 
In cell culture DC2.4 cells and RAW macrophages were maintained in DMEM (Life Technologies, 
#61965026) supplemented with 10 % heat-inactivated fetal bovine serum (FBS, Life 
Technologies, #10270106), 100 U/mL penicillin (Life Technologies, #15140122), and 100 µg/mL 
streptomycin (Life Technologies, #15140122). NUP progenitor cells (hematopoietic progenitors 
immortalized using a NUP98/HOXB4 transgene, described in [21]) and NUP-derived myeloid-
derived suppressor cells (MDSC) were cultured in complete RPMI consisting of RPMI 1640 
medium (Life Technologies, #21875-034) supplemented with 10 % FBS, 100 U/mL penicillin, 
100 µg/mL streptomycin, 1 mM sodium pyruvate (Life Technologies, #11360070), 50 µM 
2-mercaptoethanol (Life Technologies, #31350-010) and 1 × non-essential amino acids (Life 
Technologies, #11140-035). MDSC were differentiated from NUP cells by 4 days of incubation in 
the presence of 20 ng/mL IL-6 (Biolegend, #570802) and 20 ng/mL murine GM-CSF (Biolegend, 
#576304) [22]. Splenocytes were isolated from a C57BL6/J mouse by mashing the spleen in a 
70 µm cell strainer (Corning, #352350) and washing cells in FACS buffer (1fold PBS (Life 
Technologies, #14190-094) with 2 % FBS). Cells were resuspended in 1 mL ACK (ammonium-
chloride-potassium) lysing buffer (Thermo Fisher Scientific, #A10492-01) to remove red cells, 
incubated 5 min at room temperature, followed by addition of 5 mL FACS buffer and re-
centrifuged.  
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For binding experiments 1 × 105 DC2.4 cells or RAW macrophages were seeded in a 96-well plate 
in 200 µL medium and kept overnight at 37 °C in the presence of 5 % CO2 before addition of 
liposomes. 2 × 105 NUP cells, MDSC or splenocytes were seeded in a 96-well plate in 200 µL. 
100 µM of PEGhigh-LS or PEGlow-LS (based on total lipid content of FITC-labeled formulation, 
either as ligand free control (G5-LS), VHH ENH-decorated or VHH DC13-decorated liposomes) in 
200 µL complete RPMI medium were added to each sample in V-bottom-shaped 96-well plates 
and incubated at 37 °C for 4 h in the presence of 5 % CO2. Afterwards, cells were centrifugated 
(300 x g for 1 min). The supernatant containing unbound liposomes was removed, followed by 
redispersion of the cells in FACS buffer by multiple pipetting cycles. Antibody staining of cells 
was performed in presence of Fc receptor block (TruStain fcX BioLegend, #422302) in FACS 
buffer. SytoxBlue (Thermo Fisher Scientific, S34857) was used for exclusion of dead cells. 
Following antibodies from BioLegend were used for flow cytometry: Brilliant Violet 605 
anti-Gr-1 (#108439), PerCP-anti-CD11b (#101229), BV605-anti-CD3 (#100237) and APC-anti-
CD19 (#115511). 
For confocal microscopy, 0.5 × 106 RAW macrophages were seeded in a total volume of 200 µL 
complete RPMI. 100 µM liposomes were added to each sample in V-bottom-shaped 
96-well plates and incubated at 37 °C for 4 h in the presence of 5 % CO2. Cells were stained with 
CellMask Deep Red Plasma membrane stain (1:5000) (Life Technologies, #C10046) and Hoechst 
33342 (1:2000) (Thermo Scientific, #62249) for 15 min at 37 °C in the presence of 5 % CO2. The 
medium was removed by centrifugation (1 min at 300 × g), cells were washed with FACS buffer, 
transferred in 100 µL FACS buffer on polyethyleneimine-coated cover slips (microscope cover 
glasses from Marienfeld, 18 mm diameter, #0117580) and incubated for 10 min at 37 °C. Cells 
were fixed on cover slips with paraformaldehyde (final concentration 4 %) for 15 min and 
washed with 1 × PBS. Cover slips were mounted on cover glass (neoLab, #1-6273) using anti-
fade ProLong Diamond mounting medium (Invitrogen, #P36961) and analyzed 18 h later with a 
Leica TCS SP5 confocal microscope using an HCX Plan APO 40 × /1.30 Oil CS objective. For image 
analysis the Leica Application Suite software was used. 
3.5. In vivo targeting of MDSC 
C57BL/6J mice were maintained under specific pathogen-free conditions in the animal facility of 
the University of Heidelberg. All animal experiments were done in accordance with German 
legislation governing animal studies (approved project G-250/14 by the Regierungspräsidium 
Karlsruhe). Female C57BL/6J mice (8 weeks old, Charles River) were injected intravenously with 
PBS (one animal) or 0.6 mM (based on total lipid content) of either VHH ENH-PEGlow-LS, 
VHH DC13-PEGhigh-LS or VHH DC13-PEGlow-LS in 200 µL PBS (each 3 animals per group). After 2 h, 
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mice were sacrificed and splenocytes were isolated as described above. Splenocytes were 
stained for flow cytometry analysis using the same antibodies as described above. Statistically 
significant differences (p < 0.05) of FACS measurements were determined by unpaired t-test 
(Graph Pad Prism 7.03). 
4. Results and discussion  
4.1. VHH conjugation, purification and stability of the immunoliposomes 
To investigate the formulation- and purification-dependent stability of liposomes conjugated 
with VHHs via Sortase-A, two sortaggable liposome types differing in the bilayer surface 
properties were prepared by solvent injection. Physicochemical parameters are described in 
Table 1. Sortase-A was used to ligate a LPETG-modified VHH (VHH “enhancer”, described in [20]) 
towards the liposomes, followed by a dialysis step to remove the enzyme and unbound VHH. 
The sortagging and dialysis process had no relevant influence on size or PDI (Figure 1A) as 
relative changes were below 10 %. Zeta potential showed a shift towards neutral values with 
relative changes > 30 %, however absolute changes were small (Table 1).  
Table 1: Physico-chemical properties of unmodified and VHH-modified PEGhigh-LS and PEGlow-LS (data shown as mean 
± standard deviation of three reactions from one liposome bulk) 
formulation  dh [nm] PDI zeta potential [mV] 
PEGhigh-LS    
PEGhigh-LS (unmodified) 140 0.22 -9.3 
VHH ENH-PEGhigh-LS (dialysis) 141 ± 1 0.22 ± 0.01 -5.7 ± 0.3 
VHH ENH-PEGhigh-LS (bead) 143 ± 0 0.22 ± 0.02 -6.1 ± 0.1 
PEGlow-LS    
PEGlow-LS (unmodified) 175 0.23 -25.8 
VHH ENH-PEGlow-LS (dialysis) 186 ± 4 0.23 ± 0.01 -17.3 ± 0.8 
VHH ENH-PEGlow-LS (bead) 187 ± 2 0.23 ± 0.01 -17.2 ± 0.7 
 
We previously observed a formulation dependent retention of Sortase-A after a dialysis 
purification step [17]. This encouraged us here to add an additional magnetic bead purification 
step [18] after the dialysis protocol to enhance removal of free Sortase-A from the liposomal 
dispersion. Here, his-tagged Sortase-A is bound towards Ni2+-chelate beads. As the use of such 
magnetic bead systems for purification of liposomes was previously not described, we 
investigated compatibility regarding physical (size, PDI and zeta potential) and chemical 
properties (bilayer composition and VHH-density) of the liposomes. Neither size, PDI nor zeta 
potential showed relevant changes during the incubation process, indicating no alteration of the 
particle size distribution or surface properties by shear forces or other impacts through the 
beads (Figure 1, Table 1). Furthermore, we investigated the influence of the sortagging and 
purification processes on the bilayer composition of the liposomes. The bilayer fraction of the 
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reaction educt DMA-PEG-G5 showed a clear decrease after sortagging, showing the 
consumption of this lipid by the transpeptidation reaction. No other major changes occurred, 
indicating no adsorption to the dialysis membrane or device housing. Absolute lipid yields from 
dialysis devices were > 88 % for PEGhigh-LS and > 97 % for PEGlow-LS. Bead purification was 
compatible with both liposomal compositions as the bilayer compositions were maintained 
(Table 2). This and the high overall lipid yields (> 90 % for both formulation types, Table 2) 
indicated no adsorption of lipids to the sepharose bead material. 
 
Figure 1: Physico-chemical impact of VHH conjugation (A) and bead purification (B) on PEGhigh-LS and PEGlow-LS. 
A: Minor affection of hydrodynamic diameter and PDI indicates colloidal stability of the nanoparticulate dispersion 
during ligand modification. Zeta potential showed low absolute, but clear relative changes due to surface modification 
and thereby charge alteration. B: His-tag affinity-based magnetic bead purification does not affect integrity of 
targeted liposomal formulations as neither dh, PDI nor zeta potential showed relevant changes. Data shown as mean 
± standard deviation of three reactions and purifications from one liposome bulk. 
Table 2: Molecular composition and purification yield of VHH ENH-modified formulations (data shown as mean ± 
standard deviation of three reactions and purification procedures). 
  
DMA-PEG-G5 
[mol%] 
CHOL 
[mol%] 
DPPC 
[mol%] 
DPPG/DSPE-mPEG 
[mol%] 
yield  
[%] 
PEGhigh-LS      
PEGhigh-LS (unmodified) 1.0 35.2 59.4 4.5  
VHH ENH-PEGhigh-LS (dialysis) 0.6 ± 0.0 34.8 ± 0.3 60.4 ± 0.2 4.2 ± 0.1 88.1 ± 1.4 
VHH ENH-PEGhigh-LS (bead) 0.6 ± 0.0 35 ± 0.6 60.5 ± 0.6 3.8 ± 0.1 90.4 ± 4.0 
      
PEGlow-LS      
PEGlow-LS (unmodified) 1.0 35.2 59.5 4.3  
VHH ENH-PEGlow-LS (dialysis) 0.7 ± 0.0 34.3 ± 0.6 60.9 ± 0.9 4.2 ± 0.4 97.2 ± 2.5 
VHH ENH-PEGlow-LS (bead) 0.7 ± 0.0 34.9 ± 0.4 60.1 ± 0.3 4.4 ± 0.1 96.8 ± 3.6 
  
Residual Sortase-A levels were analyzed after dialysis and bead purification. PEGhigh-LS retained 
high amounts of Sortase-A after dialysis (Figure 2, Table 3). This is a surprising result as the 
cut-off of the dialysis device was ≈50fold larger than the molecular weight of this Sortase-A 
variant (20.9 kDa). It is expected that an unspecific binding towards the PEGhigh-LS may have 
occurred. The DPPG-stabilized formulation did hardly retain any non-lipidated protein over the 
dialysis process. A reason for the lower adsorption tendency of Sortase-A to the DPPG stabilized 
bilayers may be the significantly lower zeta potential. This may lead to a higher repulsion 
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between Sortase-A and liposome surface, and finally a more effective dialysis purification. It was 
tested whether an additional affinity-based bead purification could further reduce Sortase-A 
residuals in the liposomal formulations. Though the Ni2+-chelate beads should bind and 
therefore be able to remove the his-tagged enzyme, Sortase-A content in PEGhigh-LS formulation 
was reduced only to a minor extent (Table 3).  
 
Figure 2: Purification of PEGhigh-LS (A) and PEGlow-LS (B) by dialysis (dotted) and magnetic beads (dashed). Solid 
chromatogram indicates unpurified reaction bulk. Peak at 5.0-5.3 min: Sortase-A, peak at 5.3-6.5 min: unbound VHH, 
peak at 7.8 min: lipidated VHH. 
Table 3: Purification and VHH conjugation efficacy. Residual Sortase-A levels were below limit of quantification (LOQ) 
for PEGlow-LS. PEGhigh-LS retained considerable amounts of the enzyme over dialysis and the additional bead 
purification procedure. Data shown as mean ± standard deviation of three reactions and purification procedures. 
formulation residual Sortase-A [µM] reaction efficacy [%] 
VHH ENH-PEGhigh-LS (dialysis) 6.0 ± 0.6 33 ± 2 
VHH ENH-PEGhigh-LS (bead) 4.8 ± 0.6 34 ± 1 
VHH ENH-PEGlow-LS (dialysis) < 3.1 (LOQ) 28 ± 1 
VHH ENH-PEGlow-LS (bead) < 3.1 (LOQ) 28 ± 4 
 
This indicates a strong interaction with the liposomal surface, and may be origin of product 
instabilities, meaning a cleavage of the targeting ligand from the liposomal system via the 
reverse reaction of Sortase-A. Stability of the differently purified liposomal dispersions were 
therefore analyzed for cleavage of the targeting ligand upon storage at 2-8 °C. Non-purified 
feedstock from conjugation bulk of both formulations showed a pronounced loss of targeting 
ligand over storage (Figure 3). Degradation rates were significantly higher for PEGlow-LS 
compared to PEGhigh-LS. This is in congruence with results obtained earlier for the monitoring of 
the reaction kinetics on these two formulations, which showed a predominant reverse reaction 
for PEGlow-LS already after 14 h [17]. Most surprisingly, extent of targeting cleavage was 
independent of residual Sortase-A content. Although PEGhigh-LS contained significant amounts 
of Sortase-A after both dialysis and bead purification steps, hardly any cleavage of the lipidated 
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VHH was observed over the stability study (Figure 3). In contrast to that, dialyzed PEGlow-LS 
showed a decrease of the VHH conjugated to the liposomes over 8 weeks (Figure 3B, triangles). 
Assuming a homogenous loss of ligand over the liposomal dispersion, the average ligand density 
on a single liposome decreased about 20 % during storage. As latter is a critical value for an 
effective targeting [23], such a decrease would be inacceptable for a commercial product. 
Though not correlated in a quantitative manner with residual Sortase-A levels due to the 
quantification limit of the rp-HPLC method, this instability was overcome by the additional bead 
purification, since the bead purified PEGlow-LS did not show degradation over the study time. 
 
Figure 3: Stability of VHH conjugated to the liposomes. Extent of targeting ligand cleavage by Sortase-A during storage 
is dependent on the PEGylation status. A: PEGhigh-LS. B: PEGlow-LS. Circles: unpurified feedstock containing Sortase-A, 
triangles: dialyzed feedstock, squares: dialyzed and bead purified feedstock. Data shown as mean ± standard 
deviation of three reactions and purification procedures. 
It is suggested that a further reduction of the Sortase-A residuals by a his-tag mediated removal 
through the Ni2+-chelate beads increased overall storage stability. It remains unclear why 
PEGlow-LS are more prone to the reverse reaction and hence lability during storage. Comparing 
surface properties of both formulations, PEGhigh-LS contain an additional 2 kDa PEG-layer, that 
may protect the newly formed LPETG-motif after transpeptidation against a second recognition 
via Sortase-A. It is known that PEG-layers adopt different conformations (brush, mushroom) on 
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liposomes [24]. These depend on the molar fraction of the PEGylated lipid due to interactions 
between adjacent polymer chains, leading to a brush-like conformation at a total PEG-densities 
> 4 mol% [25]. Suggesting this extended polymer conformation for DSPE-mPEG in PEGhigh-LS, this 
could explain the resistance of this formulation against the reverse reaction via a steric shielding 
of the LPETG motif (Scheme 1) by neighboring PEG-groups.  
 
Scheme 1: Steric accessibility of LPETG-motifs on differently PEGylated bilayers. Neighboring PEG-groups in PEGhigh-LS 
may shield the LPETG-motif from re-recognition by Sortase-A and therefore reduce the propensity of the reverse 
reaction. PEGlow-LS exhibit higher steric accessibility and are therefore prone for ligand cleavage by residuals of 
Sortase-A.  
Furthermore, polydispersity of PEG-groups in DSPE-mPEG, but not in DMA-PEG-G5 [17], may 
extent this shielding effect by presence of PEG-chains in DSPE-mPEG with a molecular weight 
larger than the 2 kDa spacer in DMA-PEG-G5. Interestingly, the PEG-layer seems to inhibit only 
the reverse reaction and not the recognition of the pentaglycine motif prior transpeptidation, 
as overall reaction efficacy of both formulations was comparable (Table 3). Compared to that, 
PEGlow-LS probably possess an exposed LPETG-motif in mushroom conformation due to the low 
(DMA-PEG-G5 derived) PEG-fraction of 1 mol%. Low interaction with neighboring polymer coils 
could enhance steric accessibility of the LPETG-motif between VHH and lipid anchor, leading to 
a pronounced reverse reaction. We furthermore tested dh, PDI and zeta potential during 
storage. No relevant changes were observed over the tested time (size and PDI changes < 10 %, 
absolute zeta potential changes < 4 mV, Figure 4).  
Sortase-A is currently gaining attraction as versatile tool to conjugate ligands on particulate drug 
delivery systems [5-7, 9, 12, 17, 26]. Due to the immunogenic potential of bacteria-derived 
protein residuals and the enzyme’s inherent reversibility of the reaction, efficient purification 
methods are essential to ensure drug product stability and quality. 
5
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Figure 4: Stability of VHH ENH-modified liposomes after different purification protocols. No considerable changes in 
size, PDI or zeta potential occurred over an 8 weeks storage at 2-8 °C (circles: PEGhigh-LS, triangles: PEGlow-LS, black 
filling: dialysis, white filling: bead purification). Data shown as mean ± standard deviation of three reactions and 
purification procedures. 
Such methods may include, especially in larger production scale, size exclusion or affinity-based 
chromatography. Our results indicate that especially latter frequently used method may be 
challenging, since considerable residuals of Sortase-A remained in the highly PEGylated 
formulation after affinity bead purification. Estimating a lipid dosing for the presented dialyzed 
PEGhigh-LS comparable to marketed liposomal doxorubicin (Doxil®; maximum dose for the 
treatment of ovarian carcinoma is 50 mg doxorubicin or 400 mg total lipid per square meter of 
body surface), this would result in an application of 20 mg Sortase-A residuals to an average 
patient (1.73 m2). The presented results therefore raise the consciousness on the drawbacks of 
the use of such novel conjugation techniques, which obviously put special demands on 
manufacturing and purification protocols. Especially the separation of Sortase or other catalytic 
proteins from nanoparticulate drug delivery systems can be challenging due to unspecific 
adsorption to the large surface of the nano-sized dispersions. Besides improvements of 
purification techniques, advancement of the manufacturing strategies may contribute to an 
avoidance of drug product instabilities by enzymatic reverse reactions. For Sortase-A, this may 
include the usage of primary amines (e.g. a DSPE-PEG-amine) instead of oligoglycine acceptor 
motifs. Primary amines are known as alternative nucleophiles during the transpeptidation [27]. 
As the final product would not contain a LPxTG-motif, the so obtained constructs may not be 
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susceptible for the reverse reaction, avoiding at least stability, but not immunogenic problems. 
Other strategies, especially suitable for liposome modification, could involve post-insertion 
processes, meaning a separation of ligand lipidation and particle modification [28]. This would 
avoid exposure of the particulate surface with Sortase-A, thereby avoiding unspecific 
adsorption. Also, pre-immobilization of Sortase-A on sepharose beads could help to simplify the 
downstream purification of sortaggable nanoparticulate drug delivery systems [29-31]. 
4.2. VHH DC13-liposomes show cell type specific binding in vitro and in vivo 
Liposomes functionalized with the CD11b-specific VHH DC13 or a control VHH (eGFP-specific 
enhancer) were tested for specific binding to cells that are CD11b positive or negative. CD11b+ 
cells included DC2.4 murine dendritic cell line [32], RAW macrophage cell line [33] and MDSC 
differentiated from NUP cells [22] while CD11b-negative cells included undifferentiated 
NUP cells [22], T cells [34] and B cells [35]. Cell lines or primary splenocytes were incubated with 
100 µM FITC-labeled liposomes (based on total lipid content) for 4 h and analyzed by FACS and 
microscopy.  
Untargeted PEGlow or PEGhigh pentaglycine liposomes (G5-LS) and isotype control-modified 
VHH ENH-LS did not bind to any cell type (Figure 5A). The minor shift of the FITC signal on DC2.4 
and RAW cells might be due to the ability of these antigen presenting cells to phagocytose small 
particles without any specific surface binding. Decoration with VHH DC13 induced specific 
surface binding on cell lines expressing CD11b (DC2.4, RAW). NUP cells did not show any superior 
interaction with the VHH DC13-modified formulations. In contrast, both VHH DC13-modified 
formulations were able to bind towards CD11b+Gr-1+ MDSC differentiated from NUP cells [22]. 
Specificity of binding was tested using a murine splenocyte mix containing CD11b+Gr-1+ cells, 
CD11b-CD3+ T cells and CD11b-CD19+ B cells. Parallel staining of their relevant cell surface 
receptors and simultaneous analysis for the liposomal FITC fluorescence revealed a specific 
binding towards CD11b+Gr-1+ cells, while other cell types like T cells and B cells were unaffected 
(Figure 5A). 
In all cases, VHH DC13-PEGlow-LS showed superior binding compared to VHH DC13-PEGhigh-LS. 
We demonstrated comparable VHH loading (Table 3) and antigen capturing [17] of both 
formulations, however, FITC-dextran encapsulation efficiency was higher for 
VHH DC13-PEGlow-LS (0.42 %) than for VHH DC13-PEGhigh-LS (0.25 %). As concentrations of the 
dye were kept similar during solvent injection, these differences may be due to the slightly larger 
liposome diameter of the PEGlow-LS. Despite the different FITC-dextran loadings, the observed 
differences of in vitro binding may be due to a decreased uptake of the PEGylated liposomes 
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after binding. PEGylation is a widely used method to prevent uptake of the formulation by the 
mononuclear phagocyte system (MPS), thereby increasing in vivo circulation times [24]. In vitro, 
PEGylation was previously shown to reduce the uptake of liposomes by macrophages even at 
low molar bilayer ratios (0.5 mol%) [36]. It might therefore be that here the PEG-layer decreased 
uptake of the liposomes, e.g. via a PEG-induced hindrance of an effective liposome 
internalization. Furthermore, the additional PEG layer may reduce the steric flexibility of the 
conjugated VHH, and thereby decrease the cell-VHH interaction compared to the PEGlow-LS.  
 
Figure 5: In vitro binding of CD11b-targeted liposomes. A: CD11b-positive (MDSC, DC2.4, RAW) and CD11b-negative 
(NUP cells) cell lines were tested for the specific binding of liposomes modified with anti-CD11b VHH DC13. 
Furthermore, specificity of binding was investigated on isolated splenocytes including CD11b+ MDSC and CD11b- T and 
B cells. Both PEGhigh-LS and PEGlow-LS bound to the cells in a ligand dependent fashion. B: Incubation of G5-PEGlow-LS, 
VHH ENH-PEGlow-LS and VHH DC13-PEGlow-LS with RAW macrophages. Confocal microscopy revealed cellular surface 
and cytosolic localization of VHH DC13-PEGlow-LS, but not of the control groups. 
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Confocal microscopy was used to investigate the specific uptake of VHH DC13-PEGlow-LS into 
RAW cells (Figure 5B). Association with the cell surface and internalization to the cytosol was 
observed for VHH DC13 targeted liposomes, but not for the isotype or uncoated control. This 
indicates that the sortagging of liposomes with VHH DC13 enabled the specific delivery of FITC-
loaded liposomes to target cells. 
Although surface marker specific targeting and cellular uptake did work in vitro this may be 
different in vivo as the liposomes might encounter additional hurdles, such as unspecific 
attachment to endothelial cells, loss of target specificity, fast clearance from circulation via the 
MPS or blockage of the antigen-ligand interaction via plasma proteins. We injected 3 mice each 
intravenously with 0.6 mM of the respective VHH-conjugated liposomes (VHH ENH-LS, 
VHH DC13-LS, either as PEGlow-LS or PEGhigh-LS) in 200 µL PBS and isolated the spleen 2 hours 
later. The splenocytes were then stained for flow cytometry analysis to differentiate between 
CD11b- T cells and B cells or CD11b+Gr-1+ cells. ENH-PEGlow-LS were used as isotype control and 
did not bind to any analyzed cell type (Figure 6).  
 
Figure 6: In vivo targeting of splenic CD11b+Gr-1+ MDSC. C57BL/6J mice were injected with 0.6 mM (total lipid) of 
VHH DC13-modified, FITC-dextran-labeled PEGhigh-LS or PEGlow-LS. After 2 h incubation, mice were sacrificed and the 
splenocytes were analyzed for the liposomal FITC fluorescence by flow cytometry after co-staining of MDSC, T and 
B cell determining surface markers. A: Representative flow cytometry histograms. B: Threefold increase in MFI over 
the isotype control group was found for both VHH DC13 targeted formulations (significant for VHH DC13-PEGlow-LS 
(p < 0.05)).  
The uptake of VHH DC13-PEGlow-LS was increased significantly leading to a threefold increased 
FITC signal compared to VHH ENH-PEGlow-LS (Figure 6B). Surprisingly this was true to the same 
extent for both liposomal surface types and not increased with the PEGlow-LS as it was the case 
in vitro. This might be due to different pharmacokinetic behavior of the strongly PEGylated and 
the anionic, charge stabilized formulation. It is known that increasing amounts of 2 kDa PEG 
grafting on liposomal surfaces increase the circulation time of the drug delivery system [37]. The 
increased circulation may therefore compensate a decreased overall binding and uptake of 
PEGylated formulations by the target cells. Furthermore, the presence of a broad variety of 
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plasma proteins in vivo (which cannot be entirely simulated by the presence of FBS in vitro) may 
lead to enhanced alteration of lowly PEGylated surfaces due to increased unspecific protein 
adsorption [38]. This may lead to a decreased accessibility of the VHH on the liposomal surface 
and subsequently a decreased recognition of the targeted cells. These considerations indicate 
the need for thorough and early in vivo characterization of such targeted nanoparticulate drug 
delivery systems.  
5. Conclusion and outlook 
In the present study, Sortase-A was used to conjugate single-domain antibodies (VHHs) towards 
two differently PEGylated, pentaglycine-modified liposomal surfaces. The resulting 
immunoliposomes were analyzed regarding stability against the Sortase-A inherent reverse 
reaction. DSPE-mPEG stabilized liposomal formulations revealed resistance against the reverse 
reaction, though considerable enzyme residuals were detected after a dialysis purification. 
DPPG stabilized PEGlow-LS having low PEGylation degree were prone for ligand cleavage by 
Sortase residuals. This could be overcome by improvement of the purification procedure and 
demonstrates challenges in the usage of enzyme-based conjugation methods for drug delivery 
system modification. 
We investigated the in vitro and in vivo targeting potential of the sortagged, VHH carrying 
liposomes. In vitro, liposomes modified with an anti-CD11b single-domain antibody were 
targeted to various CD11b+ myeloid cells. This observation was successfully verified in vivo, 
where splenic CD11b+Gr-1+ cells were targeted with clear specificity over CD11b- cells. High 
degree of PEGylation seemed to decrease the target cell binding in vitro. Surprisingly, this was 
not observed when splenic CD11b+Gr-1+ cells were targeted in vivo, as both formulations 
performed equally. It is assumed that the extension of circulation time and reduction of 
unspecific plasma protein adsorption via the PEG-shell is responsible for this contrary 
observation. This indicates the need for an early in vivo characterization of nanoparticulate drug 
delivery systems, with a special regard to formulation parameters such as particle surface 
design.  
The CD11b+ and Gr-1+ phenotype determines murine myeloid-derived suppressors cells. This cell 
population exhibits the ability to suppress T cells, leading to a negative impact on the individual 
immune response in diseases such as cancer [19]. Thus, the here presented approach to target 
MDSC is attractive, e.g. for the delivery of toxins which may diminish immune suppression in the 
tumor microenvironment. Since CD11b is present on various other myeloid cells, a more specific 
targeting of MDSC may be achieved with ligands binding epitopes of Gr-1. VHHs specific for this 
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target were recently described [18], and a combination of such ligands with nanoparticulate 
drug delivery systems would be a favorable option for further development. Nevertheless, 
CD11b+ targeting may involve other promising applications such as a selective vaccine delivery 
[39, 40] or delivery of drugs towards atherosclerotic plaques [41].  
With the presented work, manufacturing demands and formulation parameters determining the 
in vivo targeting of sortagged, VHH-modified liposomes were highlighted. They underline 
important challenges, but also the potential of such novel targeted drug delivery systems. 
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Abstract 
Purpose: Membrane engineering has versatile applications in adoptive cell therapies, immune 
therapy or drug delivery. Incorporation of lipidated ligands into cells may enforce 
supraphysiological cell interactions that offer new therapeutic approaches. A challenge is the 
defined synthesis of lipidated ligands that effectively interact with such membranes.  
Methods: Sortase-A was used to attach a PEGylated, dimyristyl anchor on single-domain 
antibodies (VHH). The membrane insertion was investigated on artificial liposomal bilayers, 
myeloid-derived suppressor cells (MDSC) and T cells.  
Results: The lipidated VHHs remodeled artificial liposomal as well as cellular membranes. The 
VHH carrying liposomes were successfully targeted towards epitope-positive cells. MDSC and 
T cells were both modified with lipidated VHHs as detected with an FITC-anti-llama antibody. 
T cells that carried an anti-CD11b VHH showed cellular association in vitro with CD11b+Gr-1+ 
MDSC in a two-dimensional magnetic activated cell sorting / flow-cytometry assay.  
Conclusion: The applied combination of chemoenzymatic ligation, PEGylated lipid and single-
domain antibody delivers water-soluble and chemically defined lipidated ligands. Since the 
membrane-inserted constructs enabled liposomal targeting or cell-cell interactions, they are 
suitable for further application in the field of drug delivery and cell-based therapies.  
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1. Introduction 
Cell membrane engineering is a means to induce or enforce cell-cell or cell-extracellular matrix 
interactions [1, 2]. This has been proven valuable for cell-based therapies such as chimeric 
antigen receptor (CAR)-T cell therapy [3], the regulation of immune responses by surface-
modified cells [2] or in the field of regenerative medicine [1]. A prerequisite of such membrane 
engineering is the anchoring of typically proteinaceous structures into the cell membrane. One 
option for this anchorage is genetic engineering, leading to the expression of the protein of 
choice together with a transmembrane domain and intracellular sequences for signal 
transduction as applied in (CAR)-T cell therapies. In this approach, T cells are transfected with a 
construct that contains an extracellular scFv fragment linked to activating domains that induce 
T cell activation upon target engagement on tumor cells [3]. However, genome engineering has 
several drawbacks including safety related to genome editing [4, 5] or over-activation due to 
constitutive expression [6]. Additionally, display of proteins via genetic engineering may be 
challenging, since correct protein transduction across the cell membrane is required after a 
susceptible protein expression, folding, and intracellular trafficking process [7]. If the protein to 
be displayed on cells does not require an intracellular signal transduction or genetic 
inheritability, it can also be engineered to the cell surface by non-genetic techniques [1]. Possible 
applications include the support of immune therapies by anchorage of cytokines [8], increased 
chemotaxis for mesenchymal stem cells during regenerative therapies [9, 10] or treatment of 
autoimmune diseases [11, 12]. 
Non-genetic techniques for cell surface engineering are the covalent anchorage through on-site 
reactions with other components of the cell membrane [2, 11, 13, 14], or a spontaneous 
hydrophobic insertion of the structure of interest into the bilayer due to a previously attached 
lipid group [1, 15]. The latter strategy offers high control of the density of the displayed protein, 
avoids exposure of cells to toxic reagents and works in a rapid fashion [7]. Further advantages 
are the negligible toxicity, the maintenance of normal cellular activities and the participation of 
the inserted molecules in the cell membrane dynamics, although the latter may also lead to an 
undesired endocytosis of the inserted compound [1]. Despite these advantages, protein 
lipidation is technically difficult, since established chemical conjugation techniques (relying on 
reactive amino acid side chains) suffer from poor selectivity, leading to heterogeneous reaction 
products [16]. A further problem is the low solubility of lipophilic anchors [15] that causes strong 
increases of hydrophobicity of the lipidated protein. This can lead to a high aggregation 
tendency. Such solubility issues may be alleviated by the use of detergents such as 
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n-dodecyl-maltoside [15], however with unfavorable impact on the application of such lipidated 
proteins on living systems. 
Therefore, in this study a PEGylated dimyristyl anchor was attached to single-domain antibodies 
of camelid heavy chain only antibodies (VHH) using chemoenzymatic ligation via the bacterial 
enzyme Sortase-A (Scheme 1). The inherent site-specificity of Sortase-A leads to highly defined 
reaction products [17]. Furthermore, PEGylated lipid anchors with two medium length (C14) 
alkyl chains [18], together with highly soluble VHHs [19], deliver reaction products with good 
aqueous solubility. This avoids usage of detergents or organic co-solvents, and hence enables 
direct application of such lipidated proteins on living cells while providing reliable anchorage in 
membranes [15, 20]. Sortaggable VHHs binding the enhanced green fluorescent protein eGFP 
(VHH ENH) or a myeloid cell surface receptor CD11b (VHH DC13) have been previously described 
[21, 22]. Therefore, the influence of the lipidation and isolation process on product purity, yield 
and binding activity was investigated here. Membrane insertion of lipidated VHHs into an 
artificial bilayer of fluorophore-labeled liposomes was analyzed via the binding of the so 
obtained immunoliposomes towards CD11b+ myeloid-derived suppressor cells (MDSC). In vitro 
display of lipidated VHHs on MDSC and T cells was investigated by detection of the VHHs on the 
cells using an antibody directed against the VHHs. Furthermore, it was in question whether the 
VHHs retain their ability to recognize the corresponding antigen if inserted into the cellular 
membrane. For that purpose, cells remodeled with lipidated VHH ENH were analyzed for their 
ability to capture the antigen eGFP. Finally, to demonstrate the ability of the lipidated VHHs to 
mediate cell-cell interactions, purified murine T cells were modified with VHH DC13 and 
analyzed by a two-dimensional magnetic activated cell sorting (MACS) / flow cytometry assay to 
determine interaction with CD11b+ myeloid-derived suppressor cells.  
 
Scheme 1: Sortase-A mediated conjugation of LPETG-modified VHH with the pentaglycine-modified lipid anchor 
DMA-PEG-G5. 
2. Materials 
Sortase-A variant SortA7m and LPETG (leucine, proline, glutamic acid, threonine, glycine)-
modified single-domain antibodies (Structure 1 in Scheme 1) of camelid heavy chain only 
antibodies (VHH) VHH ENH and VHH DC13 were prepared as described elsewhere [23]. VHH ENH 
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binds to enhanced green fluorescent protein eGFP whose fluorescence intensity increases upon 
binding [21]. VHH DC13 recognizes the myeloid cell surface receptor CD11b [24]. DMA-PEG-G5 
(Structure 2 in Scheme 1, 2554 Da) is a 2 kDa PEG-spacer modified on one end with a 
pentaglycine motif and on the other end with a dimyristyl lipid anchor and was obtained from 
Merck & Cie (Schaffhausen, Switzerland). Lipoid GmbH (Ludwigshafen, Germany) was supplier 
of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-dipalmitoyl-sn-glycero-3-
phospho-(1'-rac-glycerol) (DPPG). Sigma-Aldrich (St. Louis, MO, USA) was supplier of Dulbecco’s 
phosphate buffered saline (DPBS, D1408), fluorescein isothiocyanate-dextran (FITC-dextran) 
10 kDa and cholesterol. Chloroform, acetonitrile, trifluoroacetic acid (TFA), methanol and 
ethanol (both gradient grade) were obtained from Merck KGaA (Darmstadt, Germany). Milli-Q, 
MilliporeSigma (Billerica, MA, USA) was used for the preparation of purified water.  
3. Methods  
3.1. Conjugate synthesis, isolation and analysis 
DMA-PEG-G5 stock (25 mg/mL in chloroform) was aliquoted in a HPLC vial. Chloroform was 
evaporated under a gentle stream of nitrogen creating a thin lipid film, which was hydrated with 
DPBS pH 7.4 as micellar aqueous lipid dispersion (2 mM). 400 µL of 50 µM VHH, 25 µM Sortase-A 
and 1 mM DMA-PEG-G5, which corresponded to a target product mass of 320 µg, were 
incubated for 4 h at 4 °C, until the conjugate was isolated using reversed-phase HPLC (rp-HPLC). 
Reaction bulk and product were separated utilizing an Aeris Widepore C4 column (3.6 µm 
particle size, 100 mm length, 2.1 mm diameter, Waters Corporation, Milford, Massachusetts, 
USA) and a binary gradient pattern (Table 1). 
Table 1: rp-HPLC gradient pattern for separation of reaction bulk and product (A: water with 0.1 % TFA v/v, B: 
acetonitrile with 0.05 % TFA v/v). 
time [min] solvent composition 
0.0 95.0 % A 
5.5 45.5 % A 
15.0 18.5 % A 
15.1 5.0 % A 
18.0 5.0 % A 
18.1 95.0 % A 
20.0 95.0 % A 
 
Eluent A was water with 0.1 % TFA, eluent B was acetonitrile with 0.05 % TFA. Analysis was 
performed on an Agilent 1110 HPLC system equipped with a degasser, binary pump, 
temperature controlled autosampler, column oven, diode array detector (DAD) and an analytical 
fraction collector (AFC), controlled by EZChrom Elite Software (Agilent Technologies, Santa Clara, 
CA, USA). Column temperature was set to 30 °C, autosampler temperature was 4 °C. Standard 
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analytical or isolation injection volume was 5 µL or 25-100 µL, respectively. Flow rate was 
0.5 mL/min. Data was recorded using DAD at 214 and 280 nm.  
The conjugate peak was collected either manually or using an automated fraction collector. 
Collections of single injections were stored on ice, until the eluent mixture was removed using 
a vacuum centrifuge (RVC 2-33 IR, Martin Christ, Osterode am Harz, Germany; speed: 1500 rpm, 
temperature: 40 °C, pressure settings: 100 mbar for 10 min, followed by 20 mbar for 20 min and 
further evaporation at 2 mbar). The resulting pellet was hydrated with water, and protein 
concentrations were determined by UV spectroscopy (NP80, Implen, Westlake Village, CA, USA) 
using extinction coefficients calculated by ExPASy ProtParam web application 
(https://web.expasy.org/protparam, SIB, Lausanne, Switzerland). Yield was calculated based on 
the mass and concentration of the recovered protein solution and the target product mass. 
Purity was determined by rp-HPLC analysis at 214 nm with automated peak detection between 
2-15 min and a threshold level obtained from background noise of a water blank.  
3.2. Mass spectroscopy 
To verify the reaction product, the method was transferred to a similar HPLC system equipped 
with an electrospray ionization mass spectrometer (ESI-MS, amaZon SL, Bruker Corporation, 
Billerica, Massachusetts, USA). Ion source type was set to ESI with positive polarity. Capillary exit 
was 140 V, trap drive was set to “94”. The mass range mode was set to enhanced resolution, 
with a scanning range from 100-2200 m/z. 5 spectra were averaged per run. Masses were 
calculated using deconvolution of raw spectra. 
3.3. Activity of lipidated VHH ENH 
The isolated VHH ENH conjugate or native VHH ENH (100 nM) was spiked to 100 nM eGFP. 
Increase in fluorescence intensity compared to sole eGFP was measured in a black 96-well plate 
(Thermo Fisher Scientific, Waltham, Massachusetts, USA) utilizing a Spark Plate Reader (Tecan 
Group, Männedorf, Switzerland) with excitation and emission set to 485 nm and 535 nm, 
respectively. 
3.4. Liposome preparation and post-insertion 
FITC (fluorescein isothiocyanate)-labeled liposomes were prepared as described elsewhere [25]. 
In brief, a mixture of DPPC, cholesterol, DPPG and DMA-PEG-G5 (59.4 : 34.6 : 5.0 : 1.0, molar 
fractions) was dissolved to 32 mM in methanol and injected via a computer-controlled binary 
pumping system into a 10 mg/mL FITC-dextran solution in DPBS pH 7.4 utilizing a customized 
T-piece with a 27 G needle. The dispersion was purified and concentrated by tangential flow 
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filtration. Lipid concentration was determined by an rp-HPLC method with evaporative light 
scattering detection described elsewhere [18]. To prepare immunoliposomes, the lipidated 
VHH ENH or VHH DC13 were added to the liposomal dispersion to 0.25-2 nM 
VHH per µM phospholipid (PL). The mixture was thoroughly vortexed and incubated at 50 °C for 
30 min. Hydrodynamic diameter (dh) and polydispersity index (PDI) were measured by dynamic 
light scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK).  
3.5. Immunoliposome binding and VHH display on MDSC 
Murine myeloid-derived suppressor cells (MDSC) were derived from bone marrow-derived 
NUP-progenitor cells [26]. MDSC were differentiated for four days in complete RPMI (RPMI 1640 
medium, Life Technologies, #21875-034, Carlsbad, CA, USA) supplemented with 10 % heat-
inactivated fetal bovine serum, 100 U/mL penicillin (Life Technologies, #15140122), 100 µg/mL 
streptomycin (Life Technologies, #15140122), 1 mM sodium pyruvate (Life Technologies, 
#11360070), 50 µM 2-mercaptoethanol (Life Technologies, #31350-010), and 1 × non-essential 
amino acids (Life Technologies, #11140-035) supplemented with 20 ng/mL interleukine-6 and 
20 ng/mL granulocyte-macrophage colony-stimulating factor (Biolegend, #576304, San Diego, 
USA). To investigate membrane insertion of lipidated VHHs, MDSC (107 cells/mL) were incubated 
for 30 min at 4 °C with 500 nM of native or lipidated VHH ENH or VHH DC13. To investigate 
binding of VHH-modified liposomes, MDSC were incubated with 500 µM of the liposomes (based 
on total lipid content) for 4 h at 4 °C. In both cases, cells were washed with FACS buffer (1 × PBS 
+ 2 % heat-inactivated fetal bovine serum) and antibody staining of cells was performed in 
presence of Fc receptor block (TruStain FcX, BioLegend, #422302) in FACS buffer. SytoxBlue 
(Thermo Fisher Scientific, S34857) was used for exclusion of dead cells. Liposomes were 
detected via encapsulated FITC-dextran. Lipidated VHH inserted into the cell membrane was 
detected by a FITC-anti-llama antibody (Invitrogen, #A16061). Alternatively, cells were 
incubated with 100 µg/mL eGFP at 4 °C for 30 min to detect binding of eGFP to lipidated 
VHH ENH being inserted into the cell membrane. All analyses of cells were performed by flow 
cytometry. Flow cytometry was performed on a FACSAria II (Beckton, Dickinson and Company, 
Franklin Lakes, NJ, USA) and results were analyzed by FlowJo (Tree Star, V.10.0.8).  
3.6. Display of VHHs on T cells and cell-cell interaction experiments 
For cell-cell interaction experiments, T cells were isolated from spleens of C57BL/6j mice 
maintained under specific pathogen-free conditions at the animal facility of the University of 
Heidelberg and euthanized under the registered protocol T47/16. Spleens were mashed and 
CD8+ cells isolated after red cell lysis (ACK lysing buffer, #A1049201, Thermo Fisher Scientific) 
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using a mouse CD8a+ T cell isolation kit (#130-104-075, Miltenyi Biotec, Bergisch-Gladbach, 
Germany) and magnetic cell isolation (LS columns, #130-042-401, Miltenyi Biotec) used 
according to manufacturer’s instructions. Purified CD8+ T cells were stained by 1 nM Cell Tracer 
Far Red (#C34564, Thermo Fisher Scientific) for 5 min at 35 °C and washed with FACS buffer. 
Stained T cells (1.65 × 108 cells/mL) were incubated with 650 nM native or lipidated VHH DC13 
and VHH ENH for 1 h at 4 °C. Lipidated VHH binding to T cells was detected by an FITC-anti-llama 
antibody. VHH-labeled T cells were washed twice with FACS buffer and 3 × 107 T cells were 
incubated with 1.1 × 107 MDSC for 1 h at 4 °C. T cells and MDSC were loaded on LS columns for 
magnetic bead isolation of CD8+ T cells and co-purification of MDSC bound to T cells. Eluted cells 
were stained by anti-CD11b-Brilliant Violet 605 and anti-Gr-1-FITC (#101237 and #108405, 
Biolegend) and analyzed by flow cytometry as described above. 
4. Results 
4.1. VHH lipidation, isolation and activity 
VHHs were conjugated to the PEGylated dimyristyl anchor DMA-PEG-G5 lipid using 
chemoenzymatic Sortase-A mediated transpeptidation (Scheme 1). For that purpose, 
DMA-PEG-G5 was dissolved in chloroform, aliquoted, dried by solvent evaporation and hydrated 
with DPBS in an ultrasonic bath. This film hydration yielded a micellar dispersion with a colloidal 
hydrodynamic diameter of 18-32 nm (measured by DLS). 1 mM DMA-PEG-G5 was incubated 
with 25 µM Sortase-A and 50 µM LPETG-VHH to achieve a high conversion yield through surplus 
of the pentaglycine nucleophile. Two different VHHs were tested for conjugation, namely 
VHH ENH, binding to eGFP and enhancing its fluorescence [21], or VHH DC13, binding to cell 
surface marker CD11b of myeloid cells [24]. An analytical rp-HPLC column with large pore size 
(200 Å) and low hydrophobicity (C4) provided adequate separation of Sortase-A (5.2 min), 
unconjugated VHH (5.6 min) and DMA-PEG-G5 (8.4 min) from the reaction product (7.6 min). 
Rp-HPLC analysis showed effective lipidation of the VHHs (Figure 1A), indicated by a hydrophobic 
shift of the retention time of the VHH. The expected peak of the lipidated VHHs was analyzed 
by LC-ESI-MS and good accuracy was found with the calculated mass for the two examined VHHs 
(Figure 1B, calculated / determined mass for VHH DC13: 15804 Da/ 15812 Da; VHH ENH 
15835 Da / 15843 Da (data for VHH ENH conjugate available in Chapter 3, Figure 4)).  
The described rp-HPLC method was compatible with injection volumes up to 100 µL (equalizing 
a maximum of 80 µg product) and therefore suitable for small scale purification of the lipidated 
VHH in sub milligram batch sizes. Up to four collected peak fractions were combined, and the 
eluent was removed by vacuum centrifugation. The pellets were dissolved in water to 1 mg/mL 
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and showed high purity (> 95 %, Figure 1C, Table 2). Yield was typically above 50 % for both VHH 
types. Lot #3 of VHH ENH conjugate was collected using a fraction collector and had a lower 
yield (27 %). Furthermore, slightly increased turbidity was measured during UV-quantification 
(A350 nm, 10 mm = 0.06 for lot #3 and < 0.02 for lot #2 and #3). VHH ENH is known for its ability to 
increase the fluorescence intensity of eGFP upon binding [21].This characteristic was employed 
as tool to test whether the isolated, lipidated VHH ENH recognize and bind its target protein 
comparably to the native VHH ENH. Native VHH ENH increased the fluorescence intensity by a 
factor of 1.9. No significant differences (p > 0.3) in fluorescence intensity increase were obtained 
comparing lot # 1, lot #2 of the isolated, lipidated VHH ENH and the native VHH ENH (Figure 1D). 
Lot #3 showed a lower increase in fluorescence (p = 0.013). It may be that lack of cooling of the 
column effluent in the AFC is responsible for lower yield and loss of activity of lot #3. 
 
Figure 1: A: rp-HPLC analysis of reaction bulk containing Sortase-A, LPETG-modified VHH ENH, the lipidated VHH ENH 
and unconjugated DMA-PEG-G5. B: ESI-MS verification of VHH DC13 lipidation. Target mass was calculated as native 
VHH mass plus lipid mass minus mass of the his-tag cleaved off from the native VHH during transpeptidation (GGH6, 
955 Da). C: rp-HPLC of the isolated lipidated VHH ENH revealed high purity of the final product. D: Activity of VHH ENH 
after lipidation. Either native or conjugated and isolated VHH ENH bound eGFP and increased its fluorescence signal 
at 525 nm after excitation at 485 nm (mean ± standard deviation, n=3). 
Table 2: Isolation of lipidated VHHs via rp-HPLC. 
conjugate purity [area%] yield 
VHH ENH lot #1 96 % 50 % 
VHH ENH lot #2 97 % 52 % 
VHH ENH lot #3 95 % 27 % 
VHH DC13 lot #1 97 % 60 % 
 
4.2. VHH insertion in liposomal bilayers 
It was of interest whether the VHH can be anchored in membranes after the Sortase-A mediated 
lipidation. Therefore, dipalmitoyl-phosphatidylcholine-based, fluorophore-labeled liposomes 
(dh = 149 nm, PDI = 0.23) were used as artificial membrane system [25]. The liposomes were 
incubated above the phase transition temperature of the lipid blend (determined to be 42 °C by 
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differential scanning calorimetry) at 50 °C for 30 min either with lipidated VHH ENH or VHH DC13 
at different VHH to phospholipid ratios (Figure 2A). Dynamic light scattering was used to 
investigate influence of membrane insertion on the dh of the dispersion. An increase of dh with 
increasing ligand density of up to 20 nm at 2 nM VHH / µM PL was observed for VHH DC13-
modified liposomes (Figure 2A, bars), indicating insertion of the ligand into the liposomal 
membrane. Since the PDI (Figure 2A, dots) did not change during the incubation process, the 
ligand insertion had no negative impact on the polydispersity of the dispersion. 
 
Figure 2: Liposome modification with lipidated VHHs and cellular binding. A: Post-insertion of lipidated VHHs 
monitored by dynamic light scattering. Slight increases in liposome diameter were observed depending on targeting 
ligand density (error bars indicate standard deviations of triplicate measurements; PL: phospholipid)). B: Influence of 
ligand density on cellular binding of VHH DC13-modified liposomes on myeloid-derived suppressor cells. Error bars 
indicate range of two experiments. C: Flow cytometry dot plots of binding of unmodified liposomes, isotype control 
(VHH ENH) and CD11b-targeted VHH DC13 liposomes (2 nM/µM phospholipid) towards MDSC. Detection of liposome 
binding using liposome-encapsulated FITC-dextran. The number within each dot plot indicates the percentage of 
events within the marked gate. 
To investigate whether post-inserted VHH DC13 can target liposomes towards CD11b+ cells, the 
ligand-modified, FITC-dextran-labeled liposomes were incubated with CD11b- NUP cells or 
CD11b+ MDSC for 4 h at 4 °C. NUP cells are MDSC progenitors that can be differentiated to 
express MDSC characteristic surface markers (CD11b and Gr-1) [26]. Binding towards these 
off-target cells occurred only to a negligible extent and independent of the VHH DC13 density 
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on the liposomes (Figure 2B). Compared to that, a significant binding (> 60 % FITC-positive cells) 
was observed for all VHH DC13-modified liposomes on CD11b+ MDSC. The binding efficiency was 
ligand-density dependent with a maximum at 0.5 nM VHH per µM phospholipid. VHH-free 
liposomes or VHH ENH isotype control liposomes did not stain cells to a relevant degree (< 4 %, 
Figure 2B and C). This indicates the specificity of the binding of VHH DC13-modified liposomes 
towards CD11b+ MDSC.  
4.3. Display of lipidated VHHs on cells 
It was in question whether the lipidated VHHs can also interact with biological membranes of 
living cells. It was therefore tested if lipidated VHH ENH or VHH DC13 can associate with cellular 
membranes of CD11b+ MDSC or CD8+ T cells. MDSC were found positive for lipidated VHH ENH, 
as detected with a FITC-labeled antibody against llama antibody epitopes after incubation of 
lipidated VHH ENH and cells (Figure 3A). 
 
Figure 3: Display of lipidated VHHs on cell membranes. A: Display of lipidated VHH ENH and VHH DC13 on MDSC and 
T cells. Detection by FITC-anti-llama antibody. B: Antigen capturing ability of native and lipidated VHH ENH in cell 
membranes of MDSC compared with native and lipidated control VHH DC13. Detection of eGFP (intrinsic 
fluorescence) binding to MDSC. The number within each dot plot indicates the percentage of events within the 
marked gate. 
Unspecific cell association of native VHH occurred only to a negligible degree, as no difference 
of native VHH and buffer control without VHH was observed (data not shown). Incubation with 
lipidated and native VHH DC13 with CD11b expressing MDSC resulted in detection of VHH DC13 
by anti-llama antibody without differences (Figure 3A). The binding to its antigen masked the 
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potential additional insertion of lipidated VHH in the cell membrane. Compared to that, a 
successful display of both lipidated VHHs on CD11b- T cells was detected (Figure 3A).  
It was in question whether the VHH-engineered cells can capture the VHH-corresponding 
antigen. Therefore, MDSC were incubated with 500 nM of lipidated VHH ENH, followed by 
incubation with eGFP (Figure 3B). The VHH ENH-modified cells bound to eGFP by obtaining a 
significant eGFP signal in flow cytometry (20 % positive cells). Control groups included cells 
which had been incubated with native VHH ENH or native or lipidated VHH DC13, serving here 
as a non-binding VHH. All showed an approximately 20fold lower eGFP-signal.  
4.4. Lipidated VHH DC13 promotes supraphysiological cell-cell interaction 
The enforcement of cellular accumulations in desired tissues through cell membrane 
engineering may offer novel therapeutic approaches, e.g. in adoptive cell therapies. It was 
therefore investigated whether the lipidated VHH DC13 can promote cellular interaction 
between MDSC and T cells. For that, murine T cells were isolated using ferromagnetic CD8 
affinity beads for MACS. The isolated T cells were modified with lipidated VHH DC13 or controls, 
further incubated with CD11b+ MDSC and again separated via MACS utilizing CD8 affinity beads 
present on the cell surface. The CD8+ retentate was stained for CD11b and Gr-1 with 
fluorophore-labeled antibodies and analyzed by flow cytometry (Figure 4).  
 
Figure 4: Lipidated VHH DC13 promotes T cell-MDSC interaction. A: T cells and MDSC were stained by anti-CD11b and 
anti-Gr-1 antibodies for flow cytometry analysis. Both markers are expressed only by MDSC. B and C: CD8+CD11b-Gr-1-
T cells were labeled by anti-CD8 ferromagnetic beads for MACS isolation. Isolated T cells were incubated with lipidated 
anti-CD11b VHH DC13 or controls (native VHH ENH, lipidated VHH ENH, native VHH DC13), followed by incubation 
with CD11b+Gr-1+ MDSC and again purified by MACS isolation. CD8+ retentate was stained for CD11b and Gr-1 and 
analyzed by flow cytometry. Cellular populations pre-incubated with lipidated VHH DC13 caused higher signals for 
MDSC in the LS column retentate, indicating that VHH DC13 promoted cellular interaction between MDSC and T cells. 
Percentages given in the dot plots indicate the fraction of cells in CD11b+ / Gr-1+ subset.  
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This two-dimensional approach of MACS and FACS enabled the detection of the interaction 
between CD8+ T cells and CD11b+ MDSC mediated by the inserted lipidated VHH. As expected, 
isolated, single T cells hardly showed any CD11b or Gr-1 expression compared to MDSC (Figure 
4A). T cells which were incubated with either native or lipidated control VHH or native VHH DC13 
showed a subset of approximately 7 % positive cells which were retained by the column on the 
magnet, probably due to unspecific cell-column interaction (Figure 4C). This subset doubled to 
14 % CD11b+Gr-1+ events when the T cells were pre-treated with lipidated VHH DC13. This 
indicates that lipidated anti-CD11b VHH DC13 was efficiently inserted into cell membranes of T 
cells, and that the paratope region of DC13 was further sterically accessible for interaction with 
the CD11b+ MDSC.  
5. Discussion 
The results reported in this study reveal important perspectives for the use of lipidated 
single-domain antibodies for membrane engineering. The lipidation of proteins is a challenging 
step, as heterogeneity of the reaction product is strongly dependent on the applied ligation 
method. Most protein modification reactions are chemically-based, making use of amino acid 
side chains to be conjugated either directly or after a preceding activation step towards the lipid. 
These activations include introduction of sulfhydryl groups by simple reduction [27] or thiolation 
reagents [28], oxidation of hydroxyl groups from carbohydrate, serine or threonine to aldehydes 
[29] or frequently used carboxylic-acid activation by 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDC) [30]. However, reaction conditions and lack of site-specificity may influence 
paratope regions going along with affinity losses, stability issues and finally a heterogeneous 
product profile due to a huge and undefined number of lipid molecules per protein [31]. 
Heterogeneous product profiles were revealed as critical safety hurdle in the design of antibody-
drug conjugates [16] and led to increased research efforts in development of site-specific 
conjugation techniques [32, 33]. Amongst them, Sortase-A transpeptidase is established as 
versatile “swiss army” promoting chemo-selective, bioorthogonal conjugation between 
C-terminal LPxTG-modified and N-terminal glycine-carrying peptides or proteins [17]. This 
technology was previously used by Antos et al. to ligate via 1 % (w/v) n-dodecyl maltoside 
solubilized triglycine-lipid nucleophiles to LPETG-modified eGFP with good yields between 
60-90 % [15]. The lipidated eGFP molecules did then readily insert into HeLa cells with an 
increasing efficiency with increase in lipid tail length. Compared to that study, the here 
presented PEGylated dimyristyl anchor has good aqueous solubility, hence detergents were 
omitted without the risk of product precipitation. Antos et al. further reported the removal of 
His6-tagged Sortase-A via a Ni-NTA resin, and also non-conjugated substrate protein (the His6-tag 
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is cleaved during the transpeptidation reaction). Although this is a very gentle approach to 
remove enzyme and non-tagged protein, such a strategy disregards purification from non-
conjugated lipid. Reversed-phase HPLC was previously described for the isolation of lipopeptides 
[34]. Therefore rp-HPLC was here chosen for product purification from Sortase-A, unreacted 
VHH and pentaglycine lipid. We used an analytical chromatographic system and column for 
purification of low volume (400 µL) and minimal mass (320 µg) batch sizes, which was found to 
be suitable for protein handling in early research (product yields from conjugation and 
subsequent purification were above 50 %). The reaction and purification process did not impact 
the binding of the model VHH ENH to its corresponding antigen eGFP. This was demonstrated 
by an equal ability of both native and lipidated VHH to increase the fluorescence of eGFP, as 
long the column effluent was treated under cooled conditions during conjugate purification. 
The isolated VHH-lipid conjugates were inserted into the artificial bilayer of a liposomal drug 
delivery system [25]. This “post-insertion” technique enables a combinatorial approach to 
derivatize non-targeted liposomes into immunoliposomes. This is very suitable for small-scale 
screenings in lab-scale. Furthermore, it opens the perspective towards patient-individual or 
stratified nanomedicine. Here, a bulk of drug-loaded liposomes may be transformed to different 
immunoliposomal formulations without the need of separate manufacturing lines [35, 36]. We 
incubated FITC-labeled liposomes with various concentrations of the micellar ligand dispersion 
and found an increasing hydrodynamic diameter dependent on the ligand density (Figure 2A). 
Size increase of liposomes is known from the insertion of PEG-derivatized distearyl-
phosphoethanolamine [37], where 2-16 nm net diameter increases were reported, related to 
the molar fraction of the applied PEGylated lipid and the resulting PEG-conformation at the 
bilayer. Sterically stabilized liposomes containing 6 % PEG-lipids (2 kDa) previously showed a size 
increase of 32-36 nm when modified with PEG-spaced full-length antibodies [38]. Compared to 
that, lower absolute diameter increases were found here which ranged from 8-20 nm with 
increasing ligand density. We attribute this increase in part to the additional VHH-layer on the 
liposomes, whose dimensions are about 2.5 x 4 nm and hence significantly smaller than a full 
length antibody of 8.5 x 14.2 nm [19]. Furthermore, additional conformational changes of the 
PEG-pentaglycine groups in our formulation may occur upon insertion of the PEGylated ligand. 
The binding efficacy to CD11b+ MDSC had a ligand-density dependent maximum at 0.5 nM VHH 
per µM phospholipid (Figure 2B). Latter corresponds to ≈129 VHHs per liposome, calculated 
from the assumption of an average lipid headgroup area of 0.6 nm2, the lipid concentration and 
the dh of the unmodified liposomes. Effective targeting at comparable ligand densities between 
0.2-0.7 nM / µM PL was described for Fab’, scFv or mAb ligands on doxorubicin-loaded 
liposomes. Those were targeted against CD19 on human B cells and exhibited good activity 
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against raji-tumors in mice [35, 39]. The binding maximum at 0.5 nM VHH / µM PL (Figure 2B) 
may be explained by a steric interaction and a subsequent hindrance of paratope-epitope 
interaction between liposome and cell if a higher density is applied [40]. Furthermore, there may 
be a fraction of lipidated DC13 which did not integrate into the liposome and may therefore 
decrease the availability of free CD11b receptors on the cellular surfaces. A thorough 
optimization of the ligand density on the drug delivery system was not purpose of this study. 
Instead, it should be noted that here described post-insertion offers several advantages over 
previously reported, on-site sortagging of ligands to liposomes [25, 41-44]. As one can expect 
high insertion rates (> 80 % in liposomes with a PEGylation degree below 2 mol%) for lipidated 
ligands [38], subsequent purification steps to remove unbound ligands are not necessary. This 
enables minimization of batch sizes, what is extremely helpful in early research phases, since 
experiments can be conducted without regard to device design of dialysis chambers or 
ultracentrifugation filter devices. Furthermore, Sortase-A has no contact to the drug delivery 
system itself. This is highly appreciated, since large-surface nanoparticle dispersions are known 
to adsorb proteins in relevant quantities in an unspecific fashion, hence making complete 
enzyme removal challenging. Such Sortase-A residuals may cause immunogenic reactions or 
stability issues due to the enzymatic reverse reaction [17, 25, 43]. 
Besides the above discussed display of lipidated eGFP on cells [15], Sortase technology was used 
to attach functional proteins on living cells. Tomita et al. inserted a triglycine bearing lipid in 
murine thymoma cells (E.G7), which was then conjugated to a LPETG-modified Fc domain via 
Sortase-A [7]. The so modified tumor cells underwent a fourfold higher phagocytosis rate after 
co-culture with dendritic cells [7]. In a very recent study, Pishesha et al. used CRISPR/Cas9 to 
genetically introduce a LPETG-motif in the Kell-protein of red blood cells (RBC) in a murine germ 
line. The RBCs were then sortagged with various disease-associated autoantigens, and 
autologous treatment with those cells protected the mice against the respective autoimmune 
disease (encephalomyelitis, diabetes type 1) [11]. Swee et al. utilized a biotinylated LPETG-probe 
to firstly investigate the general sortagging feasibility of endogenous, exposed glycine residues 
on various cells. The authors reported that presumably most cells have glycines that are 
amenable for sortagging [14]. This sheds light on bioorthogonality of Sortase-A reaction, which 
is per se a site-specific reaction for the LPETG-carrying educt, however loses specificity in living 
systems where alternative nucleophiles such as endogenous proteins with N-terminal glycines 
are ubiquitously present. The authors further demonstrated that grafting a VHH specific for 
murine class-II MHC on activated T cells led to a specific, VHH-density related killing of MHC-II+ 
B cells, but not of MHC-II- CD4 T cells. This indicated a cellular redirection of cytotoxic T cells to 
the lymphocytes via the VHH. Similar results were obtained by Shi et al., who directed red blood 
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cells (RBCs) equipped with the same VHH towards B cells [13]. In the study presented here, 
MDSC were successfully remodeled with the lipidated VHH ENH specific for eGFP. Compared to 
that, the lipidated VHH DC13 specific for the MDSC epitope CD11b did not show a superior 
presence on the MDSC surface compared to its native form. This is most likely due to the 
predominant binding between antibody and antigen, which masks the membrane insertion 
process. Although the lipidated VHH ENH was detected on the MDSC surface with a 
FITC-anti-llama antibody, the activity of the paratope regions after cell insertion was unknown. 
It was therefore tested whether the VHH ENH-functionalized MDSC can capture the 
corresponding antigen eGFP. A specific binding of eGFP to VHH ENH-modified MDSC was found 
by flow cytometry. This shows that the paratope regions remain accessible for soluble target 
proteins on cellular surfaces after membrane insertion, hence enabling artificial interactions 
between proteins and cells. 
Besides MDSC, also T cells were successfully remodeled with the lipidated VHH ENH and 
VHH DC13. T cells which displayed VHH DC13 showed association with CD11b+Gr-1+ MDSC in a 
co-incubation assay. A functional cytotoxicity read-out (which would have required activated 
T cells) was not focus of the study here. Both MDSC and T cells rather served as model cell types 
to demonstrate an artificial cell-cell interaction introduced by hydrophobic insertion of lipidated 
VHHs, and that this process has decisive advantages over the “on-cell” sortagging approach 
demonstrated in the above explained studies [13, 14]. Firstly, reaction with various endogenous 
available glycines is obviated, since the enzyme has no contact to cells. This avoids formation of 
unspecific reaction products and alleviates hazards through auto-immunogenic response or 
impairment of cellular functions. Also, no removal of Sortase-A from the cells is required. This is 
especially useful for clinical application, where additional steps such as enzyme depletion in cell 
preparations for autologous therapies increase risks and costs of such procedures. Furthermore, 
risk of immunogenic reactions against potential Sortase-A residuals is drastically reduced. 
Hydrophobic insertion of a lipidated ligand is a rapid process [10] and is most likely easier to 
control than on-site reactions on genetically introduced LPETG-motifs [11, 13] or endogenous 
glycines [14]. Usage of lipidated ligands may therefore offer a better control of the density on 
the cells. Additionally, no genetic modification of cells is required. This is particularly suitable for 
therapies requiring only temporary modifications of the cell surface and avoids risks related to 
genetic engineering, such as de novo tumorigenesis. Therapeutic areas with a promising 
applicability to hydrophobic insertion-based cell membrane engineering include, besides the 
already discussed treatment of autoimmune diseases [11], cancer immunotherapy or 
regenerative medicine. Tang et al. reported an increased therapeutic index when a 
interleukin-15 superagonist was administered as nanogel immobilized via an anti-CD45 antibody 
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on T cells [8]. This led to increased tumor clearance by (CAR)-T cell therapies in vivo. Hydrophobic 
insertion of interleukins may be an important alternative due to the straightforward 
manufacturability and therewith related lower safety and regulatory hurdles. In order to 
improve the treatment of myocardial infarctions in a regenerative manner, Won et al. 
conjugated a recombinant CXC chemokine receptor 4 (CXCR4) to PEGylated lipids and modified 
the surface of mesenchymal stem cells (MSC) [10]. This improved the migration of the MSCs in 
an in vitro assay, thus potentially increasing the homing of MSCs to ischemic sites in the 
myocardium [1]. Since CXCR4 possesses 8 cysteines which are accessible for reaction with the 
utilized maleimide linker, several structural isomers of lipidated CXCR4 or multiple-conjugated 
species can be expected after lipid modification [10]. These may have different biological 
activities or may interact in different manner with the cellular bilayer, leading to different steric 
accessibilities of the binding regions. Such heterogeneity may be mitigated with the here 
proposed bioorthogonal conjugation strategy. Further therapeutic objectives of hydrophobically 
inserted compounds on cells include the combination of cell-based immunotherapy and 
antibody-drug conjugates [45] or diagnostic approaches like cell tracking using membrane-
inserted contrast agents [9]. Also the immobilization of enzymes on cells may be a promising 
application for the here proposed protein lipidation and membrane insertion process, since an 
islet surface modification with urokinase suppressed an islet graft loss after transplantation [12]. 
6. Conclusion 
A concept to attach a PEGylated dimyristyl-motif on single-domain antibodies (VHH) by means 
of Sortase-A is presented. The water-soluble, lipidated VHH was successfully inserted into the 
artificial bilayer of liposomes, which led to a targeting of the drug delivery system towards 
antigen-positive cells. Furthermore, the lipidated VHHs successfully remodeled the cell surface 
of myeloid-derived suppressor cells and T cells. T cells that carried an anti-CD11b VHH were 
redirected towards CD11b+ myeloid-derived suppressor cells. Since the installation of the 
lipidated ligand worked reliably on the different bilayer and cell types, the presented anchor and 
conjugation system opens the door for display of other functional proteins on cells or bilayer-
based drug delivery systems.  
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Abstract 
Purpose: Pseudomonas exotoxin A, more precisely it’s subunit PE38, is a potent cytotoxin. It may 
effectively suppress distinct cell populations, such as cancer cells or immune cells if delivered 
cell-specifically to the cytosol. Here, different actively targeted liposomal drug delivery systems 
(immunoliposomes) are evaluated for the specific PE38 delivery to murine CD11b+Gr-1+ cells. 
Methods: PE38-loaded liposomes differing in surface properties and lipid composition were 
prepared by the solvent injection method. The PE38-loaded liposomes were conjugated by 
means of Sortase-A transpeptidation with a single-domain antibody specific for CD11b, a 
myeloid cell marker. The cytotoxicity of the immunoliposomes was assessed on murine 
CD11b+Gr-1+ cells. 
Results: The preparation of PE38-loaded liposomes by solvent injection was feasible yielding 
liposomes with hydrodynamic diameters between 141 nm and 162 nm (polydispersity index: 
< 0.25). Sortase-A modified all formulation concepts with single-domain antibodies as verified 
by rp-HPLC. None of the constructs exhibited a specific cytotoxic effect on murine CD11b+Gr-1+ 
cells. Reasons for the lack of toxicity are discussed. 
Conclusion: Despite a successful manufacturing of PE38-loaded immunoliposomes and the 
previously shown proof of targeting with model compounds, no specific cytotoxicity on target 
cells was achieved. This report therefore describes challenges faced when a cargo is switched 
from a model to an active ingredient and discusses reasons and further options for formulation 
improvement.
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1. Introduction 
Plants, fungi or bacteria can produce highly potent enzymatic cytotoxins whose pharmaceutical 
application as anti-cancer agents is a desirable aim [1]. Prominent examples are Pseudomonas 
exotoxin A (origin: Pseudomonas aeruginosa), diphtheria toxin (origin: Corynebacterium 
diphtheriae), ricin (origin: seeds of Ricinus communis) and saporin (origin: Saponaria 
officinalis) [1]. The toxins are enzymes and hence of proteinaceous nature, what hinders them 
from a passive membrane permeation. Therefore, the toxins are typically composed of several 
subunits, which possess catalytic, but also cell-binding and internalization-mediating 
functions [1]. For example, Pseudomonas exotoxin A consists in its natural form of four 
structural domains [2]. Domain Ia and II are responsible for binding the cellular target structure 
(CD91) and further intracellular processing over the endosome, the Golgi apparatus and the 
endoplasmic reticulum (ER) [2]. As soon as the catalytic domains Ib and III are delivered from ER 
to the cytosol, they inhibit the protein biosynthesis by ADP-ribosylation of the eukaryotic 
elongation factor-2 (eEF-2) at the ribosomes, leading to apoptosis of the host cell [2]. 
Therapeutic immunotoxins aim at exploiting the high potency of such natural derived toxins 
while increasing their specificity [1]. For that purpose, the cell-binding domain is replaced 
through antibodies or their substructures, e.g. via molecular genetic means. Those may bind 
selected anti-cancer targets with high specificity, leading to an internalization of the toxic 
domain and subsequently cause cell death. 
Despite a proven efficacy in cancer treatment and clinical success of some immunotoxins [3], 
the maximum parenteral dose is often limited by an unspecific toxicity, e.g. towards to liver 
cells [4, 5]. Also, immunogenicity is a major concern, related to the development of toxin 
neutralizing antibodies or strong allergic reactions [4, 5]. Although these drawbacks may partly 
be alleviated by local, intratumoral administration, such a strategy would only be applicable to 
solid tumors accessible for external medical interventions (e.g. melanoma [6]). Additionally, 
laborious administration procedures would likely decrease the patient acceptance towards the 
therapy and also decrease the pharmacoeconomic efficiency of the potential drug.  
Targeted nanoparticulate drug delivery systems may be a promising alternative to 
counterbalance the prementioned disadvantages [7-9]. The encapsulation of the catalytic 
domains into a carrier decreases immunogenicity compared to administration of free 
immunotoxins [7]. Furthermore, drug delivery systems of various formats (such as liposomes or 
poly(lactic-co-glycolic acid)-based nanoparticles) have demonstrated to decrease unspecific 
drug toxicity, e.g. for doxorubicin or docetaxel [10, 11]. Active targeting of such drug carriers via 
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conjugation of disease-specific ligands on the particle-surface aids improvement in target 
specificity and intracellular delivery of the cargo [12].  
Myeloid-derived suppressor cells (MDSC) have been described to decrease immune responses 
against tumors, hence making the selective killing of such cell populations an attractive target in 
immuno-oncology [13]. In mice, MDSC are characterized by a CD11b+Gr-1+ phenotype. In this 
study, a truncated form of Pseudomonas exotoxin A (PE38) lacking the cell-binding domain was 
encapsulated into different liposomal formulations. The liposomes were targeted to 
CD11b+Gr-1+ cells using a CD11b-specific single-domain antibody [14]. This antibody was 
conjugated to the liposomes using the site-specific Sortase-A technology, requiring the 
integration of a pentaglycine-modified lipid in the formulation [15]. The liposomal surface 
properties such as polyethylene glycol (PEG) presence were altered to investigate the impact on 
the cytotoxicity of the immunoliposomes. Furthermore, the liposomal lipid composition may 
have significant influence on the cytosolic delivery of large molecules such as proteins [16]. 
Therefore, “rigid” liposomes composed of saturated dipalmitoyl-phosphatidylcholine and 
cholesterol were compared with liposomes composed of a mixture of 2-dioleoyl-sn-glycero-3-
phosphotethanolamine (DOPE) and 3β-hydroxy-5-cholestene 3-hemisuccinate (CHEMS). Latter 
lipids are known for their pH-responsiveness and may exhibit enhanced cytosolic delivery after 
an endosomal uptake and endo-lysosomal acidification [16-19]. The presented results highlight 
challenges faced in the transfer of binding studies with fluorophore-labeled liposomes 
(Chapter 3 and 4) towards the delivery of actually “active” pharmaceutical ingredients.  
2. Materials 
DMA-PEG-G5 is a pentaglycine-modified lipid suitable for Sortase-A mediated transpeptidation 
[20]. It was obtained from Merck & Cie (Schaffhausen, Switzerland) and consisted of a dimyristyl-
amino-propandiol scaffold (DMA) linked via a 2 kDa PEG spacer to a pentaglycine-motif (G5). 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-
rac-glycerol) (DPPG), 2-dioleoyl-sn-glycero-3-phosphotethanolamine (DOPE) and 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-mPEG) were 
a kind gift of Lipoid GmbH (Ludwigshafen, Germany). 3β-hydroxy-5-cholestene 3-hemisuccinate 
(CHEMS), Triton X-100, acridine orange and Dulbecco’s phosphate buffered saline (DPBS, D1408, 
10fold stock) was obtained from Sigma-Aldrich (St. Louis, MO, USA). Water was purified by a Milli-Q 
system (Merck Millipore, Billerica, MA, USA). LPETG (leucine, proline, glutamic acid, threonine, 
glycine)-modified single-domain antibodies of camelid heavy-chain only antibodies (VHH) VHH ENH, 
VHH DC13, Sortase-A variant SortA7m and a truncated variant of Pseudomonas exotoxin A (PE38) 
were provided by BioMed X GmbH (Heidelberg, Germany) and were prepared as described in [14].  
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3. Methods 
3.1. Liposome preparation and ligand conjugation  
Liposomes were prepared by solvent injection using a binary pumping system as described in 
detail in Chapter 3 [21]. Therefore, the following section provides only a brief overview of the 
applied manufacturing and analytical procedures. Three different liposomal formulations (Table 
1) were prepared in DPBS pH 7.4 supplemented with different concentrations of PE38 (Table 2). 
Alternatively, PEGhigh-LS were loaded with doxorubicin. The formulation development and 
manufacturing of these liposomes is described in Chapter 7.  
Table 1: Liposomal compositions. 
formulation composition [mol%] 
PEGhigh-LS 
DPPC : CHOL : DSPE-mPEG : DMA-PEG-G5  
(59.4 : 34.7 : 5.0 : 1.0) 
PEGlow-LS 
DPPC : CHOL : DPPG : DMA-PEG-G5 
(59.4 : 34.7 : 5.0 : 1.0) 
pH-sensitive-LS DOPE : CHEMS : DSPE-mPEG : DMA-PEG-G5 
(57.6 : 38.4 : 3.0 : 1.0) 
 
Table 2: Liposomal manufacturing parameters (FR: flow rate). 
formulation 
lipid solvent and total 
lipid concentration buffer for injection 
FR buffer 
[mL/min] 
FR lipid 
[mL/min] 
PEGhigh-LS ethanol (90 mM) 
 
ethanol (90 mM) 
 
DPBS (0, 0.1 or 2 mg/mL PE38) 
 
250 mM (NH4)2SO4 pH 5.4 rebuffered 
to 10 mM HEPES pH 7.0 
80.0 
 
120.0 
10.0 
 
10.0 
PEGlow-LS ethanol (32 mM) DPBS (0 or 0.1 mg/mL PE38) 90.0 13.5 
pH-sensitive-LS ethanol (75 mM) 
 
ethanol (50 mm) 
DPBS (0 or 0.5 mg/mL PE38) 
 
250 mM (NH4)2SO4 pH 9.0 rebuffered 
to 10 mM HEPES pH 7.4 
80.0 
 
120.0 
10.0 
 
15.0 
 
To adjust the mean hydrodynamic diameter of pH-sensitive-LS according to previously described 
PEGhigh-LS and PEGlow-LS, a flow rate screening was conducted. Finally applied manufacturing 
parameters can be found in Table 2. After solvent injection, the liposomes were purified and 
concentrated by TFF (tangential flow filtration, MicroKros® filter module, 500 kDa cut-off, 
Spectrum Labs, Los Angeles, CA, USA). Subsequently, ligands were conjugated to the liposomes. 
For that purpose, 100 µM of liposomes (based on pentaglycine lipid content) were incubated 
with 50 µM VHH and 25 µM Sortase-A at 4 °C. Afterwards, the liposome dispersion was purified 
using dialysis chambers (Float-A-Lyzer, 1000 kDa cut-off, G235037, Spectrum Labs, Los Angeles, 
CA, USA).  
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3.2. Liposome characterization 
Lipid-individual content of the different formulations was simultaneously assessed via an 
rp-HPLC-ELSD method [20]. Hydrodynamic diameter (dh), polydispersity index (PDI) and zeta 
potential (zp) were determined by dynamic light scattering (DynaPro Plate Reader II, Wyatt, 
Santa Barbara, CA, USA) or laser Doppler electrophoresis (Malvern Zetasizer Nano ZS, 
Worcestershire, UK), respectively. PE38 content was determined after solvent injection and 
after the sortagging and purification process. An rp-HPLC method based on a C4-column which 
separated proteinaceous formulation components (residual Sortase-A, VHHs and PE38) and lipid 
components was utilized (Figure 3, method details described in Chapter 3). Theoretical drug load 
after injection (DLt; a.i.) includes the sum of encapsulated and non-encapsulated PE38 and was 
calculated according to Equation  1. 
Equation 1 
𝐷𝐷𝐿𝐿𝑆𝑆; 𝑆𝑆.𝑑𝑑.  �%𝑚𝑚𝑚𝑚� =  𝑐𝑐𝑃𝑃𝑃𝑃38(𝑠𝑠𝑜𝑜𝑒𝑒𝑒𝑒𝑦𝑦𝑎𝑎) ∗ 𝑇𝑇𝑅𝑅𝑏𝑏𝑐𝑐𝑏𝑏𝑏𝑏𝑆𝑆𝑆𝑆 𝑐𝑐𝑙𝑙𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑(𝑜𝑜𝑎𝑎𝑚𝑚𝑎𝑎𝑖𝑖𝑦𝑦𝑐𝑐 𝑐𝑐𝑜𝑜𝑜𝑜𝑐𝑐𝑠𝑠) ∗ 𝑇𝑇𝑅𝑅𝑙𝑙𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑  ∗ 100 
The actual, measured drug load DLa was calculated as follows: 
Equation 2 
𝐷𝐷𝐿𝐿𝑆𝑆  [%𝑚𝑚𝑚𝑚] = 𝑐𝑐𝑃𝑃𝑃𝑃38 [𝑚𝑚𝑚𝑚𝑚𝑚𝐿𝐿]𝑐𝑐𝑙𝑙𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑[𝑚𝑚𝑚𝑚𝑚𝑚𝐿𝐿] ∗ 100 
To estimate the amount of PE38 encapsulated inside the liposome, the interior volume (Vi) of 
an “ideal” liposome (spherical, unilamellar and monomodal liposomes with a bilayer thickness 
of 5 nm) was calculated according to Equation 3.  
Equation 3 
𝑉𝑉𝑑𝑑 [𝑚𝑚𝐿𝐿] = 43 ∗ 𝜋𝜋 ∗ �𝑦𝑦ℎ2 − 5 𝑖𝑖𝑚𝑚�3 : 1021 
To estimate the number of liposomes per volume, first the average number of lipids per 
liposome (nl) was calculated using the liposomal hydrodynamic diameter dh, the number of lipids 
per inner and outer bilayer leaflet and the assumption of an average lipid headgroup density of 
0.6 nm2 (Equation 4). The concentration of the liposomes was then calculated using the total 
lipid concentration (Equation 5, NA = Avogadro constant).  
Equation 4 
𝑖𝑖𝑙𝑙 = �4 ∗  𝜋𝜋 ∗ �𝑦𝑦ℎ2 �2 + 4 ∗  𝜋𝜋 ∗ �𝑦𝑦ℎ − 2 ∗ 5 𝑖𝑖𝑚𝑚2 �2� : 0.6 𝑖𝑖𝑚𝑚2 
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Equation 5 
𝑐𝑐𝑙𝑙𝑑𝑑𝑑𝑑𝑆𝑆𝑆𝑆𝑆𝑆𝑙𝑙𝑆𝑆𝑆𝑆 [𝑦𝑦𝑦𝑦𝑖𝑖𝑜𝑜𝑐𝑐𝑜𝑜𝑚𝑚𝑦𝑦𝑐𝑐𝑚𝑚𝐿𝐿 ] = (𝑐𝑐𝑙𝑙𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑  [𝑚𝑚]  ∗ 𝑁𝑁𝐴𝐴)𝑖𝑖𝑙𝑙 ∶ 1000  
The total interior liposome volume per volume increment equals the theoretically, passively 
encapsulated fraction (EFt, Equation 6). 
Equation 6 
𝐸𝐸𝑇𝑇𝑆𝑆  [%] = 𝑉𝑉𝑙𝑙 ∗ 𝑐𝑐𝑙𝑙𝑑𝑑𝑑𝑑𝑆𝑆𝑆𝑆𝑆𝑆𝑙𝑙𝑆𝑆𝑆𝑆 ∗ 100  
None of the encapsulated cargo is assumed to be lost during processing, and all non-
encapsulated material should in theory be washed off during purification. Hence, the theoretical 
drug load after final purification (DLt; f) is calculated according to Equation 7. 
Equation 7 
𝐷𝐷𝐿𝐿𝑆𝑆;𝑏𝑏 �%𝑚𝑚𝑚𝑚� = 𝐷𝐷𝐿𝐿𝑆𝑆;𝑆𝑆.𝑑𝑑. ∗ 𝐸𝐸𝑇𝑇𝑆𝑆 
3.3. Acridine orange release assay 
pH-sensitive-LS and PEGhigh-LS were prepared in ammonium sulfate buffer and rebuffered to 
10 mM HEPES pH 7.4 (Table 2). This led to a pH- and salt-gradient over the liposomal bilayer, 
suitable for the “active” entrapment of weak bases in the liposome interior [22]. The 
pH-sensitivity was then investigated using the fluorescence of acridine orange, which changes 
upon liposomal entrapment and subsequent release (quenching / dequenching) [23]. The 
liposomes were diluted in HEPES pH 7.4 in a black 96 well plate to 90 µL (1.11 mM total lipid). 
10 µL of an acridine orange stock solution (1 mM) were injected using a binary autotitration 
system connected to a fluorescence plate reader (F200, Tecan Group, Männedorf, Switzerland), 
so that final liposome concentration was 1 mM total lipid. The fluorescence was tracked at an 
excitation of 485 nm and emission of 535 nm for 150 s, until a second injection of either 18 µL 
0.025 N HCl (leading to a pH of 5.5 +/- 0.04) or 100 µL Triton X-100 (TX-100) 5 % (final 2.5 % v/v) 
was performed. The fluorescence was then further tracked for 30 s. The fluorescence intensities 
of the liposomal samples were normalized on the fluorescence intensity of a similarly treated 
buffer reference. All samples were analyzed in triplicate wells. 
3.4. Cell culture and cytotoxicity assays 
Murine CD11b+Gr-1+ MDSC were cultured in RPMI complete and 20 ng/mL mGM-CSF (mouse 
granulocyte macrophage colony stimulating factor) as described elsewhere [14, 24]. For 
cytotoxicity experiments, 50,000 cells were seeded per well (final volume: 100 µL). The cells 
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were incubated for 24 h (PEGhigh-LS and PEGlow-LS with low drug load) or 48 h (PEGhigh-LS with 
high drug load and pH-sensitive-LS) with VHH-free, isotype control (VHH ENH) or CD11b-specific 
VHH DC13-modified liposomes at different PE38 concentrations at 37 °C. Alternatively, the cells 
were incubated with 0.001-100 µg/mL doxorubicin-loaded liposomes (based on doxorubicin) for 
48 h. In two cases, a washout was performed. For that purpose, the cell culture medium with 
unbound liposomes was removed after 1 h or 4 h, cells were washed once in 200 µL PBS and 
resuspended in 100 µL RPMI complete and 20 ng/mL mGM-CSF. Cells were then further 
incubated at 37 °C to a total incubation time of 48 h.  
To assess cell viability, 20 µL of Cell Titer Blue Cell Viability Assay reagent (#G8080, Promega, 
Madison, WI, USA) was added to each well and the samples were incubated for 2 h 
(pH-sensitive-LS: 1 h). Subsequently, the fluorescence was measured according to the 
manufacturer’s protocol in a GloMax Multi plate reader (Promega). The relative survival (survival 
index) was calculated by comparison of the fluorescence values to untreated controls after 
subtraction of background value. All experiments were conducted in triplicate wells.  
4. Results and discussion 
4.1. PE38 loading to rigid liposomes 
Three liposomal formulations (Table 1) were screened for suitability as actively targeted, 
PE38-loaded drug delivery system. PEGhigh-LS and PEGlow-LS are primary composed of the 
saturated 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, transition temperature: 41 °C 
[25]) and cholesterol. Hence, both can be considered as liposomes having a “rigid” bilayer at 
physiological temperatures (37 °C) since the main transition temperature was determined at 
43.7 ± 1.8 °C (Chapter 7). Both differ in their surface properties and stabilization mechanism. 
PEGhigh-LS carry 2 kDa PEG-groups, which are derived from DSPE-mPEG (5 mol%). PEG is known 
to decrease unspecific uptake of liposomes by the mononuclear phagocyte system (MPS) [10]. 
Therefore, increases of in vivo half-life can be expected. PEG further serves as steric stabilizer of 
the liposomal dispersion [10]. PEGlow-LS are modified with DPPG, an anionic phosphoglycerol 
that leads to stable dispersions via charge-mediated stabilization. PEGlow-LS served as control 
formulation to investigate whether PEG may hinder an efficient delivery of PE38 to cells [26]. 
Both formulations effectively delivered a fluorescence marker towards humane and murine 
myeloid cells when they were modified with a myeloid cell specific single-domain antibody 
(Chapter 3 and 4). In those reports, PEGhigh-LS had a mean hydrodynamic diameter of ≈140 nm, 
whereas PEGlow-LS appeared slightly larger (≈190 nm). To load PE38 into liposomes having a 
Results and discussion 
135 
similar composition and a comparable manufacturing process, differently concentrated PE38 
solutions were used as aqueous phase during solvent injection (Table 3).  
Table 3: Physico-chemical characterization of PE38-loaded liposomes after the final processing including solvent 
injection, tangential flow filtration, ligand conjugation and dialysis (data shown as mean ± standard deviation of three 
measurements). 
PE38 conc. dh PDI zp dh PDI zp dh PDI zp 
[mg/mL] [nm]  [mV] [nm]  [mV] [nm]  [mV] 
 
PEGhigh-LS VHH-free + control VHH + VHH DC13 
0.1 141 ± 1 
0.22 ± 
0.01 
-15 ± 0 135 ± 4 
0.23 ± 
0.01 
-7 ± 0 138 ± 2 
0.23 ± 
0.01 
-6 ± 0 
2.0 149 ± 4 
0.23 ± 
0.01 
-13 ± 0 148 ± 15 
0.26 ± 
0.06 
-12 ± 1 149 ± 5 
0.21 ± 
0.04 
-10 ± 0 
 
PEGlow-LS VHH-free + control VHH + VHH DC13 
0.1 162 ± 1 
0.22 ± 
0.01 
-25 ± 1 199 ± 7 
0.50 ± 
0.44 
-16 ± 1 171 ± 1 
0.21 ± 
0.01 
-16 ± 1 
 
pH- 
sensitive-LS VHH-free + control VHH + VHH DC13 
0.5 159 ± 0 
0.24 ± 
0.00 
-38 ± 2 180 ± 0 
0.25 ± 
0.01 
-29 ± 2 165 ± 5 
0.85 ± 
0.26 
-31 ± 2 
 
PE38 presence had no relevant impact on the liposome formation, since the injection process 
was feasible without aggregation for both PEGhigh-LS (at 0.1 and 2 mg/mL PE38 concentration) 
and PEGlow-LS (at 0.1 mg/mL PE38 concentration). Mean hydrodynamic diameters were in a 
similar range compared with previous manufactured batches in pure DPBS or 10 mg/mL 
FITC-Dextran in DPBS (compare with Table 2, Chapter 3). PDI values below 0.25 indicated a low 
polydispersity of the dispersion. As expected, the zeta potential was negative for both PE38-
loaded formulations due to the anionic formal charges of the phospho-groups of DPPG and 
DSPE-mPEG, respectively. 
4.2. Formulation development of pH-sensitive liposomes 
To investigate whether the bilayer composition of the liposomes had an impact on the 
cytotoxicity of PE38-loaded liposomes, a third formulation composed of DOPE, CHEMS and 
DSPE-mPEG (“pH-sensitive-LS”) was additionally selected. Lipid combinations of DOPE and 
CHEMS have been previously described as pH-sensitive [16-18]. This means these drug carriers 
exhibit a destabilization of the liposomal bilayer upon acidification and hence a release of 
encapsulated cargo. This may improve the cargo release inside the acidic environment of 
endosomes after drug carrier internalization, and subsequently an increase of the cytosolic 
availability of the toxin. To obtain pH-sensitive-LS in physical dimensions comparable to 
PEGhigh-LS and PEGlow-LS, flow rates for the solvent injection of the ethanolic lipid stock into DPBS 
were screened (Figure 1). A decrease of the mean hydrodynamic diameter was observed with 
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increasing total flow rates. All applied flow rates delivered liposomes between 200 nm and 
100 nm, and the polydispersity index was maintained below 0.25. The flow rate combination of 
80 mL/min (buffer flow) : 10 mL/min (lipid flow) was chosen for PE38 loading (0.5 mg/mL in the 
aqueous phase). As expected from the size screening with pure buffer, liposomes with a mean 
hydrodynamic diameter of 159 ± 0 nm were obtained (Table 3). The zeta potential was strongly 
negative (-38 mV), what is due to the negatively charged acid groups of CHEMS, which is 
integrated to a high molar extent (38.4 mol%). 
 
Figure 1: Size adjustment of DOPE and CHEMS-based, PEGylated and pentaglycine-modified liposomes by variation 
of flow rates during solvent injection of 75 mM lipid solution into DPBS. Standard deviations shown for the 
manufacturing of three batches. 
PEGylation was previously reported to be compatible with the pH-sensitive function of DOPE-
CHEMS liposomes [18], although there are concerns whether PEG may decrease the 
pH-responsiveness of such drug carriers [19, 27]. It was here in question whether pH-sensitive-LS 
(carrying PEG-groups and an additional pentaglycine modification) show a release of 
encapsulated material after acidification to a pH of 5.5, which is present in late endosomes [28]. 
For that purpose, pH-sensitive-LS were prepared in ammonium sulfate buffer (manufacturing 
parameters: Table 2), and an ammonium sulfate gradient was established over the membrane 
to yield liposomes compatible with active loading techniques [22]. Acridine orange is a 
fluorescent dye which can accumulate inside such gradient liposomes. Upon accumulation, the 
fluorescence quantum yield is drastically decreased (quenching). Acridine orange was therefore 
spiked either to gradient PEGhigh-LS or to gradient pH-sensitive-LS with an autotitration system. 
The fluorescence intensity was monitored online. PEGhigh-LS showed a time-dependent decrease 
of the fluorescence intensity, indicating a diffusion of the dye inside the vesicles within 20 s 
(Figure 2). This was going along with a pronounced quenching. Interestingly, this kinetic 
fluorescence loss was not observed for pH-sensitive-LS, which showed a weak fluorescence 
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signal directly after dye injection. This may be due to the primary used lipid DOPE, which has a 
transition temperature of -16 °C [29]. Hence, the fluidity of the pH-sensitive-LS is higher than 
those of PEGhigh-LS, and accumulation of acridine orange can occur quicker. After a plateau time 
of 150 s, the acridine orange-loaded liposomes were exposed to HCl or TX-100, which served as 
acridine orange release stimuli. After detergent addition, both pH-sensitive-LS and PEGhigh-LS 
showed a pronounced increase in fluorescence. This indicates the unspecific, detergent induced 
bilayer interference, which leads to dye release and subsequent de-quenching of the 
fluorescence. In contrast to that, only the pH-sensitive-LS, but not the PEGhigh-LS changed their 
fluorescence intensity upon injection of HCl. This shows the pH-sensitivity of the formulation. 
However, the overall increase in fluorescence was weak compared to the TX-100 control, hence 
pH-sensitivity may offer room for optimization of this drug delivery system.  
 
Figure 2: Evaluation of pH-sensitivity of PEGhigh-LS and pH-sensitive-LS. 0 s: addition of acridine orange, 150 s: addition 
of HCl or TX-100. Only each 8th data point shown due to clarification. Data shown as mean ± standard deviation of 
three experiments conducted with one liposomal batch. 
4.3. PE38 drug load analysis 
The drug load, defined as the ratio of PE38 mass to lipid mass, was measured after solvent 
injection and after the final liposome purification step. Slightly lower drug loads compared to 
the theoretical values were determined after solvent injection. This may indicate a protein loss, 
e.g. due to adsorption to the tubing in use or due to denaturation through the organic solvent 
or shear stress during pumping. Interestingly, the drug load showed only slight decrease after 
the final dialysis compared to the value after injection. The measured drug loads exceed the 
ones expected from a sole passive encapsulation process by more than an order of magnitude 
(Table 4, brackets. Detailed calculations are described in methods.). This indicates that PE38 
loading during solvent injection is predominantly based on adsorption processes between the 
liposomal bilayer and the proteinaceous toxin. This was especially observed for the PEGhigh-LS, 
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whose drug load did not decrease by more than 25 % after dialysis. A comparable protein 
adsorption to PEGhigh-LS was previously observed for Sortase-A and single-domain antibodies 
(Chapter 3 and 4). Though PEG is known to reduce the overall extent of (serum) protein 
adsorption to surfaces, it also shifts the affinity towards different protein populations, e.g. from 
coagulation factors towards lipoproteins [30, 31]. This change in composition of the protein 
corona is finally responsible for the stealth effect. It is therefore likely that the PEG-group of 
DSPE-mPEG increases the affinity of PE38 towards the liposome surface. 
Table 4: PE38 drug load (DL, defined as PE38 mass divided by calculated or measured total lipid mass) during the 
different processing steps of immunoliposome preparation. In brackets: theoretical drug load after final processing, 
assuming a passive encapsulation process (DLt; f). 
formulation 
cPE38 
(in buffer) 
DLt, a.i. DLa, a.i. DLa, f (brackets: DLt, f) 
    VHH-free + control VHH + VHH DC13 
PEGhigh-LS 
0.1 mg/mL 
2.0 mg/mL 
1.2 % 
24.2 % 
1.0 % 
19.9 % 
1.1 % (0.05 %) 
17.5 % (1.01 %) 
1.0 %  
14.9 %  
1.0 %  
15.6 %  
PEGlow-LS 0.1 mg/mL 3.3 % 2.7 % 1.4 % (0.06 %) 1.5 %  1.4 %  
pH-sensitive-LS 0.5 mg/mL 7.4 % n.a. 3.7 % (0.28 %) 2.8 %  3.6 %  
 
4.4. Sortagging of PE38-loaded liposomes 
Sortase-A transpeptidation was applied to anchor targeting ligands on the three liposomal 
formulations. This chemoenzymatic technique offers site-specific conjugation between LPETG-
motif carrying proteins and glycine nucleophiles under mild conditions in aqueous media [15]. 
For that purpose, all formulations carried a pentaglycine-modified lipid to 1 mol% in the 
liposomal bilayer. The liposomes were incubated with Sortase-A and LPETG-modified 
single-domain antibodies (VHHs) at 4 °C. Afterwards, the reaction bulk was purified from 
enzyme and unbound VHH by dialysis. An rp-HPLC method (Chapter 3 and 4) was used to 
separate proteinaceous and lipid ingredients of the formulations (Figure 3). It confirmed the 
presence of the lipidated VHH (retention time: 7.9 min, peak 3, mass spectroscopic peak 
identification described in Chapter 3 and 5) on all PE38-loaded liposomal constructs. This 
indicates that the pentaglycine motifs are accessible for the Sortase-A reaction. This was not 
self-evident, as above described PE38 adsorption on the liposome may have hindered an 
effective conjugation. In case of PEGhigh-LS and pH-sensitive-LS, no relevant changes in the dh or 
PDI occurred after conjugation, indicating physical stability during ligand conjugation (Table 3). 
PEGlow-LS showed increases in dh and PDI for modification with VHH ENH, what indicates that 
subvisible aggregation may have occurred whereas no visible aggregation was observed. Similar 
to previously described liposome modifications with VHH ENH and DC13 (Chapter 3 and 4), slight 
changes in the zeta potential towards neutral values were observed (Table 3). This additionally 
indicates surface alteration of the liposomes through VHH-conjugation.  
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Figure 3: Separation of proteinaceous formulation ingredients by rp-HPLC: (1) - residuals of Sortase-A and VHH after 
dialysis, (2) - PE38 main peak, (3) - VHH conjugated to the lipid anchor DMA-PEG-G5, (4) - lipid excipients of liposomes. 
Presence of conjugate peak (3) indicates that the conjugation was feasible on all different PE38-loaded, pentaglycine-
modified formulations.  
4.5. Cytotoxicity of PE38-loaded liposomes 
An immunotoxin conjugate of VHH DC13 and PE38 has previously been described to kill CD11b+ 
cells [14]. Furthermore, VHH DC13 targeted immunoliposomes loaded with a fluorescent marker 
showed a specific targeting of CD11b+ cells in vitro and in vivo (Chapter 3 and 4). It was therefore 
expected that PE38-loaded, via VHH DC13 targeted liposomes of similar composition and 
dimension offer a suitable drug delivery system for PE38.  
PE38-loaded liposomes, either as VHH-free control, modified with an unspecific control VHH 
(VHH ENH) or with the CD11b-specific VHH DC13 were incubated with CD11b+Gr-1+ cells. 
Subsequently, cell viability was assessed. PEGhigh-LS and PEGlow-LS loaded with 1.0-1.5 % PE38 
(Table 4) were screened in vitro up to 1 µg/mL toxin, however without cytotoxic effect on the 
cells (Figure 4). Hence, the drug load was increased for PEGhigh-LS. Only ≈40 % of the cells 
survived at the highest applied concentration (100 µg/mL), however without any specific effect 
for the CD11b-specific immunoliposomes. In this high concentration, PE38 is known to cause 
unspecific toxicity even without internalization-promoting domain [14]. It was suggested that 
the rigid bilayer composition of PEGhigh-LS and PEGlow-LS is responsible for the low cytotoxicity, 
as this may lead to insufficient intracellular toxin release. Hence, pH-sensitive-LS composed of 
low-melting and pH-sensitive lipid combination DOPE and CHEMS were tested (Figure 4). 
pH-sensitive-LS did not exhibit CD11b-target related cytotoxicity as well, but a higher unspecific 
toxicity was observed (≈30 % survival at 10 µg/mL PE38) compared to PEGhigh-LS (Figure 4). This 
indicates that the pH-sensitive formulation may exhibit higher cytotoxic potential than the rigid 
liposomes, especially if the 5-6fold lower drug loads (compared to PEGhigh-LS, Table 4) are 
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considered. It was further verified that drug free PEGhigh-LS, PEGlow-LS or pH-sensitive-LS do not 
exhibit cytotoxicity within the here applied lipid concentrations (data not shown). Furthermore, 
a PE38 sample recovered from the filtrate of the TFF was tested against loss of enzymatic activity 
using an assay described in [32]. Compared to a PE38 sample that did not face stress during 
solvent injection and purification, similar inhibition of the protein biosynthesis was observed 
(data not shown). This excludes that the manufacturing process has activity-decreasing 
influence on PE38 and indicates that stress from manufacturing is not responsible for lower 
cytotoxicity. 
 
Figure 4: Cytotoxicity of PE38-loaded, actively targeted liposomes. No specific cytotoxicity was observed with 
VHH DC13-modified liposomes on CD11b+Gr-1+ MDSC. The reader is kindly advised to the differently scaled abscissa. 
Error bars indicate standard deviations of duplicate (upper row) or triplicate (lower row) analyses of single liposomal 
batches. 
Compared with previous reports describing the liposomal delivery of PE38 [8, 9], it is unclear 
why the here presented systems failed to exhibit target-specific cytotoxicity. The presented 
results indicate that the drug load as well as the bilayer composition are relevant for the 
observation of cytotoxic effects, irrelevant whether liposomes are targeted or not. Gao et al. 
used a combination of egg phosphatidylcholine (transition temperature: -7 to -15 °C [33]), 
cholesterol and DSPE-mPEG (65 : 32 : 3 mol%) for film hydration with a 2 mg/mL PE38 solution. 
The group observed an IC50 of 36 pM (≈0.0014 µg/mL) for HER2-specific liposomes on target-
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positive cells. Zhang et al. prepared anti-hepatoma immunoliposomes composed of soybean 
phosphatidylcholine, cholesterol (5:4 m/m) and a PEGylated cholesterol derivate (2 to 6 mol%). 
Here, PE38 loading to the liposomes was described as an incubation step of a 1 mg/mL toxin 
solution with a non-described amount of already formed liposomes. They reported an IC50 of 
0.47 µg/mL on target-positive cells. In both reports, significant differences between targeted 
and non-targeted liposomes were shown. This was not achieved with the here presented 
CD11b-specifc liposomes and may have eclectic reasons. 
First reason is the liposome manufacturing strategy. Although hardly comparable due to 
different targets, ligands, cell types and experiment conditions, it its noticeable that Gao et al. 
showed IC50 values more than 300fold lower than Zhang et al. and also than the presented data, 
indicating a much higher cytotoxicity. Film hydration used by Gao et al. usually results in high 
lipid concentrations after liposome formation, leading to a high ratio of interior to exterior 
volume. Hence, capacity for passive protein encapsulation is high. This may be advantageous 
compared to an adsorption-based loading used by Zhang et al. and the here utilized solvent 
injection. After solvent injection, the liposome concentration is typically low, making additional 
concentration steps necessary, for example by TFF. Hence, a low liposome-interior acceptor 
volume is available for encapsulation after the initial liposome formation. Additionally, repulsive 
effects at the water-alcohol interface may decrease encapsulation and lead to an adsorption-
based drug loading. Therefore, total amount of protein inside the liposome may be very low, 
and high amounts of PE38 are present on the liposome surface (adsorption-based loading,  
Table 4). Adsorbed cargo may impede uptake of the carrier, or after a potential uptake, be less 
efficiently delivered into the cytosol compared to encapsulated material, e.g. due to desorption 
of the cargo in physiological media or degradation during internalization processes.  
Secondly, the liposomal bilayer composition is crucial for an effective intracellular delivery of 
large molecules. Both Gao et al. and Zhang et al. used naturally derived phosphatidylcholines 
with low transition temperatures as predominant lipid, leading to “fluid” liposomes. Those may 
have advantageous release properties for large molecules compared to the rigid PEGhigh-LS and 
PEGlow-LS utilized here. Suggesting such an inadequate release of PE38 from rigid liposomes, a 
third formulation of low-melting DOPE and CHEMS, which has been described as suitable for the 
delivery of such proteinaceous toxins was tested [16-18]. However, only minor increases in 
cytotoxicity and no improvement of specificity of targeted formulations was achieved. To 
directly compare delivery of large and small molecules, it was additionally tested whether 
targeted PEGhigh-LS loaded with the anticancer drug doxorubicin (543.5 Da) can exhibit specific 
toxicity on CD11b+ cells (Figure 5).  
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Figure 5: Cytotoxicity of doxorubicin-loaded, actively targeted liposomes. Error bars indicate the standard deviations 
of triplicate analyses of single liposomal batches.  
Due to the small size and higher permeability, it was suggested that doxorubicin may not suffer 
from poor intracellular release. Interestingly, also no differences between targeted and non-
targeted formulations were observed. This was also the case when different incubation times, 
meaning the time frame in which the liposomes have contact with the cells before the medium 
is replaced, were investigated to avoid unspecific, drug release related cytotoxic effects. This 
lack of specificity observed with doxorubicin-loaded liposomes further indicates that an 
insufficient intracellular PE38 release may not be the sole problem of the presented 
formulations.  
Third possible reason for the lack of specific cytotoxicity may be the target CD11b itself or the 
corresponding binder VHH DC13. Bachran et al. showed much more effective killing of 
CD11b+Gr-1+ cells using a PE38 immunotoxin specific for Gr-1 [14]. This may hint towards an 
insufficient internalization-promoting function of CD11b upon binding or towards an overall low 
affinity of VHH DC13. 
Fourth, observations of a targeted cytotoxicity may be superimposed by the phagocytic activity 
of the myeloid cells in vitro. Here, cells are exposed to the particulate drug delivery system for 
several hours to days, different to the 4 h exposure applied for targeting experiments with 
fluorophore-labeled liposomes (Chapter 3 and 4). It may be that, irrespective of a ligand induced 
cell-liposome interaction, the liposomes are phagocytized by the myeloid immune cells. 
Therefore, different wash-outs after 1 h and 4 h steps or no wash-out were tested for 
doxorubicin-loaded liposomes, but also without the observation of a specific cytotoxicity for the 
targeted systems (Figure 5). 
Taken the points raised above together, reasons for the lack of specific cytotoxicity remain 
elusive. A combination of insufficient drug load, weak internalization-activity of the target or 
ligand and low intracellular drug release are most likely. Further screenings covering these 
Conclusion 
143 
parameters would be required to achieve sufficient cell killing, which would exceed the scope of 
this work. 
Additionally, further technological variations may improve specific toxin delivery. This may 
include usage of a cleavable PEG-coating. PEG was demonstrated to decrease pH-sensitivity of 
DOPE-CHEMS-based liposomes [27]. This was overcome by usage of linkers between liposome 
and PEG which are sensitive for a cleavage through lysosomal enzymes [18]. Other strategies 
may include the co-encapsulation of endosome-disruptive peptides together with 
proteinaceous toxins, what led to drastic increases in cytotoxicity of diphtheria toxin-loaded 
immunoliposomes (major lipid: egg phosphatidylcholine) [34]. Furthermore, usage of positively 
charged lipids [26] or coating of the liposomes with cell-penetrating peptides [35] may exhibit 
positive effects through an increased internalization, although convincing in vivo data for the 
latter is missing [36]. 
5. Conclusion 
The formulation development of Pseudomonas exotoxin A (PE38)-loaded immunoliposomes is 
presented. Three sortaggable liposomal concepts differing in surface properties and 
responsiveness against acidic pH were loaded with PE38 during a solvent injection process. All 
drug-loaded formulations were successfully modified with a ligand specific for the murine 
myeloid cell marker CD11b by means of Sortase-A technology. Despite promising targeting 
experiments with fluorophore-labeled liposomes and CD11b-specific immunotoxins, none of the 
developed immunoliposomes exhibited specific cytotoxic activity on CD11b+Gr-1+ cells. Possible 
reasons for this unexpected result are evaluated. This chapter therefore discusses the challenges 
faced during the switch of marker molecules to active ingredients and gives a valuable outlook 
for further possibilities of formulation improvement. 
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Abstract 
Purpose: Conventional chemotherapy is associated with therapy-limiting side effects, which 
may be alleviated by targeted chemotherapeutics such as immunoliposomes. The targeting 
ligands of immunoliposomes are commonly attached by unspecific chemical conjugation, 
bearing risk of structural heterogeneity and therewith related biological consequences. 
Chemoenzymatic methods may mitigate such risks through site-specific conjugation. 
Methods: The formulation parameters for pentaglycine-modified, doxorubicin-loaded 
liposomes and the reaction conditions for a site-specific, Sortase-A mediated conjugation with 
monoclonal antibodies were thoroughly evaluated. The cytotoxicity of such sortagged, 
epidermal growth factor receptor (EGFR)-specific immunoliposomes was tested on human 
breast cancer cells.  
Results: Sortaggable liposomes with a defined size (140 nm, PDI < 0.25) and high encapsulation 
efficiency (> 90 %) were obtained after manufacturing optimization. A ratio of 1.0-2.5 µM 
mAb / 100 µM pentaglycine yielded stable dispersions and circumvented carrier precipitation 
during ligand grafting. The cytotoxicity on EGFR+ MDA-MB-468 cells was up to threefold higher 
for EGFR-specific immunoliposomes than for the nontargeted controls. 
Conclusions: Sortase-A is suitable to generate immunoliposomes with a site-specific 
ligand-carrier linkage and hence improves chemical homogeneity of targeted therapeutics. 
However, the sweet spot for manufacturability utilizing mAbs with two Sortase-A recognition 
sites is narrow, making mono-reactive binders such as scFvs or Fab’s preferable for a further 
development. Despite this, the immunoliposomes demonstrated a targeted delivery of 
doxorubicin, indicating the potential to increase the therapeutic window during the treatment 
of EGFR+ tumors.  
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1. Introduction 
The major drawback of conventional anticancer drugs are dose-limiting adverse events that 
result in a narrowed therapeutic window. One strategy to overcome serious side effects is a 
targeted drug delivery, which leads to an accumulation of the drug in the tumor while omitting 
healthy tissues. Today, several concepts for targeted drug delivery have already successfully 
been applied, e.g. antibody-drug conjugates (ADCs) or drugs encapsulated in a targeted 
nanoparticulate carrier system such as immunoliposomes [1]. The latter requires the 
conjugation of a mostly proteinaceous ligand with an appropriate lipid anchor. For that, various 
chemistry-based coupling techniques, including maleimide-thiol conjugation with cysteines, 
amine condensation of lysines or N-hydroxysuccineimide-ester-based coupling with carboxylic 
acid groups have been developed and have recently been extensively reviewed [2]. Although 
some immunoliposomal formulations have been clinically investigated [3-5], manufacturing 
hurdles and hence regulatory concerns remain high. Besides causing a tremendous effort in 
manufacturing a nano-sized drug carrier within the required specifications [6], chemistry-based 
conjugation methods additionally increase product heterogeneity [7]. Furthermore, stability of 
the linkers is a critical issue. Especially the widely used maleimide-linker can undergo a 
retro-Michael addition and exchange with albumin cysteine residues in vivo [8]. This includes 
cleavage between drug carrier and ligand, and thereby a loss of the targeting functionality. Site-
specific, chemoenzymatic conjugation methods such as Sortase-A mediated transpeptidation 
have gained increasing interest for the synthesis of tailored antibody-drug conjugates (ADCs) 
[9]. The enzyme-catalyzed modification of large protein structures at defined reaction sites leads 
to homogenous reaction products connected by a stable amide bond [10]. These reaction sites 
can be introduced by genetic engineering at uncritical parts of monoclonal antibodies such as 
the C-termini of the Fc part or constant domains of light chains [11]. This avoids the conjugation 
dependent decrease of antigen recognition in paratope regions observed after lysine-based 
conjugations [12], or a destabilization of antibodies during or after the reaction, as observed for 
cysteine conjugations [13, 14]. Hence, deploying a chemoenzymatic method for the site-specific 
anchoring of targeting ligands would significantly improve the manufacturing process of 
immunoliposomes. 
Doxorubicin (DXR) is a cytotoxic, DNA-intercalating anticancer agent with a broad applicability 
against many tumors, however also with a dose-limiting anthracycline induced cardiomyopathy 
as most severe adverse event [6, 15]. The cardiotoxicity was alleviated by encapsulation of DXR 
into liposomal drug delivery systems [16]. This technology was commercialized as the “first 
nano-drug” Doxil®, developed by Barenholz and coworkers [6]. It is based on the efficient 
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encapsulation of DXR by a remote loading technique [17], the use of high melting lipids together 
with cholesterol and finally a polyethylene glycol coating. Especially the latter leads to a 
prolonged circulation time and reduced uptake by the mononuclear phagocyte system (MPS) 
[6]. In addition to the reduced cardiotoxicity, compared to free DXR PEGylated liposomal DXR 
was found to accumulate to higher extents in human tumor effusions [18] or in human bone 
metastases of breast carcinoma than in adjacent muscle tissue [19]. This was interpreted as a 
passive drug targeting via the enhanced permeation and retention effect [6]. However, off-site 
effects such as mucositis or palmar-plantar erythrodysesthesia (skin toxicity) are still dose-
limiting toxicities with PEGylated liposomal DXR [20]. This led to the approach of “active” 
targeting of liposomal DXR towards tumors by conjugation of tumor-specific ligands on the 
liposomal bilayer [1]. An established tumor target is the epidermal growth factor receptor 
(EGFR), whose overexpression is correlated with the pathogenesis of many tumors [21, 22]. 
Treatments which utilize monoclonal antibodies (mAb) inhibiting the EGFR are efficacious and 
well-tolerated therapies [21, 23]. One example is cetuximab (C225, Erbitux®), which is currently 
approved for the treatment of colorectal and head- and neck cancer. A sortaggable variant of 
cetuximab, on both heavy chains C-terminally conjugated via Sortase-A to the tubulin inhibitor 
monomethyl auristatin E (MMAE), was recently demonstrated to exhibit specific cytotoxicity on 
EGFR overexpressing cells [24]. This antibody was therefore regarded as suitable model binder 
to explore the site-specific Sortase-A conjugation technology on liposomes, with the aim to 
combine two established concepts – DXR-loaded, PEGylated liposomes and the EGFR-specific 
mAb cetuximab. Therefore, we first thoroughly evaluated the manufacturing of pentaglycine-
modified, PEGylated liposomes by a continuous solvent injection process. We characterized the 
pentaglycine liposomes regarding liposome stability, doxorubicin loading and particle shape. 
Engineered monoclonal antibodies carrying a Sortase-A pentapeptide at their heavy chain 
C-termini specific for EGFR (CH-LPETG-C225) or hen egg lysozyme (CH-LPETG-aHEL) were 
conjugated to the pentaglycine liposomes. The chemoenzymatic transpeptidation was 
evaluated for reaction kinetics and physical stability of the reaction product. To investigate the 
in vitro targeting ability, the EGFR-specific immunoliposomes were tested for their toxicity on a 
human breast cancer cell line (MDA-MB-468). 
2. Materials 
Dimyristyl-modified, PEGylated pentaglycine lipid DMA-PEG-G5 (structure shown in [25]) was 
from Merck & Cie (Schaffhausen, Switzerland). 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC), hydrogenated phosphatidylcholine from soybean (HSPC) and 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-mPEG) were acquired 
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from Lipoid GmbH (Ludwigshafen, Germany). Dulbecco’s phosphate buffered saline (DPBS, 
D1408), cholesterol, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) and 
Triton X-100 were obtained from Sigma-Aldrich (St. Louis, Missouri, USA). Ammonium sulfate 
and ethanol were obtained from Merck KGaA (Darmstadt, Germany). MilliQ water (Merck 
Millipore, Billerica, Massachusetts, USA) was used for preparation and analytical purposes. 
Doxorubicin was from Ark Pharma (Arlington Heights, Illinois, USA). Ca2+-independent Sortase-
A variant SortA7m and a single-domain antibody of camelid heavy chain only antibodies with 
one LPETG (leucine, proline, glutamic acid, threonine, glycine)-motif (LPETG-VHH) were a kind 
gift of BioMed X GmbH (Heidelberg, Germany) and prepared as described elsewhere [26]. 
3. Methods 
3.1. Pentaglycine-liposome preparation 
Liposomes were prepared by a continuous solvent injection process described in detail in [27]. 
In brief, DPPC, cholesterol, DSPE-mPEG and pentaglycine-modified DMA-PEG-G5 
(59.4 : 34.7 : 5.0 : 1.0, mol%) were dissolved to 90 mM in ethanol. The lipid solution was injected 
into 250 mM ammonium sulfate buffer pH 5.4 utilizing a binary pumping system combined with 
a custom-made T-piece at various flow rates. If DPPC was replaced by HSPC (as indicated in 
results), lipids were dissolved to 100 mM in ethanol and injected at 5 mL/min into 250 mM 
ammonium sulfate heated to 65 °C (40 mL/min). Buffer was exchanged to DPBS pH 7.4 or 10 mM 
HEPES pH 7.0 (as indicated in results) by tangential flow filtration (MicroKros® hollow fiber 
module, 500 kDa cut-off, 20 cm2 filter area, Spectrum Labs, Los Angeles, CA, USA) to establish a 
pH and ammonium sulfate gradient over the liposomal membrane [28]. 
3.2. Liposome characterization 
The hydrodynamic diameter and polydispersity index (PDI) were measured by dynamic light 
scattering (DLS) using a DynaPro Plate Reader II (Wyatt, Santa Barbara, California, USA). The 
liposome dispersion was diluted to 3 % v/v with surrounding buffer to achieve measurable count 
rates. The zeta potential (zp) was assessed using a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK) after a dilution in 10 mM NaCl to 3 % v/v. Content of each lipid component 
was determined by an rp-HPLC method with an evaporative light scattering detector as 
described earlier [25]. The lipid stability of pentaglycine-modified liposomes was evaluated over 
an eight weeks storage at 2-8 °C.  
Differential scanning calorimetry (DSC1, Mettler Toledo, Columbus, Ohio, USA) was used to 
determine the transition temperature of the liposomal bilayer. Aqueous lipid slurries 
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(100-200 mg/mL) were prepared by 30 min hydration of preformed lipid films in an ultrasound 
bath. 100 µL of slurry was transferred to 160 µL aluminum pans. Pans were covered with a 
pierced lid. DSC measurement was performed with a temperature profile of 5 min equilibration 
at 5 °C, followed by a heating step (5 K/min) to 75 °C, a plateau phase at 75 °C for 3 minutes and 
return to 5 °C (-20 K/min). Two cycles were applied per sample, second cycle was used to 
calculate the melting temperature.  
3.3. Doxorubicin loading and quantification 
To screen DXR loading into the liposomes, DXR (10 mg/mL in water) and liposomes were mixed 
to a lipid-to-DXR ratio of 5:1 (m/m). In some cases, 10fold DPBS stock was added to adjust salt 
concentration to 1fold DPBS as indicated in the results. The liposomes were incubated for 30 min 
to 24 h in 1.5 mL tubes in an Eppendorf Thermomixer Comfort heating block (1000 rpm, 49 °C). 
Afterwards, the dispersion was immediately transferred into dialysis bags (Slide-A-Lyzer, 
MWCO 10 kDa, Thermo Fisher, Waltham, Massachusetts, USA) and dialyzed for at least 24 h 
with five buffer changes against DPBS pH 7.4 until the concentration of DXR in the dialysis buffer 
was < 0.2 µg/mL.  
DXR content was determined as follows: liposomal samples were diluted in 5 % Triton X-100 
(v/v) and incubated for 30 min at 50 °C to ensure a complete vesicle lysis with subsequent 
dequenching of the encapsulated DXR. Fluorescence intensity (excitation: 485 nm, emission 
595 nm) was measured in a 96-well plate reader (M200, Tecan Group, Männedorf, Switzerland) 
and DXR was quantified using a calibration row in lysis medium (0.06-2 µg/mL). The method 
typically showed good linearity (r2 > 0.999), accuracy (95-105 % of individually prepared 1 µg/mL 
samples) and specificity as lipid matrix had negligible influence on DXR quantification. Lipid and 
DXR content were used to calculate the encapsulation efficiency (EE) according to Equation 1. 
Equation 1 
𝐸𝐸𝐸𝐸 [%] = 100 ∗ 𝑐𝑐(𝐷𝐷𝐷𝐷𝑅𝑅)𝑐𝑐(𝐿𝐿𝑦𝑦𝑖𝑖𝑦𝑦𝑦𝑦) (𝑎𝑎𝑒𝑒𝑜𝑜𝑦𝑦𝑎𝑎 𝑦𝑦𝑦𝑦𝑎𝑎𝑦𝑦𝑦𝑦𝑐𝑐𝑦𝑦𝑐𝑐)
𝑐𝑐(𝐷𝐷𝐷𝐷𝑅𝑅)
𝑐𝑐(𝐿𝐿𝑦𝑦𝑖𝑖𝑦𝑦𝑦𝑦) (𝑦𝑦𝑜𝑜𝑎𝑎𝑦𝑦𝑖𝑖𝑚𝑚 𝑦𝑦𝑜𝑜𝑎𝑎𝑦𝑦𝑦𝑦𝑖𝑖𝑚𝑚) 
3.4. Recombinant expression and purification of monoclonal antibodies 
Antibodies for Sortase-A mediated conjugation (CH-LPETG-mAb) were manufactured using 
established recombinant expression and purification procedures. Briefly, mammalian 
expression vectors encoding for EGFR-specific C225 (cetuximab) and a hen egg lysozyme-specific 
IgG1 (aHEL) fused to a Sortase-A recognition motif (LPETGS) at their heavy chain C-termini were 
synthesized by GeneArt (Thermo Fisher Scientific, Waltham, MA, USA). Antibodies were 
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recombinantly expressed in transiently transfected mammalian cells for five days using Expi293 
expression system (Thermo Fisher Scientific, Waltham, MA, USA) and afterwards purified from 
the supernatant by protein A affinity chromatography.  
3.5. Ligand conjugation: Reaction conditions and kinetic monitoring 
Chemoenzymatic Sortase-A transpeptidation was used to conjugate CH-LPETG-mAbs to 
pentaglycine-modified liposomes. The reaction behavior was investigated by spiking different 
concentrations of CH-LPETG-C225 to the DXR-LS (100 µM pentaglycine, from which roughly 
50 µM were expected to be accessible at the outer leaflet of the bilayer). The mixture was 
equilibrated at 4 °C, and hydrodynamic diameter, PDI and attenuation-corrected light scattering 
count rate were determined using a Zetasizer Nano ZS. Detection angle was set to 173° (back 
scatter), data was analyzed via cumulants fit. After addition of 25 µM Sortase-A, the colloidal 
stability was tracked during the transpeptidation reaction over 4 h to determine feasible 
reaction conditions. To further evaluate reaction kinetics and endpoint, 1.0 µM CH-LPETG-aHEL, 
DXR free liposomes (100 µM pentaglycine) and 25 µM Sortase-A were incubated at 4 °C. 5 µL of 
the mixture were sampled in 30 min intervals and analyzed by an rp-HPLC-DAD method 
published earlier for the analysis of single-domain antibody conjugation to pentaglycine-lipids 
[27]. The chromatographic conditions, namely the column temperature (60 °C) and the flow rate 
(1 mL/min) were modified to achieve sharp protein elution. This led to separation of Sortase-A, 
unmodified CH-LPETG-aHEL and with one ((DMA-PEG)-CH-LPETG-aHEL) or two 
((DMA-PEG)2-CH-LPETG-aHEL) lipid anchors modified mAb variants. The reaction progress was 
calculated as the relative area of each species from the area of 1.0 µM unmodified 
CH-LPETG-aHEL at 280 nm (Equation 2; sn – species of interest, ti – actual timepoint, A – peak 
area, A0 – area of 1.0 µM CH-LPETG-aHEL). At this wavelength, the influence of amide bonds 
being introduced by the pentaglycine-modified lipid was negligible. The total sum of the areas 
of the different mAb species during the reaction did never deviate to more than 6 % from the 
mean area of a 1.0 µM CH-LPETG-aHEL standard (n=3, each injected in triplicate). The double-
banded peak of mono-modified mAb was treated as single species.  
Equation 2 
𝑎𝑎𝑦𝑦𝑎𝑎𝑐𝑐𝑜𝑜𝑦𝑦𝑜𝑜𝑖𝑖 𝑖𝑖𝑎𝑎𝑜𝑜𝑚𝑚𝑎𝑎𝑦𝑦𝑐𝑐𝑐𝑐 [%] 𝑜𝑜𝑒𝑒𝑐𝑐𝑑𝑑 = 𝐴𝐴𝑆𝑆𝑛𝑛(𝑜𝑜𝑑𝑑)𝐴𝐴0  
Liposome batches for in vitro cytotoxicity experiments were conjugated with 1.0 or 2.5 µM of 
CH-LPETG-aHEL or CH-LPETG-C225 for 4 h at 4 °C to DXR-loaded liposomes (DXR loading: 4 h at 
49 °C, incubation in DPBS buffer), followed by dialysis in Float-A-Lyzer devices (MWCO 1000 kDa, 
G235037, Spectrum Labs, Los Angeles, California, USA). In case of HSPC-based liposomes, DXR 
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had been loaded for 1 h at 65 °C from 10 mM HEPES buffer pH 7.0. Liposome-bound mAb 
concentration was calculated from the peak area of both (DMA-PEG)-CH-LPETG-mAb and 
(DMA-PEG)2-CH-LPETG-mAb after analysis with above described rp-HPLC method using a 2.5 µM 
sample of non-lipidated CH-LPETG-mAb as reference.  
3.6. Cryo transmission electron microscopy 
Cryo transmission electron microscopy (cryo-TEM) studies were done according to a method 
described by Klaiber and colleagues [29]. In brief, a thin sample film stretched over the lace holes 
of a hydrophilized carbon grid was shock frozen by rapid immersion in liquid ethane (97 K). 
Microscopic examinations utilized a Zeiss / LEO EM922 Omega EFTEM (Zeiss Microscopy GmbH, 
Jena, Germany) operated at an acceleration voltage of 200 kV and a temperature of 95 K. Images 
were taken and processed by a digital camera and software system (Gatan, München, Germany).  
3.7. In vitro cytotoxicity 
Cytotoxicity of EGFR- and HEL-targeted liposomes (the latter used as an isotype control) was 
tested on EGFR-positive cells (MDA-MB-468). 10,000 cells were seeded in 80 µL growth medium 
(RPMI supplemented with 10 % fetal calf serum, 2 mM L-glutamine and 1 mM Na-pyruvate) in 
96-well plates and incubated overnight at 5 % CO2 and 37 °C in a humidified atmosphere. 
Dilution series of antibody-modified formulations or control groups were prepared in medium 
and added to the cells, spanning a final DXR concentration from 100 µg/mL to 1.2 x 10-4 µg/mL 
(5.5fold dilution series, 9 concentrations tested). Wells with cells but without test compound as 
well as without cells were included as controls. Wells were incubated for 4 h at 37 °C, carefully 
washed three times with 125 µL fresh medium each and incubated for another 3 days in 100 µL 
fresh medium. Finally, cell viability was assessed by using CellTiterGlo® luminescent cell viability 
assay (Promega, Madison, WI, USA) according to the manufacturer’s instructions. Data was 
normalized using wells with cells but without test compound as 100 % and those without cells 
as 0 %. IC50 values and statistics were determined by fitting the viability data to a 4-parameter 
regression model with GraphPad Prism software (GraphPad Software, La Jolla, CA, USA). 
4. Results and discussion  
4.1. Liposomal formulation development 
Sortaggable, pentaglycine-modified liposomes were prepared by a continuous and scalable 
solvent injection process utilizing a binary pumping system and a T-shaped mixing element as 
described earlier [27]. Buffer flow rate was screened for influence on hydrodynamic diameter 
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(dh) and PDI (Figure 1). Mean size was reduced with increased buffer flow due to increased shear 
forces at the injection site [30].  
 
Figure 1: Liposomal size adjustment. The total flow rate was varied to optimize the hydrodynamic diameter (dh) and 
polydispersity index (PDI) of the liposomal dispersion obtained from lipid injection into 250 mM ammonium sulfate 
buffer. Mean size was adjustable between 130 nm and 200 nm, PDI was < 0.25 (reference line) for all settings. Error 
bars indicate standard deviations of three individual experiments. 
Compared to previously reported manufacturing processes, slightly larger (20 nm) dh were 
obtained in ammonium sulfate buffer compared to DPBS [27], although other manufacturing 
parameters (lipid composition and molarity, organic solvent, flow rates) were equal. This 
indicates the influence of buffer type on the liposome formation mechanism or on the bilayer 
appearance. Here, lipid headgroups may interact with salts or change their protonation status 
due to different pH, leading to a change of their headgroup volume. PDI was < 0.25 for all 
settings, what indicates an acceptable polydispersity of the dispersion. A buffer flow rate of 
120 mL/min was chosen for further experiments to prepare liposomes with a mean size 
of ≈150 nm. This size was previously shown as suitable for effective targeting of myeloid immune 
cells in vitro [27] and in vivo [31] with equally composed pentaglycine liposomes. Tangential flow 
filtration was used to exchange the surrounding buffer to DPBS and to concentrate the liposomal 
dispersion. These pH and ammonium sulfate gradient pentaglycine liposomes were stable at 
2-8 °C for eight weeks regarding physical parameters (size, PDI, zeta potential; Supplementary 
Figure 1). Furthermore, the liposomes were found to be chemically stable as the bilayer 
composition was maintained during storage (Supplementary Figure 2). Active loading of drugs 
to liposomes via a pH and salt gradient typically requires heating to the transition temperature 
(tm) of the bilayer [28]. tm of the lipid blend including the pentaglycine lipids was therefore 
determined by DSC (Supplementary Figure 3). The measured tm of 43.7 ± 1.8 °C was comparable 
to the tm of the major component DPPC (tm = 41 °C [32]). As expected, the tm was not altered by 
the integrated DMA-PEG-G5 in a relevant manner compared to previous studies. Therefore, 
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loading experiments were conducted at 49 °C [28]. DXR loading duration was evaluated by 
dialyzing aliquots drawn from the loading bulk after different time points (Figure 2) in a dialysis 
bag (10 kDa membrane cut-off). This molecular weight cut-off was suitable to ensure sufficient 
permeability for the small molecule DXR (543.5 Da). Surprisingly, after lipid and DXR content 
determination, low encapsulation efficiencies (< 50 %) were obtained for short loading times up 
to 4 h (Figure 2).  
 
Figure 2: Doxorubicin loading to pentaglycine-modified, PEGylated liposomes. Encapsulation efficiency was low for 
short incubation times ≤ 4 h and increased up to 89 % after a 24 h loading. The amount of DMA-PEG-G5 in the bilayer 
concomitantly decreased with prolonged loading at elevated temperature (49 °C), indicating a thermodynamic lability 
of this amino acid lipid. Data is shown as mean ± standard deviation of loading experiments with three liposome 
batches. 
This was an unexpected result, as typical encapsulation efficiencies for doxorubicin via 
ammonium sulfate remote loading procedure are > 90 % [6]. We therefore further increased the 
loading time, achieving encapsulation efficiencies of 89 ± 5 % after 24 h, however with 
significant impact on chemical and physical stability of the liposomes. DMA-PEG-G5 bilayer 
fraction decreased upon long lasting incubation at 49 °C, indicating a temperature sensitivity of 
this lipid (Figure 2). Furthermore, liposome size and PDI increased with continuing incubation 
(Supplementary Figure 4). 
We hypothesized, that the loading buffer was the reason for initially low encapsulation 
efficiencies. A phosphate buffer was used to obtain a liposomal dispersion ready for Sortase-A 
conjugation, similar to a previously described protocol for liposome modification [27]. 
Phosphate salts are known to form a gel-like, viscous dispersion with DXR [33, 34]. This may 
hinder an efficient and fast DXR diffusion through the liposome membrane, thereby increasing 
the required time for an exhaustive loading. This was supported by an inverse correlation of 
loading efficiency and absolute phosphate concentration in the loading mix (Supplementary 
Figure 5), resulting from different mixing ratios of the DPBS-surrounded liposome dispersion and 
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the aqueous DXR stock solution. Further increases of loading efficiency were observed when an 
additional dialysis step was added after TFF, most likely by an enhancement of the salt and 
pH-gradient by a reduction of ammonium sulfate residuals. These small solutes may underlie a 
quick reverse diffusion over the TFF-membrane (molecular weight cut-off: 500 kDa) [35], 
hampering an efficient ammonium sulfate gradient generation. The additional dialysis step prior 
to DXR loading increased the encapsulation efficiency to 93 % at a phosphate concentration of 
0.58 mM (4 h incubation). 
 
Figure 3: Representative cryo-TEM pictures of pentaglycine liposomes prepared by solvent injection. A: After solvent 
injection in ammonium sulfate buffer. B: After rebuffering to DPBS. C and D: After DXR loading (4 h incubation, from 
DPBS). E: After DXR loading (1 h incubation, from DPBS). F: After DXR loading (1 h incubation, from HEPES buffer). 
Cryo-TEM was used to image the liposomes individually after solvent injection, tangential flow 
filtration and doxorubicin loading (Figure 3). Mostly spherical, uni- to bilamellar vesicles were 
observed after injection and tangential flow filtration. DXR loading had dramatic effects on the 
liposome appearance: different from frequently reported “coffee-bean” or “rugby” structures 
[17], many liposomes had a rod-like appearance, probably due to a subsequent growing 
doxorubicin precipitate in the liposome interior. These rod-like, drug-loaded liposomes had 
lengths of several hundred nanometers. Furthermore, “donut”-like structures were observed. 
The precipitate inside the vesicles had a fibrous appearance with a periodicity of about 3 nm, 
comparable to previous descriptions of such liposomes being loaded via the ammonium sulfate 
method [36]. Though partly present already after solvent injection and TFF, plenty of disk-like 
micelle structures were observed especially after doxorubicin-loading. Lasic et al. suggested that 
the presence of DSPE-mPEG stabilized these flat structures [36, 37]. Subsequent processing such 
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as tangential flow filtration and DXR loading may enhance their formation by increased stress 
factors like shearing during pumping and elevated temperature during loading. Thus, we 
investigated whether loading time or loading medium may influence the liposome appearance. 
While reduction of the incubation to 1 h did not lead to a homogenous dispersion (Figure 3E), 
exchanging the loading medium from DPBS to HEPES buffer (as frequently described by various 
groups [33, 38-41]) had considerable influence on the liposome appearance (Figure 3F). Typical 
coffee-bean structures were obtained by this method and less rod-like structures were 
observed. Interestingly, though liposomes appeared quite different in cryo-TEM, dynamic light 
scattering measurements did not indicate such distinct differences (Supplementary Table 1). It 
remains unclear why the loading medium has such a high impact on the precipitate dimension 
inside the vesicles. There might be a co-diffusion of a doxorubicin-phosphate salt inside the 
liposome interior during the loading at elevated temperature, or slight phosphate “loading” 
during the shearing caused by the peristaltic pump during TFF. Presence of different anions in 
the liposome interior are known to have significant impact on the appearance of the precipitate 
[42]. Low concentrations of phosphate anions inside the liposomes may therefore influence DXR 
precipitate morphology, thereby leading to the observed rod-like structures.  
4.2. Ligand conjugation 
Sortase-A was used to graft CH-LPETG-mAbs on the pentaglycine-modified liposomal surface 
(Scheme 1). This enzyme promotes a transpeptidation between the threonine of the LPETG-
stretch and the N-terminal amino group of the pentaglycine lipid anchor. Since the LPETG-motif 
was C-terminally attached to both heavy chain C-termini of the homodimeric antibody, two 
modifications per CH-LPETG-mAb were distinguishable (mono-modification, termed as 
(DMA-PEG)-CH-LPETG-mAb, and a di-modification, termed as (DMA-PEG)2-CH-LPETG-mAb). Both 
expected conjugate species were observed as separate peaks in an rp-HPLC analysis (Figure 4). 
 
Scheme 1: Schematic conjugation of CH-LPETG-mAb onto a PEGylated, pentaglycine-modified bilayer. 
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Figure 4: rp-HPLC analysis of Sortase-A mediated CH-LPETG-aHEL conjugation to pentaglycine-modified liposomes. 
Reaction conditions: Sortase-A (25 µM), CH-LPETG-aHEL (1.0 µM) and liposomes (100 µM based on pentaglycine 
content), incubated for 2 h at 4 °C.  
Liposomes equivalent to 100 µM pentaglycine, from which roughly 50 µM were estimated to be 
accessible for the reaction due to their presence on the outer leaflet of the bilayer (assuming an 
even distribution in the layers), were incubated with various concentrations of CH-LPETG-C225. 
Since macroscopically visible precipitation occurred with initially used high ratios of 
CH-LPETG-C225 towards the liposomes (50 µM CH-LPETG-C225 to 100 µM total pentaglycine), we 
systematically screened reaction conditions for a stable conjugation protocol (Figure 5).  
 
Figure 5: Colloidal stability of the liposomal dispersion during sortagging. CH-LPETG-C225 was spiked in different 
concentrations to 100 µM pentaglycine of DXR-loaded liposomes and 25 µM Sortase-A. The reaction progress was 
monitored by dynamic light scattering for the derived count rate, hydrodynamic diameter and polydispersity index. 
Strong losses of light scattering intensity indicated aggregation and sedimentation during the reaction. 
For that purpose, a cuvette-based dynamic light scattering measurement was deployed and the 
laser light attenuation corrected (“derived”) count rate was used as a parameter for colloidal 
stability. Here, sedimentation of insoluble aggregates decreases the optical density of the 
sample in the measurement zone of the cuvette. Monitoring of the derived count rate clearly 
showed a correlation between the initial CH-LPETG-C225 concentration and the colloidal 
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stability. The count rate decreased drastically for 5 µM and 25 µM initial CH-LPETG-C225 
concentration. Only in case of very low CH-LPETG-mAb concentrations (1.0 µM), a completely 
stable reaction was observed, indicated by an unchanged count rate, dh and PDI. The dh 
increased especially for the higher concentrations of 5 µM and 25 µM, followed by a decrease 
down to ≈100 nm due to aggregation and sedimentation. The PDI followed a similar behavior 
for those two concentrations applied. Liposomes modified with 2.5 µM CH-LPETG-C225 showed 
an intermediate behavior. Although the derived count rate decreased significantly for this group, 
no changes in mean size or PDI were observed. This indicates the formation of a fraction of 
insoluble and sedimenting aggregates, which are not suitable to be detected by DLS, since they 
are typically considered as dust by DLS algorithms. Hence, they do not contribute to calculation 
of the dh or PDI. Control groups including pure liposomes, a sample of liposomes and 25 µM 
CH-LPETG-C225 without Sortase-A as well as a mixture of liposomes, 50 µM LPETG-VHH and 
Sortase-A did not show aggregation (Supplementary Figure 6). The mass ratio of protein to lipid 
was similar for the reaction conditions of 50 µM VHH and 5 µM CH-LPETG-C225. Potentially, the 
dual mAb modification results in a cross linking of liposomes via Sortase-A and is thereby 
responsible for the high aggregation propensity at increased antibody concentrations.  
To gain deeper insights into the conjugation kinetic of CH-LPETG-mAbs towards the pentaglycine-
modified surface of the PEGylated liposomes, the reaction of 1.0 µM CH-LPETG-aHEL towards 
DXR-free liposomes was monitored over 14 h by rp-HPLC. Interestingly, the conversion followed 
a disproportionation profile (Figure 6). Since the Sortase-A recognition motif LPETG is reformed 
during the reaction and, hence, also existing in the mAb-liposome product (Scheme 1), the latter 
can serve as a substrate for another reaction cycle. This reaction can either be the reverse 
reaction, which would result in deconjugation, or hydrolysis as a general side reaction of 
sortagging. For up to 4 h, the lipidation of CH-LPETG-aHEL is the predominant reaction. After 4 h, 
most CH-LPETG-aHEL was converted into (DMA-PEG)2-CH-LPETG-aHEL (56.3 ± 1.0 mol%), with a 
minor increase after a prolonged incubation to 14 h (61.8 ± 1.5 mol%). Compared to that, the 
(DMA-PEG)-CH-LPETG-aHEL fraction reduced from 22.1 ± 3.2 mol% to 6.7 ± 0.5 mol% in the 
terminal reaction phase. Interestingly, unconjugated CH-LPETG-aHEL fraction showed an 
increase from 21.0 ± 0.5 mol% to 30.5 ± 2.6 mol% between 4 h to 14 h. CH-LPET-aHEL lacking the 
hydrolyzed terminal glycine is expected to elute with intact CH-LPETG-aHEL in the rp-HPLC 
analysis (Figure 4). Thus, the reaction kinetic indicated that not the di-modification, but a 
hydrolytic cleavage of (DMA-PEG)-CH-LPETG-aHEL towards CH-LPET-aHEL was predominant in 
the terminal phase of the reaction. The prolonged incubation therefore especially impacts the 
fraction of mono-modified mAb and reduces the total amount of ligand conjugated to the 
liposomes. On the other hand, a prolonged sortagging reaction improves chemical homogeneity 
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of the obtained immunoliposomes, since the intermediate (DMA-PEG)-CH-LPETG-aHEL fraction 
is reduced compared to the final product (DMA-PEG)2-CH-LPETG-aHEL. 
 
Figure 6: Kinetics of Sortase-A (25 µM) mediated conjugation of CH-LPETG-aHEL (1.0 µM) to pentaglycine-modified, 
PEGylated liposomes. The mono-modified (DMA-PEG)-CH-LPETG-aHEL is the major product for up to 1.5 h incubation, 
after which the di-modified (DMA-PEG)2-CH-LPETG-aHEL is the dominant fraction. A significant reverse reaction can 
be observed between 4 h and 14 h, indicated by an increase of the non-lipidated CH-LPETG-aHEL fraction in the 
terminal reaction phase. The maximum amount of aHEL conjugated to the liposomes (sum of mono- and di-modified 
mAb) was observed after 4 h (78.4 mol%). Error bars indicate standard deviations of three reactions. 
Summarizing the investigations on reaction conditions and kinetics, it can be concluded that the 
initial concentration of CH-LPETG-aHEL should not exceed 2.5 µM to prevent extensive 
aggregation of the liposomal dispersion at the investigated conditions (4 °C incubation 
temperature, 25 µM Sortase-A, 100 µM pentaglycine). The kinetic investigations identified that 
the maximal amount (78.4 mol% of 1.0 µM) was conjugated to the PEGylated liposomes after 
4 h, either as mono- or di-modified variant. Hence, these conditions were chosen to prepare 
DXR-loaded immunoliposomes for in vitro cytotoxicity tests.  
4.3. In vitro cytotoxicity of targeted DXR-liposomes on breast cancer cells 
In order to evaluate, if doxorubicin encapsulation in functionalized liposomes simultaneously 
mediated decreased unspecific toxicity but increased targeted activity against EGFR+ cells, we 
performed in vitro cytotoxicity assays. DPPC-based, DXR-loaded liposomes were modified with 
1.0 µM or 2.5 µM CH-LPETG-aHEL or CH-LPETG-C225, respectively, and purified by dialysis. For 
that purpose, a dialysis device with a membrane molecular weight cut-off of 1000 kDa was 
chosen, which should ensure a sufficient permeability for Sortase-A (20.9 kDa) as well as 
monoclonal antibodies (CH-LPETG-aHEL: 146.1 kDa, CH-LPETG-C225: 146.7 kDa). Furthermore, 
these devices were previously reported to retain the nanoparticulate liposome dispersion in a 
sufficient manner (lipid recovery > 88 %, [31]).  
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Table 1: Physico-chemical parameters of EGFR-targeted DXR-liposomes and control groups (standard deviation shown 
for triplicate analyses).  
formulation dh [nm] PDI zp [mV] DXR:mAb ratio nM mAB / µM PL 
DPPC-LS 142 ± 1 0.19 ± 0.03 -9.3 ± 0.5 - - 
1.0 µM-aHEL-DPPC-LS 143 ± 1 0.19 ± 0.01 -7.5 ± 0.4 5982 0.057 
2.5 µM-aHEL-DPPC-LS 144 ± 0 0.20 ± 0.00 -5.3 ± 0.8 2418 0.138 
1.0 µM-C225-DPPC-LS 143 ± 1 0.20 ± 0.01 -8.0 ± 0.3 6334 0.053 
2.5 µM-C225-DPPC-LS 145 ± 1 0.19 ± 0.02 -7.2 ± 0.2 2327 0.147 
      
HSPC-LS  120 ± 1 0.22 ± 0.00 -14.8 ± 0.6 - - 
1.0 µM-aHEL-HSPC-LS  101 ± 2 0.23 ± 0.01 -12.6 ± 0.3 4911 0.072 
1.0 µM-C225-HSPC-LS  121 ± 1 0.22 ± 0.01 -10.7 ± 0.2 5732 0.062 
 
DPPC-based liposomes modified with 1.0 µM or 2.5 µM CH-LPETG-C225 or CH-LPETG-aHEL 
showed neither changes in the hydrodynamic diameter nor in PDI (Table 1) after the final 
liposome processing compared to the non-conjugated control. No macroscopically visible 
precipitation or lipid loss (data not shown in publication, lipid recoveries ranged from 94-100 %) 
was observed. 
EGFR+ MDA-MB-468 cells were exposed to the dialyzed formulations for 4 h and, after careful 
medium exchange, incubated for another 3 days in pure growth medium. It should be tested 
whether the drug encapsulation firstly decreases the unspecific toxicity of pure doxorubicin, and 
secondly, whether a selective targeting via the EGF-receptor was able to re-increase the 
cytotoxicity in vitro (Figure 7). 
 
Figure 7: Viability curves of targeted, DXR-loaded DPPC-LS, HSPC-LS and controls. MDA-MB-468 cells were incubated 
with the liposomal formulations at different DXR concentrations (or equivalent lipid concentrations, according to the 
DXR:lipid ratio of drug-loaded LS). After 4 h, medium containing unbound liposomes was exchanged, followed by a 
further incubation of the cells for 3 days, until viability was assessed. Free DXR showed highest cytotoxicity, which 
was alleviated by drug encapsulation. EGFR-targeting led to a re-increase of cytotoxicity. Data shows mean ± standard 
deviation of two biological experiments. 
Pure doxorubicin had an IC50 of 0.3 ± 1.2 µg/mL (Figure 8), which is in line with previously 
reported IC50 values on this cell line (Mamot et al: 0.8 µg/mL [40]). Encapsulation of DXR in the 
pentaglycine-modified, PEGylated liposomes (DPPC-LS) led to an 18fold decrease of toxicity as 
indicated by an appropriate increase in IC50 (Figure 8A). Similar values were obtained for the 
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isotype-control CH-LPETG-aHEL carrying immunoliposomes (19fold and 21fold increase for 
1.5 µM-aHEL-DPPC-LS and 2.5 µM-aHEL-DPPC-LS, respectively, not significantly different from 
mAb-free DPPC-LS). Drug-free (empty) liposomes were not toxic (tested up to 1.3 mM total lipid, 
Figure 7). Conjugation of CH-LPETG-C225 mediated an increased cytotoxicity of the liposomes to 
an IC50 of 3.2 µg/mL for 1.0 µM-C225-DPPC-LS and 2.2 µg/mL for 2.5 µM-C225-DPPC-LS, latter 
significantly different from DPPC-LS (p < 0.05, Figure 8A). This indicates a targeted cytotoxicity, 
that is further amplified at higher ligand densities. Cellular specificity, meaning selective toxicity 
of C225-targeted liposomes on EGFR-overexpressing cells, but equal toxicity of targeted and 
non-targeted liposomes on EGFR- cells has been demonstrated several times with comparable 
liposomal constructs [40, 43] or C225-based ADCs [24]. The here presented targeted cytotoxicity 
was also not due to synergistic effects of CH-LPETG-C225 and liposomal doxorubicin, as a physical 
mixture (CH-LPETG-C225 : DXR ratio equal to 2.5 µM-C225-DPPC-LS) showed cytotoxicity 
comparable to the isotype- or unconjugated liposomes. This underlines the requirement of a 
stable (covalent) anchoring of the ligand onto the targeted drug delivery system.  
 
Figure 8: IC50 values of EGFR-targeted, DXR-loaded liposomes and controls on MDA-MB-468 cells (data is shown as 
mean ± standard deviation of two biological experiments; * indicates significant differences (p < 0.05) to the ligand 
free control). A: DPPC-based liposomes, loaded with DXR from DPBS buffer and showing significant rod-like 
morphology. B: HSPC-based liposomes, loaded with DXR from HEPES buffer and assumed to have a predominant 
“coffee-bean” structure. Targeted formulations increased cytotoxicity over non-targeted ones. No relevant 
differences were observed between the DPPC- and HSPC-based formulations. 
Previous reports suggested a density of 0.3-1.2 nM ligand / µM phospholipid for C225 Fab’ 
targeted DXR liposomes, reaching IC50 values of 1.1 µg/mL on the same cell line [38, 40]. The 
ligand density of the presented liposomes ranged from 0.05-0.15 nM ligand / µM phospholipid 
(Table 1). For direct comparison it should be considered, that monoclonal antibodies provide 
two ligand binding sites compared to a Fab’ fragment. Interestingly, we found only slightly higher 
IC50 values for the 2.5 µM-C225-DPPC-LS constructs (1.1 µg/mL described by Mamot et al. versus 
2.2 µg/mL described here). However, more drastic differences were observed for untargeted 
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DPPC-LS (32 µg/mL versus 5.8 µg/mL). The higher unspecific toxicity of the presented system led 
to the question whether the particle shape or usage of DPPC (instead of the higher melting HSPC) 
was the reason for this observation. We therefore prepared HPSC-based liposomes (HSPC-LS) 
which were loaded with DXR from HEPES buffer to achieve a predominant “coffee-bean” shape 
based on our morphological investigations (Figure 3) and previously reported cryo-TEM analysis 
of comparably prepared liposomes [42]. An overview of the different liposomal preparation 
conditions, the corresponding morphological analyses and link to cytotoxicity read-out is given 
in Supplementary Table 2. The HSPC-LS were then conjugated with either 1.0 or 2.5 µM 
CH-LPETG-aHEL or CH-LPETG-C225. The reaction behavior was found to be less stable in HEPES 
compared to DPBS, as strong precipitation was observed for the 2.5 µM group, which was 
therefore not considered for in vitro analyses. Minor aggregates in the 1.0 µM group were 
removed by centrifugation (5 min at 800 x g), leading to a lipid loss of 10-25 %. Interestingly, 
negligible impact on IC50 values compared to DPPC-LS was observed (5.3 ± 1.1, 6.4 ± 1.1 and 
2.1 ± 1.2 µg/mL for ligand free, CH-LPETG-aHEL and CH-LPETG-C225-modifed liposomes, 
respectively, Figure 8B). This suggests a minor influence of DPPC or HSPC usage and also DXR-
loading procedure on the in vitro performance. The non-targeted DPPC- and HSPC-based 
formulations showed no significant differences of unspecific toxicity, that could have been 
caused by the different morphology or bilayer rigidity. The unspecific toxicity was unexpectedly 
high, expressed in a ratio of 2.5 between the IC50 value of non-targeted HSPC-LS and 
1.0 µM-C225-HSPC-LS. Mamot et al. reported a ratio of 29 between comparably composed 
targeted or non-targeted liposomes on the same cell line [40]. This may be explained by different 
cytotoxicity experiment settings. Especially the longer exposition of cells (2 h in literature 
compared to 4 h in the presented report) to the formulations prior the wash-out may have led 
to a drug release and hence higher unspecific toxicity of the liposomes. Comparable 
observations were previously reported for CD19-targeted, DXR-loaded liposomes [44]. Although 
the authors obtained only low ratios of 4.6 (for 1 h incubation of cells with the liposomes) or 1.8 
(for 24 h incubation) in vitro, the targeted liposomes were able to significantly enhance the 
mean survival time of B-lymphoma model mice. Comparably, Zalba et al. reported a low ratio of 
1.5 between the IC50 of EGFR-targeted (26 µM) or non-targeted (39 µM), oxaliplatin-loaded 
liposomes on SW-480 cells (colorectal cancer cells) after 4 h incubation. Nevertheless, the 
targeted liposomes clearly improved tumor growth inhibition of SW-480 derived xenografts in 
mice compared to non-targeted ones [43]. These results underline that low ratios in IC50 values 
between targeted and non-targeted liposomes observed in vitro are not necessarily predictive 
for the in vivo performance of the drug delivery system. 
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5. Conclusion and outlook 
In the presented work, we thoroughly investigated the loading of doxorubicin into pentaglycine-
modified liposomes which were prepared in a controllable and scalable manufacturing process. 
The pentaglycine lipid anchor was used to conjugate CH-LPETG-mAbs as targeting ligands on the 
drug delivery system by sortagging. The conjugation required detailed analyses of reaction 
conditions and kinetics, as a strong aggregation and precipitation propensity was observed. This 
was attributed to the presence of two LPETG-motifs per mAb that may lead to cross-linking 
between liposomes. Precipitation was circumvented by a drastic reduction of the 
CH-LPETG-mAb : lipid ratio during reaction. This decrease consequently led to decreased ligand 
densities < 0.3 nM / µM PL on the liposomal system. Although the ligand density was low, the 
liposomal drug delivery system increased the specificity of doxorubicin toxicity in vitro in a 
targeted manner. This was firstly indicated by an 18fold increase of the IC50 by drug 
encapsulation in the carrier. Secondly, grafting of cetuximab on the liposomal surface led to a 
re-decrease of the IC50 on breast cancer cells carrying the targeted structure. This drug targeting 
effect was ligand specific since it was not shown by liposomes functionalized with an isotype 
control antibody. Increased ligand density may further improve binding efficacy and 
internalization of the liposomal system [40], which is known to be more effective if multivalent 
(binding of several receptors) systems are used [45]. Therefore, the use of alternative 
sortaggable ligands such as Fab’s, single-chain variable fragments (scFv) or single-domain 
antibodies employed with a single LPxTG-motif should be considered for optimization. This 
would firstly reduce the mass per ligand conjugated to the carrier and secondly avoid liposome 
cross-linking during conjugation. Furthermore, usage of ligands lacking a Fc-domain would also 
circumvent pharmacokinetic disadvantages known from full length mAbs used as targeting 
ligands for immunoliposomes [43, 46-49]. Whether such EGFR-targeted, DXR-loaded drug 
carriers may improve the treatment of solid tumors in humans was recently investigated in a 
phase I trial [3]. Interestingly, the authors reported a remarkably low skin cytotoxicity, an issue 
which is a major concern in the development of EGFR-targeted ADCs [24]. This observation may 
strengthen the consideration of particulate targeting systems, such as the described nano-sized 
liposomal system as an alternative to antibody-drug conjugates.  
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Supplementary Data 
Stability of gradient liposomes 
 
Supplementary Figure 1: Physical stability of pentaglycine-modified gradient liposomes (empty DPPS-LS). No change 
in dh, PDI or zeta potential occurred during an 8 weeks storage at 2-8 °C (data shown as mean ± standard deviation of 
three liposomal batches).  
 
Supplementary Figure 2: Chemical stability of pentaglycine-modified gradient liposomes (empty DPPC-LS). The bilayer 
composition was maintained over an 8 weeks storage at 2-8 °C (data shown as mean ± standard deviation of three 
liposomal batches).  
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Thermal analysis of lipid blend 
 
Supplementary Figure 3: DSC thermogram of a hydrated lipid blend consisting of DPPC, cholesterol, DSPE-mPEG and 
pentaglycine-modified DMA-PEG-G5 (molar ratio 59.4 : 34.7 : 5.0 : 1.0). Transition temperature (tm) was determined 
as 43.7 ± 1.8 °C (n=3). A broad phase transition was observed in the thermogram, probably due to the presence of 
cholesterol. 
Influence of doxorubicin loading on physical liposome properties 
 
Supplementary Figure 4: Influence of DXR loading on physical liposome properties. Liposomes composed of 
59.4 mol% DPPC, 34.7 mol% cholesterol, 5.0 mol% DSPE-mPEG and 1.0 mol% DMA-PEG-G5 were loaded from 1x DPBS 
as outer buffer (5:1 DXR to lipid m/m). PDI and dh increased with continuing incubation times. Data shown as mean ± 
standard deviation of three liposomal batches. 
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Influence of the phosphate concentration on doxorubicin loading 
 
Supplementary Figure 5: DXR encapsulation efficiency after loading from differently composed buffer systems. A 
loading mix was prepared from DXR (10 mg/mL in water), liposomes (ad 30 mM; in DPBS) and water to adjust a 
doxorubicin to lipid ratio of 5:1 m/m. Due to variation of lipid concentration in different liposomal batches, absolute 
phosphate concentration varied between different loading experiments, which was only in one case (1.35 mM) 
corrected by addition of 10x DPBS stock. There was an inverse correlation between phosphate concentration and 
encapsulation efficiency. If shown, error bar indicates mean ± standard deviation of results obtained from three 
liposomal batches, otherwise experiment was conducted with one single batch. 
Colloidal stability during sortagging 
 
Supplementary Figure 6: Control groups for investigation of colloidal stability of pentaglycine-modified PEGylated 
liposomes during Sortase-A reaction. Sole DXR-loaded liposomes or a Sortase-A free mixture with 25 µM 
CH-LPETG-C225 did not show sedimentation over the experiment duration (270 min). Gradient liposomes (100 µM 
pentaglycine) incubated with 50 µM of a single-domain antibody (VHH ENH) were stable during the reaction time. 
100 µM non-liposomal DMA-PEG-G5 obtained from a film-hydration showed no aggregation when incubated with 
Sortase-A and 2.5 µM CH-LPETG-C225, but with 25 µM CH-LPETG-C225. 
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Supplementary Table 1: Physico-chemical parameters of liposomes analyzed by cryo-TEM (data from one batch, 
analyzed in triplicate). 
formulation dh [nm] PDI zp [mV] 
after injection 151 ± 4 0.23 ± 0.01 -3.0 ± 0.3 
after TFF 141 ± 1 0.23 ± 0.00 -8.4 ± 0.5 
after DXR loading (4 h, from DPBS) 152 ± 2 0.17 ± 0.01 -7.0 ± 0.5 
after DXR loading (1 h, from DPBS) 147 ± 2 0.19 ± 0.01 -6.5 ± 0.6 
after DXR loading (1 h, from HEPES) 138 ± 0 0.21 ± 0.01 -8.0 ± 0.5 
 
Supplementary Table 2: Overview of liposome compositions and manufacturing conditions for DXR-loaded liposomes 
analyzed by cryo-TEM and tested for in vitro cytotoxicity.  
measured lipid 
composition 
interior 
buffer 
exterior 
buffer 
incubation 
conditions 
predominant 
structures observed in 
cryo-TEM 
description in 
cytotoxicity assay 
DPPC: 60.5 mol% 
CHOL: 34.2 mol% 
DSPE-mPEG: 4.5 mol% 
DMA-PEG-G5: 0.8 mol% 
250 mM 
(NH4)2SO4 
DPBS,  
pH 7.4 
4h, 49 °C rod-like, 
“donut”-structures 
“DPPC-LS” or 
derivatives 
(equivalent batch 
used for 
cytotoxicity assay) 
 
DPPC: 60.7 mol% 
CHOL: 34.1 mol% 
DSPE-mPEG: 4.2 mol% 
DMA-PEG-G5: 0.9 mol% 
 
250 mM 
(NH4)2SO4 
DPBS, 
pH 7.4 
1 h, 49 °C rod-like, 
“donut”-structures 
not analyzed 
DPPC: 60.7 mol% 
CHOL: 34.1 mol% 
DSPE-mPEG: 4.3 mol% 
DMA-PEG-G5: 0.9 mol% 
 
250 mM 
(NH4)2SO4 
10 mM 
HEPES, 
pH 7.0 
1 h, 49 °C “coffee beans” / 
“rugby-like” 
not analyzed 
HSPC: 59.9 mol% 
CHOL: 35.0 mol% 
DSPE-mPEG: 4.2 mol% 
DMA-PEG-G5: 0.9 mol% 
250 mM 
(NH4)2SO4 
10 mM 
HEPES,  
pH 7.0 
1 h, 65 °C HSPC-based liposomes 
were not analyzed via 
cryo-TEM. Typical 
“coffee bean” / “rugby-
like” appearance is 
expected, comparable 
to previous reports that 
analyzed similar 
prepared liposomes [1] 
“HSPC-LS” or 
derivatives 
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1. Comprehensive discussion and summary 
Eight actively targeted liposomal drug formulations, called immunoliposomes, have been 
investigated in human trials so far. This underlines the clinical relevance of such drug delivery 
systems [1]. Therefore, targeted liposomes are an important part of the formulation scientist’s 
toolbox to enable a safe and effective administration of drugs with suboptimal pharmacokinetic 
(e.g. distribution in healthy tissues) and pharmacodynamic (e.g. toxicity) profiles. They are one 
attempt to realize Paul Ehrlich’s idea of a “magic bullet”, a tailored medicine that precisely 
targets disease-affected tissues without impairment of healthy cells. Immunoliposomes are 
complex multi-component systems, and the utilized excipients like lipids and antibodies are 
mainly derived from biological systems. Those heterogeneous precursors already indicate that 
reproducible and homogenous manufacturing of drug products is a complicated and demanding 
task. Hence, protein conjugation of targeting ligands to the liposomes potentially multiplies 
heterogeneity. It is therefore of utmost technological interest to provide methods that promote 
a defined, site-specific conjugation between the liposomal carrier and the targeting ligand.  
Staphylococcus aureus derived Sortase-A is a transpeptidase with a great potential as 
chemoenzymatic “swiss army knife” [2]. It offers a site-specific conjugation between LPxTG 
(leucine, proline, any amino acid, threonine, glycine)-modified proteins and N-terminal 
glycine-carrying motifs, such as other proteins and peptides, but also towards synthetic lipids. 
Hence, the application of the Sortase-A transpeptidase for the surface modification of liposomal 
drug carriers and therewith related analytical, technological and biological questions was set as 
focus of this scientific thesis. 
Pentaglycine-modified dimyristyl lipids were investigated to serve as targeting ligand anchors in 
different liposomal constructs. Since liposome manufacturing and purification includes 
numerous steps, a suitable rp-HPLC method was developed to cover in process and final quality 
control of the liposome composition (Chapter 2). The method was validated regarding linearity, 
specificity, precision, accuracy and sample stability for the quantification of two pentaglycine 
lipids and selected helper lipids. The method represents a highly flexible tool to determine the 
exact lipid composition of various sortaggable liposomal formats, including liposomes with 
different surfaces charges, PEGylation, rigidity or pH-sensitivity. This helped to control liposome 
compositions during manufacturing and guaranteed batch consistency, setting the basis for the 
following physico-chemical and biological experiments. 
Considering the chemical composition of liposomes, PEGylation was shown to have tremendous 
impact on the pharmacokinetic behavior of the carrier [3]. However, also physical properties like 
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the hydrodynamic diameter, polydispersity and zeta potential are important factors influencing 
the biological fate [3]. A comprehensive investigation to control the liposomal hydrodynamic 
diameter of differently PEGylated liposomes during manufacturing by a solvent injection process 
was therefore conducted in Chapter 3. This manufacturing method offers an easily scalable way 
to prepare small to medium sized unilamellar liposomes. Such a scalability is of particular 
importance when translating the manufacturing of nanomedicines from lab-scale to batch sizes 
sufficient to meet clinical demands, thereby maintaining quality attributes of preclinical batches. 
Especially the commonly preclinically applied thin film hydration with subsequent extrusion 
represents a procedure with challenging scalability, e.g. due to distinct limits in vessel or 
extruder size. The here investigated solvent injection process is a promising alternative that 
demonstrated controllability of the liposomal size as well as an easy scalability. Increase of the 
flow rates, especially of the aqueous anti-solvent, led to a decrease of the liposome diameter. 
Diameters ranging from 95 nm to 230 nm were covered for differently PEGylated liposomal 
formulations with a pentaglycine-modified surface.  
The pentaglycine modification was inevitable for a subsequent conjugation of LPxTG-modified 
targeting ligands by Sortase-A. Enzymatic reactions require steric accessibility of the recognition 
motifs, which greatly varies between differently PEGylated liposomal surfaces. Pentaglycine 
motifs shielded by a surrounding 2 kDa PEG layer were suppressed from reaction with a 
single-domain antibody, whereas pentaglycines exposed via a 2 kDa PEG spacer showed 
comparable behavior on PEGylated or non-PEGylated bilayers. Temperature increase also 
enabled the sortagging of PEG-shielded pentaglycines, which may allow the selective sortagging 
of disparately accessible glycines by using different reaction conditions. This may open the door 
for a convenient manufacturing of multi-layered liposomes. Additionally, the relative efficiency 
of transpeptidation was improved from 40 % to 80 % by increasing the ratio of pentaglycine 
nucleophile to the LPETG-modified antibody. 
A potential pitfall for the use of Sortase-A is the reverse reaction, or more precisely, a product 
hydrolysis by water molecules acting as alternative nucleophiles. The depletion of Sortase-A 
from immunoliposomal reaction bulks was therefore investigated in Chapter 4, combined with 
stability studies covering the kinetic cleavage of the targeting ligand from the liposomes. 
PEGylated bilayers adsorbed Sortase-A in an unspecific fashion. However, those PEGylated 
liposomes were not prone for ligand cleavage by enzyme residuals. Although Sortase-A residuals 
were much lower for non-PEGylated bilayers, these formulations lost 20 % of the ligand bound 
to the liposome during eight weeks of cooled storage. This contrary result was explained by 
steric prevention of the reverse reaction on PEGylated bilayers. The ligand-cleavage from 
non-PEGylated bilayers was prevented by an additional Sortase-A removal step via poly-histidine 
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affinity beads. This indicates the necessity of an elaborated purification strategy for usage of the 
Sortase-A technology on liposomal carriers (Figure 1). 
 
Figure 1: “On-site sortagging” or “post-insertion” – manufacturing routes for immunoliposomes with ligands 
conjugated to the lipid anchor by means of Sortase-A. 
An alternative to extensive purification of reaction bulks is the avoidance of Sortase-A exposure 
to the liposomal surface during manufacturing. This was realized by separation of the ligand 
lipidation from liposome manufacturing (Chapter 5Figure 1). Single-domain antibodies were 
lipidated using Sortase-A and a pentaglycine-PEG-dimyristyl motif. The water-soluble reaction 
product was successfully purified by reversed-phase chromatography without loss of antigen 
binding capacities. The lipidated antibodies were inserted into the bilayer of preformed, 
fluorophore-loaded liposomes (“post-insertion”). This enabled a specific targeting of antigen-
positive cells. Hence, an alternative to the “on-site sortagging” manufacturing for single-domain 
antibody-based immunoliposomes was developed (Figure 1).  
An overview of both manufacturing routes and a comparison of their advantages and 
disadvantages is given in Figure 1. Although the sortagging on the liposomal surface is a 
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straightforward approach without requirement of additional equipment, it has several 
drawbacks. The most important one is the above discussed retention of Sortase-A, which 
requires the use of elaborated purification techniques. The post-insertion strategy avoids 
unfavorable Sortase-A residuals by circumventing enzyme exposure to the liposomal surface. 
Another drawback is the high dependency of the reaction efficiency during on-site sortagging 
from the liposomal surface, making the ligand density on the carrier hard to predict. Since the 
insertion process of lipidated ligands into liposomes is very efficient, the post-insertion strategy 
offers an easy way to adjust this ratio just by the mixing ratio of the liposome precursor and the 
purified lipidated ligand. Also, the batch volume of the immunoliposomal bulk can be freely 
adjusted and does not depend on minimal required volumes determined e.g. by dialysis devices. 
This is of importance during the early research phase, where only limited amounts of especially 
proteinaceous components such as targeting ligands are available. Besides these advantages, 
the post-insertion strategy has also several drawbacks. This is firstly an overall higher demand 
on equipment, since a suitable instrumentation for a (typically chromatographic) purification of 
the lipidated ligand is required. Secondly, the obtained product should be compatible with the 
purification process, meaning it should not show degradation (e.g. loss of binding) and it should 
be water-soluble. This was demonstrated in Chapter 5 for the combination of a PEGylated lipid 
anchor and single-domain antibodies and may be also feasible with other binders such as 
monoclonal antibodies or fragments thereof (scFv, Fab’). Thirdly, the post-insertion process is 
typically conducted at elevated temperatures above the transition temperature of the lipid mix, 
what may be incompatible with temperature-sensitive drugs. Finally, the post-insertion strategy 
includes numerous additional steps, leading to increased demands on process characterization 
and analytics for the intermediates in commercial manufacturing. This higher effort in the 
value chain should also be considered during evaluation of the manufacturing route. 
Not only liposomal bilayers, but also biological membranes were modified with the isolated, 
lipidated single-domain antibodies. Insertion of lipidated compounds into cell membranes 
(“hydrophobic insertion”) represents one of three currently described non-genetic methods for 
cell membrane engineering. This hydrophobic insertion is, compared to covalent conjugation or 
on electrostatic interaction-based cell surface modifications, a very gentle approach due to the 
negligible toxicity, the maintenance of normal cellular activities and the participation of the 
inserted molecules in the cell membrane dynamics [4]. Cell surface modifications have drawn 
increasing interest in the field of cell therapies e.g. for regenerative medicine or cancer 
immunotherapy. These therapies were revealed to be much more effective when the 
administered cells were engineered with target-specific binders, e.g. due to increased cell 
homing effects, greater tissue retention rates or improved in vivo persistency [4]. In this thesis, 
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the membranes of murine T cells were engineered with a CD11b-binding single-domain 
antibody. This promoted supraphysiological cell-cell interactions with myeloid cells in a 
co-culture assay (Chapter 5). The demonstrated membrane engineering may enable novel forms 
of autologous therapies, in which endogenous cells are redirected towards specific tissues by 
exogeneous ligands. 
Variants of myeloid cells, characterized by a CD11b+Gr-1+ phenotype, are attractive targets in 
immuno-oncology due to their suppressive influence on the immune response in the tumor 
microenvironment. A single-domain antibody specific for the human myeloid cell surface 
receptor CD11b was conjugated on fluorophore-labeled liposomes (Chapter 3). The 
immunoliposomes showed a specific binding towards antigen-positive monocytes and 
granulocytes in vitro, but not towards target-negative T or B cells. An internalization of the drug 
carrier by target-positive cells was observed with confocal microscopy. Comparable results were 
obtained with equally composed liposomes equipped with a single-domain antibody specific for 
CD11b on murine myeloid cells (Chapter 4). Moreover, after an intravenous injection of 
CD11b-specific liposomes into mice, a significant threefold increase in mean fluorescence 
intensity of CD11b+Gr-1+ splenocytes was observed compared to control liposomes carrying a 
non-specific ligand. For the first time, immunoliposomes which were prepared from a sortagging 
process demonstrated a targeting proof of principle in an animal experiment. 
These promising results led to the decision to encapsulate cytotoxic payloads into the drug 
carriers. Pseudomonas exotoxin A is a proteinaceous ribosylase that inhibits the protein 
biosynthesis in picomolar concentrations when delivered to the cytosol of eukaryotic cells. A 
truncated variant lacking the endocytosis-promoting domain was loaded into liposomes, which 
were then targeted against CD11b+Gr-1+ cells. However, no target-specific cytotoxicity was 
observed, although several liposomal formulations varying in PEGylation, drug load and lipid 
composition were screened. Also liposomes loaded with an established toxic chemical entity 
(doxorubicin) failed to exhibit specific toxicty on CD11b+Gr-1+ cells. Reasons for this failure and 
further possible strategies were extensively discussed in Chapter 6. 
Doxorubicin is clincally applied as a liposomal anti-cancer drug. The active encapsulation of 
doxorubicin into pentaglycine-modified, PEGylated liposomes was investigated in Chapter 7. 
The epidermal growth factor receptor (EGFR) was utilized as an alternative and established 
target compared to the myeloid cell target CD11b. Liposomes were directed towards EGFR+ 
cancer cells using a sortaggable variant of an approved anti-EGFR monoclonal antibody (C225, 
cetuximab). The targeted liposomes exhibited a significant higher cytotoxicity compared to their 
non-targeted counterparts. This indicated the suitability of the developed liposomal carriers to 
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act as targeted drug delivery system for doxorubicin on an established target, and suggested 
that cell line-, target- or ligand-related aspects impeded specific toxicity on myeloid cells. Similar 
doxorubicin-loaded, EGFR-targeted immunoliposomes prepared with a maleimide-based 
coupling chemistry have been successfully investigated in a clinical phase I study [5]. The same 
group is currently recruiting patients for a subsequent phase II study [6]. The site-specific 
conjugation approach demonstrated within this thesis offers an important alternative to 
manufacture such EGFR-targeted immunoliposomes. The defined reaction product obtained 
here from chemoenzymatic coupling may exhibit benefits from a toxicological and 
immunological, but also from an analytical and finally regulatory perspective. 
It is especially the lack of such a defined reaction product, or vice versa product heterogeneity that 
was associated with toxic side effects of ADCs, that led to batch recalls of PEGylated enzymes or that 
decreased the bioactivity of therapeutic proteins [7]. Sortase-A mediated site-specific 
transpeptidation is one approach to mitigate such risks during protein modification, however it 
should not remain unmentioned that also other enzymatic or chemical methods have been 
developed to address these problems. Especially transglutaminases are considered as powerful 
alternative to Sortase-A due to the vastly lower KM and the irreversible reaction mechanism [7]. Also, 
chemical conjugation techniques such as the Huisgen cycloaddition, the strain-promoted azide-
alkyne cycloaddition or the Staudinger ligation allow a site-selective derivatization of proteins, 
although side reactions have been described [7]. Comparing chemical and enzymatic techniques, it 
is important to state that many chemical methods require the introduction of novel functional 
groups like unnatural amino acids into the protein. Similarly, enzymes rely on genetically introduced 
recognition tags. Both recognition tags or unnatural amino acids may influence expression yields or 
potentially alter the protein structure. Chemical methods may additionally require catalysts such as 
copper that can be responsible for toxicity related concerns or lead to protein precipitation [7]. Thus, 
especially sensitive proteins may favor enzymatic coupling methods due to the mild reaction 
conditions that help to maintain protein conformation and activity.  
Altogether, a broad variety of conjugation methods are meanwhile available for site-selective 
protein modification [7] and thus display potential options for a defined anchorage of targeting 
ligands on liposomes. Such bioorthogonal reactions may subsequently replace the still 
predominantly applied unspecific techniques, including e.g. thiol-maleimide-based or 
carbodiimide-based coupling strategies [8]. Hence, increased elucidation of bioorthogonal 
conjugation techniques for the design of targeted liposomes can contribute to an improved 
developability, increased safety and possibly enhanced efficacy of such nanotherapeutics. The 
within this thesis described investigation of the Sortase-A technology for liposomal surface 
modification strived to contribute to this elucidation.  
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2. Conclusion and future perspectives 
The present work reveals the vast potential, but also important drawbacks of the Sortase-A 
technology used for chemoenzymatic surface modification of liposomes. Sortagging offers a 
facile approach for an efficient and highly defined conjugation of targeting ligands onto drug 
carriers. However, Sortase-A depletion from the reaction bulk was demonstrated to be a critical 
process step with a significant impact on the stability of the obtained product. Strategies to 
mitigate this risk, either by improved purification or by post-insertion manufacturing routes 
were disclosed. This work enables now the preparation of immunoliposomes with 
chemoenzymatically anchored ligands in suitable stability and decreased material consumption.  
CD11b-specific immunoliposomes prepared with Sortase-A efficiently targeted human and 
murine myeloid cells in vitro. For the first time, such sortagged liposomes were also 
demonstrated to specifically reach myeloid CD11b+Gr-1+ target cells in vivo. This shows the great 
potential for these formulations to act as drug carriers that may regulate immune responses, 
e.g. in the tumor microenvironment. The specific toxicity of doxorubicin to cancer cells using a 
sortagged, immunoliposomal formulation highlighted the capacity of the system to not only 
deliver marker molecules, but also actual drugs. However, the specific delivery of a 
proteinaceous toxin to CD11b+Gr-1+ cells was not successful. This challenge may be subject to 
further investigations. Those should especially relate liposomal formulation aspects, such as the 
bilayer composition, to the cellular fate of the carrier. In particular, thorough analysis of 
parameters promoting the intracellular release of large molecules from a targeted 
immunoliposomal system would provide essential benefit for a wide variety of therapeutic 
applications. Latter may not only include the targeted delivery of proteinaceous toxins to cancer 
or immuno-oncological cells, but also antigen delivery for vaccination or ribonucleic acid delivery 
for gene therapy.  
This broad potential applicability underlines that the drug carriers and the related surface 
modification strategies developed within this thesis provide an essential benefit in the field of 
targeted drug delivery – from a technological, but also from a therapeutic perspective.  
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Abstract (English) 
Drugs are encapsulated in nano-sized drug delivery systems to refine their pharmacokinetic, 
pharmacodynamic or physico-chemical behavior upon administration. Immunoliposomes are 
conjugates of targeting ligands and lipid-based drug carriers. These ligands are designed to 
specifically direct the encapsulated drug to the disease-affected target tissue. The conjugation 
reaction combining the carrier and ligand is a critical step since it is a possible source of product 
heterogeneities. In this work, Sortase-A transpeptidase was investigated as a chemoenzymatic 
tool to provide a site-specific anchoring of antibodies on liposomes. Liposomes bearing 
pentaglycine lipids that serve as Sortase-A acceptor motifs (“sortaggable liposomes”) were 
manufactured via a scalable solvent injection process. This process yielded small to medium 
sized liposomes differing in lipid composition, PEGylation or charge. Flow rate alterations were 
identified as suitable parameter to align the hydrodynamic diameter of the differently 
composed liposomes between 140 nm and 180 nm. A newly developed rp-HPLC method with 
evaporative light scattering detection helped to monitor the exact lipid composition of these 
liposomal formulations. This was indispensable for subsequent downstream processes like 
ligand conjugation and liposome purification steps, but also for physico-chemical and biological 
characterization. 
Both single-domain antibodies and whole monoclonal antibodies were successfully conjugated 
to the liposomes. Differently PEGylated liposomes demonstrated a high dependency of the 
reaction efficiency on the steric accessibility of the pentaglycine motif. Also, the efficiency of 
transpeptidation was improved from 40 % to 80 % by increasing the ratio of pentaglycine 
nucleophile to the antibody. Sortase-A depletion from the reaction bulk by dialysis was 
insufficient and led to a loss of liposome-associated ligand during storage. This was explained by 
the enzymatic reverse reaction. Alternative purification strategies from Sortase-A and 
manufacturing options such as a post-insertion process were disclosed.  
Sortase-A mediated conjugation of CD11b-specific single-domain antibodies led to a targeting 
of liposomes to human and murine myeloid cells in vitro. For the first time, sortagged liposomes 
were demonstrated to specifically deliver fluorescent marker molecules towards murine splenic 
CD11b+Gr-1+ cells in vivo. However, these liposomes did not exhibit specific cytotoxicity when 
loaded with cytotoxic molecules (Pseudomonas exotoxin A, doxorubicin). This was not 
circumvented through formulation optimization regarding drug load or lipid composition. 
Opposed to that, epidermal growth factor receptor targeted liposomes loaded with the 
anti-cancer drug doxorubicin exhibited a specifically higher cytotoxicity on a breast cancer cell 
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line compared to their non-targeted counterparts. This hinted at cell line-, ligand- or target-
specific circumstances that impeded specific cytotoxicity on myeloid cells.  
In this thesis, it became obvious that Sortase-A transpeptidation is a suitable technology to 
anchor targeting ligands on liposomes. The obtained results contribute therefore to the 
elucidation of site-selective conjugation strategies utilized for the design of targeted 
nanotherapeutics.  
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Abstract (German) 
Arzneistoffe werden in nanoskalierte, partikuläre Trägersysteme verkapselt, um 
pharmakokinetische, pharmakodynamische oder physikochemische Eigenschaften des 
Wirkstoffs zu verbessern. Immunoliposomen sind Konjugate zwischen Liganden und lipid-
basierten Arzneistoffträgern (Liposomen), durch die der verkapselte Stoff zielgerichtet zu 
krankheitsbefallenen Geweben und Zellen transportiert werden kann. Die 
Konjugationsreaktion, die Ligand und Träger vereint, ist ein kritischer Schritt in der Herstellung 
solcher Systeme, da sie eine mögliche Ursache für Produktheterogenität darstellt. In dieser 
Arbeit wurde daher eine chemo-enzymatische Transpeptidierung über das Enzym Sortase-A für 
das molekular ortsselektive Verankern von Liganden auf Liposomen untersucht.  
Dabei wurden Pentaglycin-tragende Liposomen über eine einfach skalierbare 
Herstellungsmethode („solvent injection“) produziert. Die Pentaglycin-Modifikation dient hier 
als Erkennungssequenz für Sortase-A zur Konjugation von LPETG-tragenden (Leucin, Prolin, 
Glutaminsäure, Tyrosin, Glycin) Liganden. Die Flussraten der für die Liposomenherstellung 
genutzten Methode wurden als geeignete Parameter identifiziert, durch deren Variation sich 
verschiedenste Formulierungen auf einen Größenbereich zwischen 140 nm und 180 nm 
einstellen ließen. Es wurde weiterhin eine rp-HPLC-Methode basierend auf massensensitiver 
Lichtstreuungsdetektion zur adäquaten chemischen Charakterisierung der Pentaglycin-
Liposomen hinsichtlich ihrer Lipid-Komposition entwickelt. 
Sowohl Einzeldomänen-Antikörper als auch intakte monoklonale Antikörper wurden erfolgreich 
an die Liposomen konjugiert. Hierbei zeigte sich eine starke Abhängigkeit der Reaktionseffizienz 
von der sterischen Akzessibilität des Pentaglycin-Nukleophils, welche sich durch verschiedene 
PEGylierungsmuster der Liposomen unterschied. Eine Verbesserung der Konjugationseffizienz 
von 40 % auf 80 % konnte durch eine Erhöhung des Verhältnisses des nukleophilen Pentaglycins 
zum LPETG-Liganden erreicht werden. Die Abreicherung von Sortase-A aus dem Reaktionsansatz 
über Dialyse war unzureichend und führte zu einem Verlust von Liposomen-gebundenen 
Liganden während der Lagerung. Dies wurde durch die von Sortase-A ebenfalls katalysierte 
Rückreaktion begründet. Eine verbesserte Aufreinigungsstrategie als auch eine optimierte 
Herstellungsoption (Post-Insertion) wurden experimentell dargelegt.  
Die Konjugation von CD11b-spezifischen Einzeldomänen-Antikörpern auf Fluorophor-beladene 
Liposomen führte zu einer erfolgreichen Targetierung von humanen und murinen myeloischen 
Zellen in vitro. Mittels Sortase-A hergestellte Immunoliposomen wurden erstmalig auch in 
einem Tierexperiment getestet, in dem die spezifische Färbung von CD11b+Gr-1+ Zellen in der 
Milz gezeigt werden konnte. Eine spezifische in vitro Zytotoxizität von Toxin-beladenen 
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Liposomen auf myeloischen Zellen konnte jedoch nicht bestätigt werden, obwohl Parameter wie 
Beladungsgrad, Lipidkomposition und Art des Toxins (Pseudomonas Exotoxin A und Doxorubicin) 
verändert wurden. Im Gegensatz dazu zeigten mit dem Zytostatikum Doxorubicin beladene und 
gegen den epidermalen Wachstumsfaktor-Rezeptor gerichtete Immunoliposomen eine 
spezifisch höhere Toxizität auf einer Brustkrebs-Zelllinie als ungerichtete Formulierungen. Dies 
deutet darauf hin, dass Zelllinien-, Ligand- oder Target-spezifische Eigenschaften für die 
fehlende spezifische Toxizität auf myeloischen Zellen verantwortlich sein können. 
Die vorliegende Arbeit demonstriert die Eignung der Sortase-A katalysierten Transpeptidierung 
als Methode zum Verankern von Liganden auf Liposomen aus technologischer wie auch 
biologischer Perspektive. Die hier erarbeiteten Resultate tragen daher zur Erforschung von 
selektiven Konjugationsstrategien für das Design von zielgerichteten Nanotherapeutika bei. 
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unbedeutender Trost für eine Menge Zeit, die uns auch durch diese Arbeit genommen wurde.  
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Ich danke an dieser Stelle meinen Geschwistern, welche mir durch ihre Präsenz in der Heimat in 
vielen wichtigen Punkten den Rücken freigehalten haben. Ebenso danke ich meinen Eltern, die 
mir ein naturwissenschaftlich-offenes Denken in die Wiege gelegt und mich in Studium und 
Promotion bedingungslos unterstützt haben. Auch meinen drei (!) Omas möchte ich hier 
ausdrücklich danken. Ich bin davon überzeugt, dass ohne eure Entbehrungen vieles in meinem 
Leben nicht möglich gewesen wäre – daher ist diese Arbeit konsequenterweise euch gewidmet. 
Zu guter Letzt danke ich meiner Freundin Katharina. Kathi, ich danke dir für deine Geduld, die 
du mit mir hattest, wenn ich mürrisch spät abends nach Hause gekommen bin, wenn ein ganzes 
Wochenende zum Schreiben verplant oder die Merck-Welt mal wieder allzu einnehmend war. 
Danke, dass du auch in den schwierigsten Phasen dieses Lebensabschnitts immer zu mir 
gestanden und mich unterstützt hast. 
 
 
